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Abstract 
The balance of the immune system between activation versus tolerance is essential 
for mounting responses to pathogens whilst preventing excessive or inappropriate 
responses that cause host damage. The β2 integrins (CD11a/b/c/d) are leukocyte-
specific adhesion receptors that play essential roles in regulating immune 
responses. Many studies have focussed on the roles of β2 integrins in contributing 
to immune activation including: leukocyte migration, immune synapse formation and 
phagocytosis. However, there is evidence that β2 integrins can also play immuno-
regulatory roles. The overall aim of this thesis was to explore the regulatory roles of 
β2 integrins in dendritic cells (DCs) and γδ T cells.  
Previous studies have shown in the absence of functional β2 integrins, DCs display 
enhanced activation and are capable of inducing greater T cell responses. I 
identified that specifically, the absence of CD11a or CD11c, but not CD11b or 
CD11d, leads to increased co-stimulatory molecule expression on DCs generated 
in vitro and greater numbers of DCs in the spleen in vivo. CD11a knockout (KO) 
DCs were also capable of inducing enhanced T cell responses. These findings are 
the first to highlight CD11a and CD11c as negative regulators of DC function.  
In studies using β2 integrin-deficient mice, the development of skin and oral mucosal 
inflammation are associated with an expansion of γδ T cells therefore, I 
hypothesised that β2 integrins are a novel regulator of γδ T cells. I characterised γδ 
T cells in β2 integrin (CD18) KO mice and found an increased number of Vγ6Vδ1+ 
γδ T cells in the spleen, blood, lungs and uterus with enhanced IL-17 production. 
Thymic development of Vγ6+ cells was unaffected by integrin loss but development 
of Vγ4+ cells was impaired. Vγ6+ cells showed similar proliferative capacity however, 
this subset was associated with reduced expression of apoptotic markers, indicating 
the accumulation of these cells is likely due to increased survival. Together, this 
data highlights a previously undescribed role for β2 integrins in promoting Vγ4+ γδ T 
cell development and regulating Vγ6+ γδ T cell numbers in the periphery. 
These findings emphasise the importance of β2 integrins in regulating immune 
responses. Further work to understand the downstream pathways of this regulation 
will identify potential therapeutic targets for diseases where DC or γδ T cell 
responses are dysregulated. 
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Chapter 1 Introduction 
1.1 The Role of the Immune System 
The primary function of the immune system is to identify and eliminate 
abnormal/foreign cells and pathogens, while remaining tolerant to self. The balance 
between activation of the immune system versus immune tolerance is important in 
maintaining responses to foreign pathogens while preventing inappropriate 
immunity against self-peptides1. In autoimmune diseases such as rheumatoid 
arthritis, psoriasis and diabetes, there is a loss of self-tolerance, however current 
therapies only target the resulting inflammation but not the underlying dysregulation 
of the immune response. Understanding the mechanisms of immune regulation and 
how this becomes aberrant in disease is required for development of the next 
generation of drugs which aim to re-establish immune tolerance2,3. 
1.2 Integrin Receptors 
The control of immune cells occurs at many levels, one of which is through receptors 
expressed on the cell surface, such as integrin receptors. Integrin receptors are 
transmembrane αβ heterodimers that are expressed on the surface of a wide variety 
of cell types, including leukocytes. There are 18 α subunits and 8 β subunits that 
together form 24 different heterodimers4 (Figure 1-1). These heterodimers differ in 
their cellular expression and in particular the β2 and β7 families are expressed 
exclusively on immune cells. Integrin receptors are involved in a range of cell 
functions including cell adhesion, leukocyte function, inflammation, cell migration, 
angiogenesis and wound healing5–8. Integrins therefore play an important role in 
regulating both homeostasis and responses to infection or disease.  
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Figure 1-1 Integrin receptor families 
Adapted from 9. The 24 different integrin heterodimers that can form from combinations of the 18 α 
subunits and 8 β subunits. Leukocyte-specific integrin receptors are highlighted with a yellow 
dotted circle.  
Integrins participate in bi-directional signalling termed ‘inside-out’ and ‘outside-in’ 
signalling which contributes to cellular function. Under steady state conditions they 
exist in an inactive form on the cell surface until receiving a stimulating signal that 
induces a conformational change enabling the receptor to bind extracellular ligands 
(inside-out signalling)10. Binding of extracellular ligands then induces intracellular 
signalling downstream of the integrin receptor that will modify aspects of cell 
behaviour such as proliferation, motility or gene expression (outside-in signalling) 7.  
Integrin receptors exist in three different conformational states (Figure 1-2). In the 
inactive conformation the extracellular region is bent, with both α and β chains folded 
inwards towards the cell membrane and the ligand-binding region is therefore 
inaccessible, giving the receptor low affinity11. The close proximity of α and β 
cytoplasmic regions is thought to retain the receptor in its inactive state12,13. In the 
intermediate affinity state the extracellular domain extends out from the cell 
membrane, the ligand binding region displays intermediate affinity and there is an 
increased distance between the α and β intracellular regions14. Transition into the 
Chapter 1 Introduction 
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high affinity conformation results in greater separation of the α and β chain 
cytoplasmic tails, altering the ligand-binding domain into its highest affinity15.  
These changes in the structure/affinity of integrin receptors are regulated by 
intracellular signalling cascades that alter interactions between integrin cytoplasmic 
tails through the binding of intracellular proteins. The triggering of these cascades 
that ultimately result in integrin activation can occur downstream of chemokine 
receptors, B- and T-cell receptors and selectins. Integrin receptors are maintained 
in an inactive state when bound to filamin, which stabilises the clasp between the 
cytoplasmic tails16. Rap1 is a GTPase that plays an important role in activating 
integrin receptors. The activation of Rap1 occurs in response to signals in the cell 
that induce the second messengers Ca2+ and diacylglycerol (DAG) or protein kinase 
C signalling, which activate guanine nucleotide exchange factors (GEFs), that in 
turn will activate the GDP to GTP exchange of Rap117. Active Rap1 can then recruit 
and activate talin18. Talin binds to the β chain cytoplasmic tail, which disrupts the 
interaction between the α and β chains and alters the structural conformation of the 
receptor, to increase ligand affinity19. The subsequent binding of kindlin to a different 
region on the β chain tail further increases the affinity of the integrin receptor20 and 
this activation of both talin and kindlin are essential for mediating cell adhesion21. 
Together, these intracellular signalling molecules contribute to inside out signalling 
by activating integrin receptors.   
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Figure 1-2 Structure and activation of integrin receptors.  
Adapted from Lefort et al. 201214. Integrin receptors can exist in three different confirmation states. 
In the bent confirmation, the receptors are bound to filamin and have low affinity for their ligand. 
They are held in this state by the protein-protein interactions (clasp) between the α and β chains. 
Activation from extracellular stimuli leads to the recruitment of talin which activates the extension 
into the intermediate affinity state and further recruitment of kindlin puts the receptor into its high 
affinity state, where it will then bind to extracellular ligands with high affinity.  
1.3 β2 Integrin Receptors 
The β2 are a family of leukocyte-specific integrins that all express the β2 chain 
(CD18) hybridised to one of four different α chains: CD11a (αL), CD11b (αM), CD11c 
(αX) or CD11d (αD). These β2 integrin family members show preferential binding to 
different but overlapping ligands, and they are expressed across all immune cells, 
but different family members predominate on different cell types (Figure 1-3). CD11a 
is highly expressed on B and T cells but is also found on dendritic cells (DCs), 
macrophages (MFs), and granulocytes. Whereas CD11b, CD11c and CD11d tend 
to be associated with myeloid cells and granulocytes. The functions of β2 integrins 
can differ according to the cell type they are expressed on and this is discussed in 
more detail below.  
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Figure 1-3 Beta2 integrin receptors, ligands and leukocyte expression 
Abbreviations: natural killer (NK), macrophages (MFs), plasmacytoid dendritic cells (pDCs).  
CD11a predominantly binds to intracellular adhesion molecules (ICAMs) and junctional adhesion 
molecule-A (JAM-A), CD11b has over 40 reported ligands including the complement cleavage 
fragment iC3b and matrix proteins, CD11c has overlapping ligands with other integrins, CD11d also 
binds vascular cell adhesion molecule 1 (VCAM-1)22–25. In mice CD11a is highly expressed on αβ, 
γδ and NK T cells26, expressed on cDCs with higher expression on CD8+ than CD8-27 and on 
pDCs28, also expressed on NK cells29, monocytes30, macrophages in the lungs but not peritoneum 
or spleen31, B cells32. In humans CD11a is expressed on T and B cells33, was shown to be higher 
on γδ than αβ T cells34 and found on uterine γδ T cells35, monocytes36, monocyte-derived DCs37, 
monocyte-derived MFs38, plasmacytoid DCs39 and NK cells40. CD11b expression is found on 
mouse neutrophils and eosinophils41, peritoneal MFs and blood monocytes42, conventional DC2s 
but not CD8+, CD103+ or pDCs27,41,43, NK cells44, and some B cells45. In humans CD11b 
expression is found on monocytes and macrophages30,36, neutrophils46, NK cells47, monocyte-
derived DCs48, B cells49. In mice CD11c is expressed on all DCs including CD103+, CD11b+, with 
lower expression on pDCs41,43,50, found on interstitial and alveolar macrophages41, NK cells51, NK 
and γδ T cells52, a small percentage of T cells in the blood and small intestine53. Unlike in mice, 
only some human DCs express CD11c including monocyte-derived DCs37,48 and cDCs, with higher 
levels on cDC2 than cDC154, but absent on plasmacytoid DCs55. Expression of CD11c is also 
found on human monocytes30, neutrophils56,57 and cervical tissue γδ T cells52. In mice CD11d 
expression has been found on peritoneal macrophages42, low levels on T cells during foetal thymic 
development58, expressed on some αβ T cells in the spleen and LNs but very low on γδ T cells59. In 
humans CD11d can be found on monocyte-derived MFs and DCs60, is expressed highly on NK 
cells, moderate levels on γδ T cells and B cells but low or absent on αβ T cells61. 
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1.3.1 Functions of β2 Integrin Receptors 
β2 integrins are involved in a range of immune cell functions whereby they mediate: 
migration into lymph nodes (LNs) and tissues, interactions with other cells to form 
immune synapses (contacts between lymphocytes and antigen presenting cells 
(APCs) or target cells) or to initiate target cell killing, phagocytosis of 
pathogens/apoptotic cells and negatively regulate signalling downstream of toll-like 
receptors (Figure 1-4).  
 
Figure 1-4 Functions of beta2 integrins 
Adapted from62,63. β2 integrins play a role in a range of immune cell functions. CD11a is important 
for migration of leukocytes into LNs and extravasation from the bloodstream into tissues. CD11a 
also mediates the formation of immune synapses to facilitate antigen presentation and the binding 
of CD8 T cells, NK cell and γδ T cells to target cells. CD11b/CD11c bind to opsonised particles to 
mediate phagocytosis by macrophages. CD18 and CD11b can also negatively regulate TLR-
mediated signalling in macrophages and dendritic cells.  
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1.3.1.1 CD11a 
CD11a is expressed on almost all leukocytes and its main role is to mediate cell 
adhesion to endothelial cells, target cells or other immune cells. The adhesion of 
circulating leukocytes to ICAM-1 on the endothelium via CD11a mediates their 
transendothelial extravasation from the bloodstream into tissues64. Following initial 
interactions with the endothelium mediated by selectins and chemokine receptors, 
CD11a mediates cell arrest and subsequent diapedesis across the endothelial 
layer65. CD11a KO neutrophils displayed reduced adhesion to endothelial cells 
under shear stress in vitro, and in vivo were less able to migrate to the site of TNF-
induced inflammation66, indicating that neutrophil firm attachment to endothelial 
cells is dependent on CD11a. In contrast, monocyte recruitment to sites of 
inflammation occurs independently of CD11a, as the infiltration of monocytes into 
the peritoneum following thioglycolate injection occurred in the absence of CD11a67. 
The migration of T cells into LNs requires CD11a-mediated adhesion to the high 
endothelial venule (HEV), but migration to the spleen occurs independently of 
CD11a68. Lymphocytes from CD11a KO mice showed impaired trafficking to 
peripheral LNs and to a lesser extent to mesenteric LNs64, likely due to the partial 
dependence on α4β7 for migration to gut-associated tissues69. There is evidence to 
suggest that leukocyte migration within the LNs occurs independently of integrins, 
the migration of T cells in LN stroma was unaffected by the absence of CD11a 
expression70. It has been suggested that in tissues leukocyte migration is 
chemokine-dependent because in the absence of shear stress, integrins are not 
activated71. The main route of DC entry into LNs is from tissues rather than from the 
blood through HEVs and this process, at least for mature DCs, is reported to be β2-
independent72,73.  
The binding of CD11a to ICAM-1 mediates formation of the immunological synapse 
between T cells and APCs74,75, B and T cells76, and the target cell binding of CD8 T 
cells77, NK cells78 and γδ T cells79,80. The immune synapse is organised into 
supramolecular activation clusters (SMAC) and CD11a is located in the peripheral 
SMAC, which encircles and stabilises interactions between the TCR and peptide-
MHC complex in the central SMAC81,82. In addition to its physical function in immune 
synapse formation, signalling downstream of CD11a has been shown to enhance 
TCR signal transduction83, lower the threshold for TCR and BCR signalling76,84, 
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enable T cell activation at a lower antigen dose85 and facilitate the effective delivery 
of cytotoxic granules to mediate target cell killing86,87. In contrast to the role of CD11a 
in promoting immune activation when expressed on lymphocytes, expression on 
DCs has been shown to inhibit T cell responses88.  
There is also evidence that demonstrates the importance of CD11a in leukocyte 
generation and differentiation. A study using CD11a KO mice identified the 
requirement for CD11a in generating optimal numbers of common lymphoid 
progenitor cells in the bone marrow89. CD11a KO mice also display reduced 
numbers of Tregs in the thymus and spleen, suggesting that CD11a is required for 
optimal Treg generation90. The development and survival of follicular T cells (Tfh) 
was also found to require CD11a, as anti-CD11a antibody treatment depleted Tfh 
cells through enhanced apoptosis and CD11a KO mice have decreased numbers 
of Tfh cells91.  
1.3.1.2 CD11b 
CD11b is primarily expressed on monocytes, macrophages (MFs), neutrophils and 
the cDC2 subset of DCs41. One of the ligands for CD11b is the complement 
cleavage product iC3b92, which is released as a by-product of the classical 
complement pathway. The binding of CD11b to particles coated with iC3b enhances 
the phagocytic ability of the cell and mediates the uptake of pathogens, immune 
complexes and apoptotic cells93. It has been shown that apoptosis in neutrophils is 
induced following CD11b-mediated phagocytosis94. However, the activation of 
CD11b can prevent the spontaneous apoptosis of neutrophils by maintaining 
mitochondrial membrane potential, yet in the presence of pro-apoptotic stimuli (such 
as anti-Fas) the engagement of CD11b contributes to the induction of apoptosis95.  
CD11b can also bind to ICAM-1, therefore plays a potential role in extravasation 
and immune synapse formation. CD11b was shown to mediate DC binding to ICAM-
1 on the lymphatic endothelium96 and active CD11b on DCs can limit DC-induced T 
cell activation97. Neutrophil recruitment to the lungs during inflammation could be 
inhibited by blocking CD11b or ICAM-198, suggesting their interaction is important 
for mediating neutrophil recruitment. However, there is also evidence for CD11b 
inhibiting the recruitment of neutrophils to sites of inflammation. Using a TNFα air 
pouch model, neutrophil extravasation was increased in CD11b KO mice66. The 
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transmigration of monocytes through the endothelial layer also requires CD11b, but 
uses a ligand distinct from ICAM-199 and CD11b has been implicated in the retention 
of macrophages in fat tissue100. These studies highlight the cell- and context-
dependent role of CD11b in mediating cell interactions and migration.  
1.3.1.3 CD11c 
The expression of CD11c is commonly associated with DCs in mice, but is also 
found on alveolar MFs50,101. A small proportion of T cells in the circulation and small 
intestine lamina propria can also express CD11c53. In humans CD11c is expressed 
on monocyte-derived DCs48 and expression on conventional DC (cDC) subsets is 
higher on cDC2 than cDC154 but absent on plasmacytoid DCs55. As with CD11b, 
CD11c also binds to iC3b which mediates effective phagocytosis, but uses a 
different binding site102. In addition to this ligand, CD11c can bind to fibrinogen and 
ICAM ligands which play a role in leukocyte adhesion and migration in response to 
chemokine-stimulation103–105. The recruitment of monocytes/MFs to sites of 
inflammation is dependent on CD11c, demonstrated using a mouse model of 
atherosclerosis, where in the absence of CD11c expression, monocytes/MFs 
showed reduced accumulation in atherosclerotic lesions which correlated with a 
reduced disease severity106. It has been suggested that CD11c expressed on MFs 
in the spleen is important for the phagocytosis of red blood cells (RBCs)107. ICAM-
4, a ligand for CD11c, is expressed on RBCs and the phagocytosis of RBCs by MFs 
could be blocked using antibodies against CD11c or ICAM-4107.  
Expression of CD11c has also been identified on some T cells and NK cells during 
cytomegalovirus infection, but the function in these cell types is unclear108. In 
humans, γδ T cells and CD8 T cells in the blood and cervical tissue can express 
CD11c52. The T cells in this study identified as CD11c+ showed enhanced 
production of IFNγ compared to their CD11c negative counterparts and expressed 
many adhesion molecules including chemokine receptors and the gut-homing 
integrin α4β7, therefore are thought to have mucosal tissue-homing properties. They 
also identified CD11c-expressing γδ T cells and NK cells in mice52, although the 
function of the integrin receptor on these cell types was not explored.  
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1.3.1.4 CD11d 
CD11d is less well characterised than the other β2 integrin family members. Similar 
to CD11b and CD11c, it is predominantly expressed on myeloid cells. CD11d has 
been detected on murine macrophages42 and human monocyte-derived MFs and 
DCs60. Engagement of the receptor in monocytes induced the production of 
inflammatory cytokines IL-8 and IL-1β as well as the monocyte chemoattractant 
protein MCP-160. This suggests that CD11d may play a role in the recruitment and 
activation of other immune cells during an inflammatory response. CD11d may also 
play a role in the response to infection. The elimination of Salmonella bacterium 
both in vitro and in vivo was reduced in the absence of CD11d, indicating that CD11d 
plays a role in bacterial clearance109. However, the phagocytic ability of CD11d KO 
MFs was comparable to WT, suggesting that CD11d is involved in activating 
intracellular killing of the bacteria rather than phagocytosis. CD11d may also play a 
functional role in NK cells. Analysis of CD11d on cells from human blood found that 
NK cells expressed higher levels of CD11d than T or B cells61, and in mice the 
activation of NK cells by neutrophils via CD11d-ICAM-3 interactions was shown to 
increase IFNγ production110.  
Despite CD11d being predominantly associated with innate cells, there is also some 
evidence for a role in T cells. Analysis of CD11d on human T cells found that γδ T 
cells from peripheral blood expressed greater levels of CD11d than αβ T cells, and 
this was upregulated in response to IL-261. In mice CD11d expression has been 
described on γδ T cells from the spleen but not LNs26 and CD11d was suggested to 
be involved in the early thymic development of αβ T cells, as transient expression 
was detected on T cells during foetal thymic development58. 
1.3.2 β2 Integrins in Inflammation and Immune Regulation 
The majority of β2 integrin functions that have been described involve the 
activation/initiation of the immune response and can contribute to inflammation. This 
includes the uptake of antigens by APCs through phagocytosis, activation of 
adaptive immune responses mediated by interactions between APCs and T cells in 
LNs, recirculation of T and B cells into LNs during immunosurveillance and the 
recruitment of the induced effector cells to the site of an infection/inflammation. In T 
cells, CD11a signalling can directly contribute to activation, whereas there is 
accumulating evidence that, in other cell types, signalling downstream of integrin 
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receptors regulates leukocyte activation and has an important role in preventing 
unwanted inflammation.  
It has been shown in both mouse models and human studies that β2 integrin loss is 
associated with development of immune-mediated disease. In humans, mutations 
that cause loss of β2 integrin expression or function lead to the development of 
leukocyte adhesion deficiency (LAD) type I and type III (LAD-I and LAD-III). In LAD-
I, mutations in the CD18 gene cause a reduction or complete loss of CD18 
expression. There are over 200 characterised mutations111 and 323 published cases 
of LAD-I to date112. Patients commonly present initially with omphalitis (infection of 
the umbilical stump) or skin ulcers that develop in early life113 and suffer from 
recurrent bacterial and fungal infections in the skin and mucous membranes 
throughout life114. The severity of disease correlates with the level of CD18 
expression, which can range from <2% to >10% of normal levels, and in over 90% 
of cases with >4% expression patients will survive into adulthood112. In LAD-III, 
patients have a mutation in the gene encoding kindlin-3 (FERMT3)115,116, which 
prevents the full activation of β1, β2 and β3 integrins. This form of LAD is less 
common than LAD-I, with less than 40 reported cases117. Similar to LAD-I, patients 
with LAD-III present with recurrent bacterial infections but in addition to this they 
also a display bleeding disorder called Glanzmann thrombasthenia, due to defective 
integrin binding to collagen by platelets, required for blood clotting118.  
Defects in β2 have also been associated with increased incidence of colitis, which 
is thought be related to defective neutrophil function119. There is an association 
between mutations in the CD11b (Itgam) and CD11c (Itgax) genes, and the 
development of systemic lupus erythematosus (SLE)120. β2 integrins are required 
for the effective activation of neutrophils in response to immune-complex binding121, 
therefore the impaired clearance of apoptotic cells may cause the release of 
intracellular components (e.g. DNA and other nuclear contents) that the immune 
system will then mount a response against.  
Mouse models also support the role of β2 integrins in inflammatory disease. The 
absence of β2 expression in mice led to the development of chronic dermatitis, an 
inflammatory skin condition5. In a mouse model of colitis the absence of CD11a was 
protective whereas CD11b deficiency exacerbated disease and correlated with 
increased plasma cell infiltration122. The protective effect of CD11a loss was likely 
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due to impaired T cell function because the establishment of normal αβ T cell 
numbers in the intestine is dependent on β2 integrin/ICAM-1 expression and the 
pathology in this model is T cell-mediated123. Using the K/Bxn serum transfer model 
of arthritis it was found that β2 integrin KO mice were resistant to the development 
of disease124. Further analysis found that disease could not be induced in CD11a 
KO mice whereas the absence of CD11b amplified disease. These discrepancies in 
results in CD11a and CD11b KO mice may be explained by impaired T cell migration 
being responsible for the protective effect in CD11a KO mice, whereas the loss of 
CD11b is associated with an accumulation of neutrophils at inflammatory sites due 
to a defect in apoptosis125, which may be the mechanism of exacerbated disease in 
CD11b KO mice. Another study using CD11b KO mice found that oral tolerance 
could not be induced in these mice, due to enhanced IL-6 production by APCs which 
increased the generation of Th17 cells and prevented the induction of oral 
tolerance126.  
This evidence clearly demonstrates that β2 integrins play an important role in the 
regulation of immune responses and suggest that dysregulation of specific β2 
integrin subunit signalling could contribute to development and/or pathogenesis of 
autoimmune and inflammatory disease. Due to the association of β2 integrin loss of 
function with autoimmune disease, it is essential that we understand how these 
receptors regulate immune cells in order to identify potential new therapeutic 
targets.  
1.4 Dendritic Cells (DCs) 
Dendritic cells (DCs) were first discovered by Ralph Steinman and Zanvil Cohn in 
the 1970s. They are the main APCs of the immune system and play an important 
role in initiating either the activation of an immune response or the induction of 
tolerance.  
1.4.1 Development of DCs 
DCs develop from committed precursors in the bone marrow. Plasmacytoid DCs 
(pDCs) and pre-conventional DCs (pre-cDCs) develop from common DC 
progenitors (CDP). The terminal differentiation of pDCs occurs in the bone 
marrow127, but pre-cDC precursors will migrate via the bloodstream to lymphoid 
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organs and tissues where they will then develop into cDCs128. There are two subsets 
of cDCs, cDC1 and cDC2, that are defined by their differential transcription factor 
requirements. cDC1 depend on IRF8, BATF3 and ID2 for development, whereas 
cDC2 require IRF4 and ZEB2129. These cDC subsets can be identified by differential 
expression of surface markers: cDC1 express CD8α and CD103, whereas cDC2 
express CD11b and CD172a130. The CD8α-expressing cDCs are located in 
lymphoid organs and the equivalent population in tissues express CD103131. The 
CD11b-expressing cDCs are predominantly lymphoid but can also be located in 
tissues101. CD172a-expressing cDCs are located in tissues including the spleen, 
lungs, liver, small intestine and colon129. 
There are also non-classical DCs, which derive from a distinct lineage than pDCs 
and cDCs. They develop from monocytes so are termed monocyte-derived DCs 
(moDCs)132. Similar to other DC subsets, moDCs can express MHC II and CD11c, 
as well as present antigens130. They can be distinguished from pDCs and cDCs by 
their expression of CD64 and Fc-gamma receptor 1 (FcγRI)133. Langerhans cells 
also develop from the monocyte lineage, and have been described as a population 
of tissue-resident DCs134, as they are found exclusively in the epidermis. However 
more recently, gene expression analysis found more similarities between LCs and 
MFs than cDCs135. 
1.4.2 Functions of DCs 
DCs are often referred to as ‘professional APCs’ as their primary function is to 
present antigen, of both self and foreign origin. They play an important role in 
bridging the innate and adaptive immune system, with the capability to induce 
immunogenic or immunoregulatory responses in CD4 and CD8 T cells.  
1.4.2.1 Activation of the immune response by DCs 
During a classical immune response, DCs in peripheral tissues will take up 
pathogens by phagocytosis and undergo maturation, then migrate to the draining 
LN where they present the foreign antigen to T cells, in order to generate an effective 
T cell response. Immature DCs have the ability to acquire antigen, but they do not 
gain the ability to effectively present antigen until their maturation is stimulated. The 
expression of MHC on the surface of immature DCs is low and many MHC 
molecules are not complexed to peptides136, then during maturation newly 
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generated MHC-peptide complexes accumulate on the cell surface137.This 
maturation of DCs occurs in response to ‘danger’ signals that come from either 
microbial products or tissue damage. These include: CPG motifs in bacterial 
DNA138,139, double-stranded viral RNA140, LPS141 and necrotic cell products e.g. heat 
shock proteins142. During maturation, DCs will lose their phagocytic ability due to 
downregulation of antigen uptake receptors (e.g. Fc receptors) and upregulate 
expression of MHC and co-stimulatory molecules143,144.  
Following antigen uptake and maturation, the migration of DCs to LNs is essential 
for the generation of an effective T cell response. The chemokine receptor CCR7 
expressed on mature DCs mediates their migration from tissues to lymphatics via 
binding to ligands CCL19 and CCL21145, where they interact with T cells to initiate 
the immune response. In combination with the production of cytokines, DCs then 
activate the clonal expansion of T cells through antigen presentation and co-
stimulation. These three signals are required to fully activate the T cell, with antigen 
presented in the context of MHC to the TCR as signal 1, co-stimulation through 
molecules such as CD80/86 binding to CD28 for signal 2, and cytokines provide 
signal 3, e.g. IL-12 for the induction of Th1 cells. DCs process exogenous antigens 
and present them on MHC Class II molecules to CD4 T cells, whereas endogenous 
antigens are presented on MHC Class I molecules to CD8 T cells. Additionally, 
some types of DC are also capable of presenting antigens acquired exogenously to 
CD8 T cells, in a process referred to as cross-presentation146,147. This is the main 
function of CD8α-expressing DCs and is important for cytotoxic responses to 
bacteria, tumours and viruses.  
There is evidence that different subsets of DCs are specialised in inducing different 
types of immune response. CD11b+ cDCs express high levels of MHCII, which 
enables them to induce robust CD4 T cell responses148,149 and they can produce 
pro-inflammatory cytokines such as IL-23, which induces Th17 cells150. IL-12 
production is important for the generation of Th1 cells151 and CD103-CD11b+ DCs 
in the intestine prime both Th1 and Th17 cells152. CD8α+ DCs in the spleen cross-
present antigen, which induces cytotoxic responses by CD8 T cells153. Whereas, 
pDCs are important for viral responses through production of type I interferons154,155. 
It is important to note that DCs display functional plasticity, and when exposed to 
different cytokines or pathogen-derived products in the microenvironment may 
perform altered functions.  
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The strategic location of immature DCs is also important for their function. CD8α+ 
DCs in the spleen are in the marginal zone where they can take up antigens from 
the blood156. Whereas DCs in LNs are located in the subcapsular sinus which is the 
site of entry for afferent lymphatic vessels that drain from tissues157. CD103+ DCs 
are predominantly located in non-lymphoid tissues, where they will acquire antigen 
before migrating to the T cell zone in the draining LN. This physical localisation of 
DCs enables their uptake of antigens to present to T cells.  
1.4.2.2 Induction of tolerance by DCs 
DC also play an important role in the induction of tolerance. Tolerance is the non-
responsiveness of the immune system against particular antigens. This is an active 
immune process, that is particularly important to prevent unwanted responses 
against factors such as self-peptides, commensal organisms and food antigens in 
the body. However, tolerance is also manipulated as an evasion strategy by cancer 
cells. DCs can contribute to the process of central tolerance through the 
presentation of self-peptides during the negative selection of T cells in the thymus, 
which will induce the death of any T cell that strongly binds to self-peptide MHC158. 
DCs can also contribute to peripheral tolerance, which involves the deletion or 
induction of anergy in autoreactive cells that were not removed during central 
tolerance and are present in peripheral tissues. Additionally, DCs contribute to 
peripheral tolerance by inducing regulatory T cells (Tregs), through the conversion 
of effector T cells into Tregs159 and enhancing Treg proliferation160. DCs in the 
intestines were shown to be important mediators of immune tolerance, as the 
expansion of DCs by Flt3L enhanced the induction of oral tolerance161. Whereas the 
depletion of DCs in mice caused the development of autoimmunity, again 
highlighting the importance of DCs in inducing tolerance162.  
Under homeostasis, many DCs present in the periphery have an immature 
phenotype, associated with low level MHC and co-stimulatory molecule expression. 
The interaction of these DCs lacking co-stimulatory molecules with T cells is known 
to lead to tolerance induction163,164. Specifically, immature DCs can induce tolerance 
through T cell deletion and/or through the generation of Tregs165. In addition to this, 
the expression of inhibitory molecules on DCs can also suppress T cell responses. 
PD-L1 binds to PD-1 on T cells to provide inhibitory signals and reduce T cell 
proliferation166. PD-L1 is expressed on both mature and immature DCs167 and 
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expression can be induced following toll-like receptor (TLR) stimulation168, 
suggesting that this inhibitory signal is important for dampening immune activation 
following infection. The binding of CD80/86 to CTLA4 expressed on the T cell, in 
contrast to CD28, will also lead to T cell suppression169. Cytokine production by DCs 
also contributes to their tolerogenic function. The phagocytosis of apoptotic cells by 
DCs reduces their pro-inflammatory cytokine production93 and the secretion of anti-
inflammatory cytokines by DCs, such as IL-10170 and TGFβ171, can promote the 
induction of Tregs.  
It is now known that tolerance is not only induced by immature DCs, but DCs 
matured under certain conditions can induce Tregs172,173. Factors present in the 
microenvironment contribute to the maturation of these so-called tolerogenic DCs. 
Treatment with IL-10 enables DCs to induce anergy in T cells174. It was also shown 
that IL-10 in combination with TGF-β induced DCs that stimulated lower levels of T 
cell proliferation and were capable of expanding Tregs175. Corticosteroids inhibited 
the ability of DCs to induce Th1 responses due to a reduced production of 
inflammatory cytokines IL-12, TNFα and IL-6, despite costimulatory molecule 
expression being unaffected176. There is also evidence that pathogen-derived 
factors can induce tolerogenic DCs, as a schistosome-derived phosphatidylserine 
was able to mature DCs capable of inducing Tregs172.  
These tolerogenic DCs (tol-DC) are required to both limit immune responses 
following infection and prevent inappropriate immune responses to self-antigens. 
They are characterised by low level MHC and co-stimulatory molecule expression, 
upregulation of inhibitory receptors such as PD-L1 and production of anti-
inflammatory cytokines, e.g. IL-10 and TGF-β177. Due to their highly 
immunosuppressive functions, tolerogenic DCs are now being explored as a 
therapeutic for the treatment of autoimmune disease3. Monocytes are cultured from 
patient blood into DCs (using GM-CSF and IL-4) then treated with dexamethasone, 
rapamycin or vitamin D3 to induce the tolerogenic phenotype, characterised by low 
expression of CD83, CD86, HLA-DR and production of IL-10178. Tol-DCs are pulsed 
with self-antigens prior to patient transfer, with the aim to re-establish tolerance in 
diseases including multiple sclerosis179, rheumatoid arthritis180 and type 1 
diabetes181. 
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Overall, it is clear that the regulation of DCs is essential for controlling the outcome 
the T cell response, whether that is the effective activation to eradicate pathogens, 
or inhibition to prevent self-reactive responses. It is therefore essential to 
understand the mechanisms underlying DC activation and localisation, to potentially 
manipulate this process for the treatment of diseases where there is an 
inappropriate activation of T cells that leads to pathology.  
1.4.3 β2 Integrins and DCs 
It was recently discovered that β2 integrin receptors are important regulators of DCs. 
For example, β2 integrins have been shown to be responsible for the negative 
regulation of TLR responses in DCs. Bone marrow-derived DCs (BMDCs) deficient 
in β2 integrins were hyperresponsive to stimulation of TLR2, 4 and 9, demonstrated 
by enhanced production of IL-6, TNFα and IL-12182. This was also true for BM-
derived macrophages (BMDM), and the mechanism of enhanced cytokine 
production in the absence of β2 integrin receptor expression was through increased 
activation of NFκB182. A similar pathway was also described in a study where 
BMDMs lacking CD11b were stimulated via TLR3, 4 or 9, produced higher levels of 
TNF, IL-6 and IFNβ183. It was identified that in β2 integrin-sufficient cells, the 
activation of Syk downstream of the integrin receptor phosphorylates and induces 
degradation of the TLR downstream adapter proteins MyD88 and TRIF183. This 
prevents further signals that induce pro-inflammatory cytokine production and NFκB 
activation. As enhanced TLR-mediated cytokine production is also found in 
BMDCs182, there may be a comparable mechanism of negative regulation of TLR-
mediated signalling downstream of β2 integrin receptors in DCs. In another study 
using CD11b KO BMDCs, they were found to enhance the activation of CD8 T cells 
when stimulated with the TLR9 ligand CpG184. However, there is contrasting 
evidence that suggests CD11b plays a role in the positive regulation of TLR4-
mediated responses in BMDCs185. Ling et al. found that CD11b KO BMDCs 
produced lower levels of IL-6 and TNFα in response to LPS than WT, and this was 
due to an impaired endocytosis of the TLR4 receptor in the absence of CD11b. 
Further work is required to dissect the precise roles of β2 integrins in regulating TLR-
mediated responses in DCs – the interplay between integrin and TLR signalling may 
be context- and TLR-specific.  
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It has also been shown that β2 integrins can regulate DCs even in the absence of 
TLR stimulation. Mice have been generated that express signalling-deficient β2 
integrin receptors (beta2TTT/AAA integrin knock-in mice), where a mutation in the 
kindlin binding site (TTT/AAA substitution; as shown in Figure 1-2) on the β2 integrin 
tail prevents kindlin binding and therefore impairs integrin function186. Beta2TTT/AAA 
integrin knock-in BMDCs expressed higher levels of activation markers and 
produced more IL-12 in the absence of activation by TLR stimuli73. The knock-in 
DCs in vivo also had a more mature and migratory phenotype. This evidence 
supports the important role for β2 integrins in regulating DC responses even in the 
absence of TLR stimulation.  
In addition to the activation status of DCs, antigen uptake is another important 
function that will affect the ability of a DC to induce a T cell response. CD11a 
expressed on endogenous DCs acts as a receptor for exosomes27, the uptake of 
which is a mechanism for acquiring antigen. In contrast to this, β2 integrin signalling-
deficient BMDCs did not show impaired uptake of fluorescently-labelled antigen, yet 
analysis of their transcriptome found that several genes associated with antigen 
uptake were downregulated compared to WT BMDCs73. These studies suggest that 
β2 integrins can influence the ability of DCs to acquire antigen, which may affect 
their ability to then present antigen to T cells.  
In order for a DC to initiate an effective T cell response, it requires an antigen to be 
presented via MHC, sufficient expression of co-stimulatory molecules, and also the 
proximity to T cells is necessary for their interactions. Therefore, the location of DCs 
is crucial for the activation of T cells, which requires the migration of DCs from 
tissues to LNs, and β2 integrins have been implicated in this process. The 
chemokine receptor CCR7 is upregulated on DCs to mediate their migration to 
LNs145 and BMDCs lacking functional β2 integrin receptors expressed higher levels 
of CCR773. This suggests that loss of β2 integrin function may enhance DC migration 
via CCR7. In agreement with this, endogenous DCs were increased in the spleen 
and LNs of mice with signalling-deficient β2 integrin receptors, due to a higher 
proportion of migratory DCs expressing CD103 and CD11b73.These data suggest 
that in the absence of functional β2 integrins, DCs are more migratory and therefore 
integrins may play a role in restricting DC migration in vivo, but β2 integrin expression 
is not required for DC migration to LNs. Other studies have also suggested that the 
migration of DCs to LNs occurs independently of β2 integrins. The adoptive transfer 
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of LPS-matured BMDCs demonstrated their ability to migrate into LNs and localise 
to the T cell zone, and DCs lacking multiple integrins including β2 (β1, β2, β3 and β7) 
showed equivalent migration to WT DCs72. In contrast to this, the number of DCs in 
the lungs was reduced in CD18 KO mice, potentially suggesting a role for β2 
integrins in mediating DC migration to the lungs. However, as these mice had a 
global-deficiency in CD18 the indirect effect of another cell population on DC 
numbers cannot be ruled out. Overall the evidence in the literature suggests that 
DCs do not require β2 integrins for migration to LNs but further work is required to 
determine whether specific DC subsets or migration to other tissues involves β2 
integrins.  
It is clear that β2 integrins can affect DC activation and may be involved in the 
antigen uptake and migration of DCs, therefore the next question is what impact this 
may have on their interactions with T cells. There is evidence to support the 
hypothesis that DC regulation by β2 integrins affects their ability to prime T cells. 
The transfer of BMDCs lacking functional β2 integrin receptors resulted in enhanced 
levels of T cell-derived IFNγ, compared to levels induced by integrin-sufficient 
BMDCs73. This suggests the loss of β2 integrin expression causes BMDCs to induce 
greater Th1 responses. Another study using BMDCs that express a constitutively 
active form of CD11a showed that when cultured with CD4 T cells, these DCs were 
less able to induce T cell proliferation, expression of T-bet and production of IFNγ 
than BMDCs with normal CD11a expression88. This again indicates that β2 integrins 
can negatively regulate DCs to limit the priming of Th1 cells. It was suggested by 
Varga et al. that CD11b, but not CD11a, is the β2 integrin receptor responsible for 
inhibiting the priming of T cells97. They showed that inducing integrin receptor 
activation in vitro using magnesium enhances the binding of BMDCs to ICAM-1, and 
this effect could be blocked using antibodies against CD18 or CD11b but not CD11a 
or CD11c. When activated BMDCs were pre-incubated with anti-CD11b they 
induced lower levels of T cell proliferation97. In a study using human monocyte-
derived DCs, the ligation of CD11b reduced their ability to induce Th17 cells through 
downregulation of cytokine production (IL-1β, IL-6 and IL-23)187. Similarly in mice, 
the ligation of CD11b on BMDCs decreased their production of IL-6, IL-12 and TNF 
and their ability to activate T cells188. These studies indicate that β2 integrins act to 
negatively regulate the activation of DCs, which in turn contributes to restricting T 
cell activation. However, the specific β2 integrin/s responsible for this effect and 
which signalling pathways they modulate are not yet fully characterised. 
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Overall, there is evidence to support the role of β2 integrins in negatively regulating 
DCs under steady state conditions and following TLR activation. This integrin-
mediated regulation also impacts on the ability of DCs to induce T cell responses. 
As DCs are essential mediators of immune activation versus tolerance, 
understanding the mechanism of β2 integrin-mediated regulation in DCs may 
provide new targets for the treatment of diseases where there is inappropriate 
immune activation due to a loss of tolerance.  
1.5 Gammadelta (γδ) T Cells 
γδ T cells are innate-like lymphocytes that share features of both innate and 
adaptive immune cells. They are found predominantly at mucosal sites in the body, 
with a lower frequency present in the blood and LNs. They are the first T cells to be 
produced during embryonic development and have an important role in neonatal 
immunity, responses to infection and immune surveillance189,190.  
1.5.1 Development of γδ T cells 
1.5.1.1 Murine γδ T cell development 
Both αβ and γδ T cells develop from a common double negative (CD4-CD8-) 
precursor in the thymus191,192. The precise mechanisms that govern the decision 
between αβ and γδ T cell fates are not completely understood - it is debated whether 
T cell fate is pre-determined or induced by specific signals during thymic 
development193. There is also evidence that epidermal γδ T cells develop from yolk 
sac precursors independently of haematopoietic precursors194. The development of 
γδ T cells in mice occurs in waves during embryonic stages, each of which is 
associated with a distinct T cell receptor (TCR) Vγ chain and localisation to specific 
tissues (Table 1-1, Figure 1-5), reviewed in195,196. The first wave of γδ T cell 
development occurs from days E13-15, when Vγ5-expressing γδ T cells are 
generated. These cells migrate to the skin to become an epidermal-resident 
population197. Following this, Vγ6+ γδ T cells then develop from E16-18, which 
migrate to the lungs, uterus, tongue, dermis and peritoneal cavity198–200. Vγ4+ and 
Vγ1+ γδ T cells are produced from E18 into post-natal life, and predominantly 
localise to the spleen and lymph nodes201. Vγ7+ cells are found in the intestines202, 
and can develop in the thymus203 but there is also evidence for extra-thymic 
development, as Vγ7-expressing cells develop in athymic mice204.  
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Each of the γδ T cell subsets described preferentially secrete either IFNγ or IL-17 
but can also produce other cytokines (Table 1-1), an effector phenotype which they 
gain during thymic development205. This allows for rapid responses in the periphery, 
whereby γδ T cells produce cytokines without the need for clonal expansion. This is 
in contrast to αβ T cells that require antigen presentation via MHC to induce their 
clonal expansion before they can secrete high levels of effector cytokines. The 
subsets of γδ T cells that produce IFNγ versus IL-17 can be separated according to 
surface marker and transcription factor expression. IFNγ-producing γδ T cells are 
CD62Lhi CD44lo CD45RB+ CD27+ and express T-bet, whereas IL-17-producing γδ T 
cells are CD62Llo CD44hi CD45RB- CD27- and express RORγt199,206,207. This 
cytokine signature of γδ T cell subsets is established during thymic development 
and is under epigenetic control that maintains the preferential cytokine production 
in the periphery208. Of note, is that Vγ1+ and Vγ4+ γδ T cells can develop as either 
IL-17-producers or IFNγ-producers and can be distinguished using the markers 
described above whereas, Vγ5+ and Vγ6+ cells produce IFNγ and IL-17, 
respectively203. 
It is still not well understood how the initial migration of different γδ T cell subsets to 
specific tissues is controlled, with the exception of Vγ5+ cells. During thymic 
development, Vγ5+ cells upregulate expression of CCR10, which is required for their 
migration to the skin209, where keratinocytes produce CCL27 (the ligand for 
CCR10)210. It has also been shown that CCL25 is produced in the intestines211, and 
the intestine-associated Vγ7+ γδ T cells express the corresponding receptor 
CCR9211. Trafficking of Vγ7+ cells to the small intestine was also found to be partially 
dependent on the integrin α4β7212. CCR6 expression on Vγ4+ and Vγ6+ γδ T cells is 
involved in their migration to the dermis under homeostasis213, but it is unclear which 
chemokines and/or adhesion receptors direct the migration of Vγ6-expressing cells 
to the lungs and uterus.  
There are some pathways that are described to play a role in the development of γδ 
T cells, but there is still much to be understood about the mechanisms underlying 
γδ T cell subset development, which is the subject of ongoing research. The 
development of the IFNγ-producing Vγ5+ and Vγ7+ subsets is dependent on 
butyrophillin (Btnl) and btnl-like molecules. Skint1 is an immunoglobulin superfamily 
member, with homology to btnl molecules214. Skint1, expressed on thymic epithelial 
cells and keratinocytes, is required for both the development and maintenance of 
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Vγ5+ γδ T cells214,215. Binding of γδ T cells to Skint1 on thymic epithelial cells 
upregulates Egr3 in the γδ T cell, which induces differentiation into IFNγ-producing 
effectors215. Btnl1 and Btnl6, expressed on epithelial cells in the small intestine 
villus, are required for the expansion and maintenance of Vγ7-expressing γδ T cells 
in the gut216, where Vγ7-expressing γδ T cells are thought to develop 
extrathymically. The receptor for Skint1 has not been identified, but there is 
evidence that the Vγ7+ TCR recognises Btnl molecules217. Several Sox family 
transcription factors have been implicated in the development of IL-17-producing γδ 
T cells. Sox13 and Sox4 are required for the thymic development of Vγ4+ cells, as 
this subset is absent in mice that lack the expression of Sox13 or Sox4218,219. 
However, the pathways that induce Vγ6+ γδ T cell subset development and 
maintenance have not yet been characterised.  
There is also evidence to suggest that TCR signal strength is one of the determining 
factors in the development of γδ T cell subsets. In SKG mice the loss of Zap-70 
function, a kinase downstream of the TCR, reduced the numbers of IL-17+ γδ T cells 
but not CD27+ IFNγ-producers220. This suggests that the generation of IL-17-
producing γδ T cells requires TCR signals. However, induction of TCR signalling 
using an anti-TCRγδ antibody inhibited the development of IL-17-producing γδ T 
cells, whereas inhibition of Erk signalling downstream of the TCR enhanced IL-17+ 
γδ production while inhibiting IFNγ+ γδ development203. The discrepancy between 
TCR signalling promoting or inhibiting IL-17+ γδ T cell development in these studies 
may suggest that Zap-70 signalling is necessary for the generation of IL-17+ γδ T 
cells but not necessarily strong TCR signals. In CD3 double-haploinsufficient mice, 
that have reduced TCR expression and downstream Erk signalling in γδ T cells, 
there is decreased development of Vγ6+ but not Vγ4+ γδ T cells221, suggesting the 
effect of TCR signalling is specific to individual γδ T cell subsets. These studies 
imply that TCR-mediated signalling is involved in γδ T cell development, but when 
and how the strength of TCR signalling in the thymus is delivered remains to be fully 
elucidated.  
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Figure 1-5 Murine γδ T cell development. 
Adapted from Carding and Egan222. Murine γδ T cell subset ‘waves’ of development are depicted, 
together with the tissue(s) in which each subset resides. 
Table 1-1 Summary of murine γδ T cell subsets 
Subset Age of development 
TCR 
Repertoire 
Tissue 
Localisation Cytokine Production 
Vγ1 E19 - postnatal Diverse Liver and 
lymphoid 
IFNγ and TNF 
Can produce IL-17 and 
IL-4 
Vγ4 E17 - postnatal Diverse Lymphoid, 
lungs and liver 
IL-17 or IFNγ 
Vγ5 E13 - E15 Invariant 
(Vγ5Vδ1) 
Epidermis IFNγ 
Can produce IL-22 and 
TNF 
Vγ6 E15 - E18 Invariant 
(Vγ6Vδ1) 
Uterus, lungs 
and tongue 
IL-17  
Can produce IFNγ 
Vγ7 E19 - postnatal Some variety Intestine IFNγ 
Adapted from223 showing γδ T cell subset development timings, TCR diversity, and specific tissue 
localisation and cytokine potential. Note that Vγ2 also exists at the mRNA level, however only a 
minority of sequences are in-frame and there is no correlation between in-frame Vγ2 transcripts 
and level of expression at the cell surface224–226.  
1.5.1.2 Human γδ T cell development 
The development of γδ T cells in humans also occurs during embryonic stages, 
however the subsets of γδ T cells differ to those in mice. Human γδ T cells are 
broadly divided according to delta chain expression into Vδ1+ and Vδ2+ cells. Vδ2+ 
cells are produced early during gestation227, whereas Vδ1+ cells are generated later 
during embryonic development, with the majority of γδ T cells expressing Vδ1 in 
cord blood228 and in the paediatric thymus229. The Vδ2+ cells then expand post-birth 
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and become the predominant population in the peripheral blood of adults230. Vδ2-
expressing γδ T cells have a limited TCR repertoire227,231, similar to the early 
developing murine γδ T cells, whereas Vδ1-expressing cells have a more diverse 
repertoire232. Unlike γδ T cells in mice with a more diverse repertoire that are located 
in the peripheral LNs, Vδ1+ cells are predominantly located in tissues such as the 
intestine, skin and spleen233,234.  
There is evidence to suggest that, unlike in mice, human γδ T cells do not undergo 
functional pre-programming in the thymus. Comparison of γδ T cells from paediatric 
thymus and blood found that those in the thymus required activation by cytokines to 
enable their IFNγ production and to perform cytotoxic functions, whereas those from 
the blood readily produced cytokines229. γδ T cells that express T-bet and are 
capable of producing IFNγ are found in humans227, but there is less evidence to 
support the presence of IL-17-producing γδ T cells in healthy individuals, unlike the 
presence of IL-17+ γδ T cells in mice during homeostasis. However, IL-17-producing 
γδ T cells can be induced in vitro by IL-7 treatment235 or a cocktail of cytokines in 
combination with phosphoantigens236. They have been detected in individuals with 
bacterial meningitis236, HIV237, psoriasis238 and pulmonary tuberculosis239. This 
suggests that in humans γδ T cells may not be pre-programmed to produce IL-17 
but under certain conditions during infection or inflammation these cells can be 
induced. In addition, most human studies use cells isolated from peripheral blood 
therefore, there may be IL-17-producing γδ T cells present in human tissues that 
are not readily accessible and rarely studied.  
Although the subsets and characterisation of γδ T cells differs between mice and 
humans, the general localisation is similar, with γδ T cells found predominantly at 
barrier sites such as the skin, lungs and intestines, but also can be located in the 
blood and LNs189. They also display similar functions including: regulation of 
keratinocytes for wound repair240, production of pro-inflammatory cytokines241 and 
recognition of stress-induced ligands for cytotoxic responses to tumour cells242. 
Therefore, the use of mouse models to understand the development and functions 
of γδ T cells has translational capacity.  
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1.5.2 Survival and maintenance of γδ T cells  
Following thymic development, γδ T cells become resident in peripheral tissues 
where they perform important effector functions. IL-17-producing γδ T cells are 
thought to develop exclusively in the embryonic thymus and are then retained in the 
periphery through self-renewal243. Using bone marrow chimeras it was shown that 
IL-17-producing γδ T cells cannot be generated in the adult thymus, regardless of 
whether the source of donor cells was from foetal or adult mice244. In line with these 
findings, following conditional depletion of γδ T cells, those with an IL-17-producing 
phenotype (CD27-CD44high), including Vγ4+ and Vγ6+ cells, did not fully reconstitute 
the spleen and peripheral LNs. In contrast, those with an IFNγ-producing phenotype 
(CD27+CD44low), including Vγ1+ cells in the spleen/LNs and Vγ7+ cells in the 
intestine, returned to normal levels after 7 weeks245. The exception was the IFNγ-
producing Vγ5+ cells in the skin, that displayed a poor recovery, presumably due to 
their exclusive generation during embryonic development. Using another approach 
where γδ T cells were labelled with RFP in a tamoxifen-inducible system, IFNγ-
producers lost their RFP expression 7 weeks post tamoxifen whereas IL-17-
producers retained the RFP label and this was true for cells in the spleen, LNs and 
liver245. This suggests that IFNγ-producing γδ T cells are constantly replenished by 
newly generated cells from the thymus, whereas the turnover of IL-17-producers is 
much slower.  
There are several cytokines and surface molecules that are thought to be involved 
in promoting the survival of γδ T cells. Studies have demonstrated the importance 
of IL-7 in γδ T cell survival. Following the labelling of proliferating cells with BrdU, in 
IL-7 KO mice there was a greater loss of BrdU+ γδ T cells compared to heterozygous 
controls246, indicating the importance of IL-7 for γδ T cell survival. γδ T cells have 
also been shown to upregulate the pro-survival molecules Bcl2, Bcl2-xL and Mcl-1 
in response to IL-7247. In contrast to this, the administration of IL-2 in vivo enhanced 
γδ T cell death, based on expression of caspase-8248. Signalling via CD28 has also 
been implicated in γδ T cell survival, as blocking B7 molecules (ligands for CD28) 
enhanced γδ T cell apoptosis whereas activating CD28 inhibited cell death249.  
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1.5.3 Functions of γδ T Cells 
Unlike αβ T cells, γδ T cells are not restricted to recognising peptides in the context 
of MHC and can instead recognise non-peptide antigens. There are several 
characterised γδ TCR ligands including phycoerythrin250, the non-classical MHC 
molecule CD1d251, herpes simplex virus glycoprotein252 and heat shock proteins253. 
In addition, the activation of γδ T cells can occur through other receptors, such as 
NKG2D, which recognises stress-related molecules expressed by epithelial cells254. 
The TCR repertoire of γδ T cells located at mucosal sites (e.g. Vγ5/Vγ6) are 
invariant, yet can respond to a variety of pathogens, suggesting that TCR 
recognition and signalling is not required for function198,255. The roles of γδ T cells in 
regulating homeostasis, activation of other immune cells and contribution to disease 
are detailed below.  
1.5.3.1 Role in physiological functions 
There is increasing evidence to show that γδ T cells can play important roles in 
maintaining tissue homeostasis, in addition to their immune functions. In response 
to tissue damage γδ T cells promote epithelial cell regeneration to maintain physical 
barriers. These barrier sites include the skin, lungs, intestines and uterus, all of 
which are sites populated by γδ T cells. For example, γδ T cells in the skin induce 
the maturation of keratinocytes and mediate tissue repair through production of IL-
13256. More recently, γδ T cells were identified in adipose tissue, where they regulate 
thermogenesis257. This function was demonstrated using TCRδ KO mice, which 
lacked the ability to restore their body temperature following exposure to cold due 
to the loss of IL-17 production257. IL-17-producing γδ T cells are also necessary for 
effective bone regeneration, as mice lacking either γδ T cells or IL-17 showed 
impaired generation of new bone following injury, and in WT mice most of the IL-17-
producing cells in the bone marrow were γδ T cells258.  
1.5.3.2 Interactions with DCs and antigen presentation 
When cultured with DCs, γδ T cells induced the upregulation of MHC, CD86 and 
CD83 on the DCs in a contact-dependent manner259. It was also shown that 
activated γδ T cells can enhance LPS-induced activation of DCs, resulting in 
increased production of IL-12 and an enhanced ability to induce Th1 responses260. 
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In turn, DCs could induce γδ T cell proliferation and increase their production of IFNγ 
and TNF, though IL-17 was not measured260.  
In addition to activating and/or enhancing antigen-presenting functions of DCs, there 
is evidence that γδ T cells themselves can present antigen. Human γδ T cells 
upregulate MHC I and MHC II, CD80/CD86 and CCR7 in response to isopentenyl 
pyrophosphate (IPP), a ligand for the human Vγ9Vδ2 TCR, and this enabled them 
to induce proliferation of naïve CD4 T cells261. The expression of MHC II could also 
be induced on murine γδ T cells in vitro by stimulation with anti-CD3 and anti-CD28 
antibodies, and these cells induced αβ T cell proliferation262. It remains to be 
determined whether γδ T cells can present antigen in vivo, although expression of 
MHC II was induced on γδ T cells in response to immunisation with CFA263.  
1.5.3.3 Interactions with B cells 
There are several studies to suggest that γδ T cells are capable of supporting B cell 
responses. In mice that lack αβ T cells, germinal centres and class-switched 
antibodies were detected, suggesting that γδ T cells may be capable of providing 
help to B cells264. In the absence of γδ T cells, mice had reduced levels of IgE and 
IgG1 in response to immunisation with ovalbumin265. More recently, it was also 
shown that in response to DNA damage in the skin, γδ T cells promoted the 
production of IgE by B cells266. The B cell-promoting effect of γδ T cells may be 
indirect, for example by influencing T follicular helper (Tfh) cells which are the main 
cell population that provides help to B cells. γδ T cells have been shown to induce 
Tfh generation, as in TCRδ KO mice immunisation with OVA/CFA resulted in 
reduced germinal centre formation, Tfh generation and antibody production267. 
1.5.3.4 Responses to infection 
γδ T cells can respond to infection or disruption of the epithelial barrier through 
recognition of stress-markers expressed on epithelial cells, such as keratinocytes 
found in the skin268. This recognition of stress markers expressed on epithelial cells 
has led to the description of γδ T cell function in lymphoid stress surveillance269. The 
activation of γδ T cells via NKG2D is induced by ligands upregulated on cells in 
response to infection or stress, such as RAE1 and H60 (in mice), MICA and MICB 
(in humans)270. This ability to recognise any cause of disruption to the epithelial 
barrier and respond immediately results in a protective response against several 
Chapter 1 Introduction 
 
  44 
different types of infection. The production of IL-17 by γδ T cells is required for the 
elimination of Staphylococcus aureus infection in the skin271. In response to oral 
Listeria monocytogenes infection, γδ T cells capable of producing IFNγ and IL-17 
migrate to the intestine and enhance bacterial clearance following secondary 
infection272. γδ T cells can also influence the recruitment of other immune cells. They 
play a protective role in the response to chikungunya virus, where in the absence of 
γδ T cells the increased infiltration of other inflammatory cells exacerbates tissue 
damage273. Finally, in the lungs, γδ T cells induced by Candida albicans infection 
recruit neutrophils to enhance fungal clearance274 and the same is true for bacterial 
clearance following Streptococcus pneumoniae infection275.  
1.5.3.5 Role in cancer 
The role of γδ T cells in tumour surveillance was first implicated by the observation 
that mice lacking γδ T cells showed enhanced tumour development and burden in 
models using injection of PVD carcinoma cells and chemical carcinogenesis 
induced by DMBA190. Further research has since found that γδ T cells can be both 
protective and pathogenic towards tumours, depending on their subset (i.e. which 
cytokine they produce) and the type of cancer. The protective effect of γδ T cells 
has been shown in B cell lymphoma, melanoma and colon cancer276–278. IFNγ-
producing γδ T cells are thought to mediate these anti-tumour effects through 
cytokine production, release of perforin to mediate cell-killing and by inducing class 
I MHC molecule expression on tumour cells that enables recognition by CD8+ T 
cells279–281.  
Several cancer models in mice have demonstrated that, unlike IFNγ-producers, IL-
17-producing γδ T cells can increase tumour formation and metastasis. In a murine 
breast cancer model system, IL-17 production by γδ T cells had a pro-tumour effect 
through the expansion of neutrophils that suppressed anti-tumour CD8+ T cells282. 
In an ovarian cancer model, γδ T cell-derived IL-17 activated peritoneal 
macrophages that enhanced tumour cell proliferation283. Similarly, in a 
hepatocellular carcinoma model, myeloid-derived suppressor cells were induced by 
γδ T cell-derived IL-17, leading to enhanced tumour growth284. Conversely, there is 
also evidence that IL-17-producing γδ T cells can be protective in cancer. The anti-
tumour effects of bladder cancer treatment using Mycobacterium bovis BCG were 
dependent on the recruitment of neutrophils mediated by IL-17+ γδ T cells285.  
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In humans, γδ T cells are also associated with both pro- and anti-tumour effects. 
Patients with breast cancer showed a positive correlation between γδ T cell infiltrate 
in the tumour and advanced tumour stages as well as lymph node metastasis, 
indicative of a pro-tumour effect286. Whereas analysis of the leukocyte infiltrate 
across 25 different cancers found that high levels of γδ T cells are associated with 
favourable outcomes, suggesting an important anti-tumour function287.  
Despite the contrasting roles for γδ T cells in cancer it is clear that γδ T cells capable 
of performing cytotoxic functions and producing IFNγ can mediate anti-tumour 
effects. This has led to the investigation of γδ T cell based immunotherapies for the 
treatment of cancer278. Most approaches involve the expansion of Vγ9Vδ2+ γδ T 
cells, as these are readily available in peripheral blood and can be expanded in vivo 
and in vitro using aminobisphosphonates223. The safety of these approaches has 
been demonstrated in pilot studies and Phase I clinical trials, with evidence for 
therapeutic effects in some patients. In patients with metastatic breast cancer, the 
combined treatment of zoledronic acid and low dose IL-2 led to a correlation 
between the number of Vγ9Vδ2+ cells and positive clinical outcomes (stable disease 
or partial remission)288. In another study using IL-2 with palmidronate, many patients 
with non-Hodgkin lymphoma or multiple myeloma showed stable disease or partial 
remission, again associated with increased Vγ9Vδ2+ cells289. γδ T cells expanded 
in patients using these approaches display an effector phenotype based on CD69 
expression, express HLA-DR indicating a potential for antigen presentation, and 
showed an enhanced capability to produce IFNγ288–290. There is contrasting data on 
the use of zoledronic acid and IL-2, as in patients with renal cell carcinoma the 
treatment reduced the percentage of Vγ9Vδ2+ cells in vivo and they displayed 
impaired proliferation in vitro 291 highlighting the need for optimisation of expansion 
protocols to deliver consistent results.  
Optimisation of these protocols to expand γδ T cells requires a better understanding 
of the pathways involved in γδ T cell proliferation and function. Vδ1+ γδ T cells have 
not yet been used in clinical trials but there is evidence they have anti-tumour effects 
and are less susceptible to activation-induced cell death than Vδ2+ cells292. The use 
of Vδ1+ γδ T cells as a therapeutic requires the development of a protocol for 
selective expansion and activation. It is still not currently well understood how γδ T 
cells are regulated in vivo. This is important to understand how the γδ T cells migrate 
to the tumour/metastasis sites, how they interact with tumour cells and other 
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immune cells to mediate anti-tumour effects, what governs the stability of their 
phenotype when transferred or expanded (e.g. cytokine production), and what 
controls their survival. Elucidating the pathways involved in γδ T cell regulation will 
improve the success of γδ T cell therapeutics through the generation of cells of the 
correct phenotype with sufficient migratory capacity and survival in vivo for them to 
carry out effector functions.  
1.5.4 β2 integrins and γδ T cells 
αβ T cells express high levels of CD11a and the function of this integrin has been 
well characterised to contribute to αβ T cell effector functions. In αβ T cells, CD11a 
has been shown to mediate cell-cell contacts for immune synapse formation and 
cytotoxic functions, as well as extravasation from the bloodstream into tissues and 
trafficking into lymph nodes64,68,87,293. The roles of CD11a may be different in γδ T 
cells.  
β2 integrins are expressed on γδ T cells in both mice and humans. In mice, γδ T 
cells express reduced β2 integrins compared to αβ T cells, and γδ T cells have been 
shown to express highest levels of CD18/CD11a and to a lesser extent CD11b, 
CD11c and CD11d59,294. Whereas in humans, analysis of T cells from peripheral 
blood identified that γδ T cells express higher levels of CD11a34 and CD11d61 than 
αβ T cells. Although the role of different β2 integrin receptors in γδ T cell function 
has not been extensively studied, there are several studies that have started to 
uncover their role.  
Some studies have assessed the role of β2 integrins in γδ T cell migration using 
disease models. In a mouse model of multiple sclerosis, experimental autoimmune 
encephalomyelitis (EAE), pathogenic γδ T cells that infiltrated the central nervous 
system (CNS) upregulated β2 integrins, whereas integrin expression on αβ T cells 
was unchanged59. This suggested that β2 integrins may be important for γδ T cell 
migration into the CNS. However, subsequent work from the same group found that 
when transferred into mice with EAE, β2 integrin-deficient γδ T cells were able to 
traffic effectively into the CNS295, indicating that beta2 integrin receptors are not 
required for γδ T cell trafficking to the site of inflammation in this model. In line with 
this, it was shown that in mice with CD18 expression at 2-16% of WT levels 
(CD18HypoPL/J), inflammatory skin lesions that spontaneously develop showed a 
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greater γδ T cell infiltrate than controls296. Again, this suggests that the migration of 
γδ T cells to effector sites is not dependent on β2 integrins. However, there is some 
evidence suggesting the involvement of β2 integrins in γδ T cell migration. Following 
corneal wound abrasion, CD11a KO mice showed reduced γδ T cell numbers in the 
epithelium compared to WT, suggesting that the migration of γδ T cells to this site 
may be partially dependent on β2 integrins. Alternatively, this may indicate the 
dependence of γδ T cells on β2 integrins for migration is a tissue-dependent effect 
or an indirect effect through altered infiltration of other cells, that reduce the 
recruitment or retention of γδ T cells. When adoptively transferred, CD18 KO γδ T 
cells predominantly migrated to the liver and lungs, and were also found in the 
spleen but not peripheral LNs297. This again suggests that migration of γδ T cells to 
certain tissues does not require β2 integrins, although they did not directly compare 
the migration with integrin-sufficient γδ T cells or characterise the subsets of γδ T 
cells that were transferred, which may influence where the cells migrate. Overall, 
evidence from the current literature supports the hypothesis that, in contrast to αβ T 
cells, γδ T cell migration occurs independently of β2 integrins. However, there are 
currently no studies that directly test the contribution of β2 integrins to γδ T cell 
migration under steady state conditions.  
There is also evidence that suggests β2 integrins are important for mediating the 
cellular interactions of γδ T cells. It was shown that γδ T cells can interact with 
endothelial cells via CD11a-ICAM-1 interactions298. However, the functional 
consequences of this interaction, and the specific requirement for individual integrin 
subunits, were not explored. Several studies describe the requirement for β2 
integrins for effective target cell killing by γδ T cells, likely also by binding to ICAMs. 
Imaging of γδ T cells bound to K562 leukaemia cells showed that CD11a localised 
to the region of contact between the two cells299. Using a blocking antibody against 
CD18, the cytotoxicity of γδ T cells against pancreatic cancer cells was inhibited79, 
and against CD11a reduced the killing of Burkitt’s lymphoma80 and Daudi lymphoma 
cells300. The expression of the β2 integrin ligands ICAM-1 and ICAM-2 were also 
found to be required for effective killing of pancreatic cancer cells by γδ T cells301. 
These studies indicate that, despite playing less of a role in γδ T cell migration, β2 
integrins are important for mediating the interactions of γδ T cells, and in particular 
are required their cytotoxic functions.  
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In addition to these studies of integrin contribution to γδ T cell migration and 
interactions, there is also evidence that the reduction or loss of β2 integrin 
expression can cause an expansion of γδ T cells suggesting a role for β2 integrins 
in γδ T cell proliferation. In mice with reduced CD18 expression there is an increased 
number of IL-17-producing γδ T cells in the skin-draining LNs which becomes 
exacerbated when they develop a spontaneous skin inflammation and γδ T cells 
migrate into the skin296. CD11a KO mice have been shown to develop periodontal 
disease with age, which also correlates with an infiltration of IL-17-producing γδ T 
cells302. Higher γδ T cell numbers have likewise been identified in β2 integrin-
deficient mice in the absence of overt signs of inflammation. An increased number 
of γδ T cells has been described in the cervical LNs of CD18 KO mice297 and a 
higher percentage of IL-17-producing γδ T cells was identified in the spleen of these 
mice303. The mechanisms underlying γδ T cell expansion in these CD18-deficient 
mouse models was not identified and the number of γδ T cells in other mucosal 
tissues where γδ T cells perform essential functions, such as the lungs or intestines 
were not determined.  
In summary, unlike for αβ T cells, there is less evidence to suggest that β2 integrins 
are important for the migration of γδ T cells. Yet, similar to αβ T cells, the optimal 
cytotoxic function of γδ T cells via binding to target cells requires β2 integrins. The 
increased number of IL-17+ γδ T cells in the absence of β2 integrin expression 
suggests a possible regulatory function, but it is unclear whether this is a direct effect 
on γδ T cells or mediated indirectly through another cell population.   
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1.6 Hypothesis and Aims 
The aims of this thesis are based on the hypothesis that β2 integrins are a negative 
regulator of DCs and γδ T cells. 
It is well characterised that β2 integrin receptors contribute to pro-immune functions. 
β2 integrins are involved in the formation of contacts between immune cells75,304 and 
enhance immune activation and signalling84. The migration of cells for entry into 
LNs68 and transmigration into tissues64 is dependent on β2 integrins. The cytotoxic 
function of immune cells is also enhanced with β2 integrin-mediated 
adhesion77,79,87,301. Despite these findings, in both mice and humans there is 
evidence that the loss of β2 integrin expression is associated with inappropriate 
inflammation and autoimmunity. In humans with mutations in β2 genes there is an 
increased incidence of colitis119 and lupus120, and in mice the loss of β2 integrin 
expression can lead to spontaneous inflammation in the skin5 and oral mucosa302. 
As the loss of β2 integrin expression is associated with an increase in inflammation, 
this suggests that in addition to their roles in promoting immune responses, β2 
integrins can also act as immune regulators. Therefore, the overall aim of this thesis 
was to explore the immuno-regulatory roles of β2 integrins. Immune regulation by β2 
integrins was explored in DCs and γδ T cells, based on evidence from the literature 
to suggest a regulatory role for integrins in these cell types.  
DCs from CD18 KO mice were hypersensitive to TLR stimulation182 and the loss of 
functional β2 integrin receptors resulted in an increased activation of DCs under 
steady state conditions73. In chapter 3 I sought to determine the specific subunits 
involved in the negative regulation of DCs and the effect integrin-mediated 
regulation of DCs has on the outcome of the subsequent T cell response.  
In mice with reduced or complete loss of CD18 expression, there is evidence of 
enhanced numbers of IL-17-producing γδ T cells in the spleen303, skin296 and 
cervical LNs297. As the loss of integrin expression causes an increase in γδ T cells, 
my hypothesis is that β2 integrins act as a novel regulator of IL-17-producing γδ T 
cells. In chapter 4 I characterised the phenotype and localisation of γδ T cells in β2 
integrin-deficient mice and in chapter 5 I explored potential mechanisms underlying 
the expansion of γδ T cells in these mice. 
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Chapter 2 Materials and Methods  
2.1 Mice 
Details of all mouse strains used are listed in Table 2-1. For CD11a, CD11c and 
CD11d KO strains mice were initially bred from the sources listed. Upon discovery 
of an additional mutation in the Dock2 gene present in these mice (detailed in 
Chapter 3), mice were crossed with C57BL/6 and selected for WT expression of 
Dock2. These Dock2WT strains with retained integrin deficiency were used as 
indicated in Chapter 3 and in Chapter 4. Mice were used at age 6-14 weeks unless 
otherwise indicated. Mice were housed at the University of Glasgow and all 
protocols were conducted under licenses issued by the U.K. Home Office under the 
Animals (Scientific Procedures) Act of 1986 and approved by the University of 
Glasgow Ethical Review Committee.  
Table 2-1 Details of Mouse Strains Used 
Name of Strain Description Caging Source 
C57BL/6J Wild type Conventional 
Envigo or transgenic 
negatives from CD18 KO 
line 
CD11a KO 
(B6.129S7-
Itgaltm1Bll/J) 
Global knockout for Itgal Conventional Jackson Laboratories (cat # 005257) 
CD11b KO 
(B6.129S4-
Itgaltm1Myd/J) 
Global knockout for Itgam Conventional Jackson Laboratories (cat # 003991) 
CD11c KO Global knockout for Itgax Conventional 
Gift from Prof Christie 
Ballantyne, Baylor 
College of Medicine, 
Texas, USA 
CD11d KO 
(B6.129S7-
Itgadtm1Bll/J) 
Global knockout for Itgad Conventional Jackson Laboratories (cat # 005258) 
CD18 KO 
(B6.129s7-
Itgb2tm2Bay/J) 
Global knockout for Itgb2 Individually ventilated cages 
Jackson Laboratories (cat 
# 003329) 
CD11a/CD11c Het Heterozygous for Itgal and Itgam Conventional 
Bred in-house by crossing 
CD11a and CD11c KO 
strains 
OT-II 
T cells express a T cell 
receptor that specifically 
recognises chicken 
ovalbumin peptide (323-
339) in the context of MHC 
Class II molecule I-Ad 305 
Conventional Bred in-house 
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2.2 Cell Isolation 
Cells were counted by trypan blue exclusion using a haemocytometer. 
2.2.1 Lymphoid Organs 
Cells were isolated from the spleen, mesenteric lymph nodes, mediastinal lymph 
nodes peripheral lymph nodes (inguinal, brachial and axillary) and thymus by 
mashing the tissue between two pieces of 45µm nylon filtration fabric NITEX 
(Cadisch) in Hank’s balanced salt solution (HBSS) (Gibco) supplemented 2% foetal 
calf serum (FCS) (Gibco). When DCs were going to be analysed, the organs were 
chopped into small pieces using a scalpel then digested in HBSS with 2% FCS and 
2.68mg/ml collagenase D (Roche) in a shaking incubator at 37°C, 220rpm for 
30mins prior to mashing. Cells were then pelleted by centrifugation at 400xg for 
5min at 4°C. Splenocytes were then red blood cell (RBC) lysed using 1ml RBC lysis 
buffer (eBioscience) incubated at room temperature for 2.5min before washing in 
PBS.  
2.2.2 Blood 
Up to 300μl of blood was collected by cardiac puncture into 10µl of 0.5M EDTA. 
RBCs were lysed by adding 1ml RBC lysis buffer (eBioscience) for 2.5min at room 
temperature then cells were washed in PBS. This process was repeated 3-4 times, 
until the cell pellets were no longer visibly red.  
2.2.3 Lungs 
Lungs were digested as described previously306. Briefly, lungs were perfused with 
10ml of 2mM EDTA prior to dissection then cut into small pieces. The tissues were 
incubated with 1.34mg/ml collagenase D (Roche) and 100μg/ml DNase (Sigma 
Aldrich) at 37°C, 200rpm for 40min then mashed through a 70μm cell strainer.  
2.2.4 Small Intestine and Colon 
SI and colons were washed in HBSS 2% FCS then fat and Peyer’s patches were 
removed. The intestines were cut longitudinally, washed in HBSS 2% FCS to 
remove luminal contents then cut into 0.5cm segments. For SI, segments were 
incubated in 10ml of 2mM EDTA/HBSS at 37°C for 10mins then the supernatant 
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was collected by filtering through 45μM nylon filtration fabric NITEX (Cadisch; SI 
only). The SI supernatant contains cells from the epithelial layer. This was repeated 
a further two times then the segments were washed using 10ml of warmed HBSS. 
SI and colon segments were digested using 0.625mg/ml Collagenase V (Sigma 
Aldrich), 0.425mg/ml Collagenase D (Roche), 1mg/ml Dispase (Gibco) and 30ug/ml 
DNase (Roche) at 37°C, shaking at 160rpm for 25mins (SI) or 45mins (colon). 
Following digestion, the cell suspension was filtered through a 100μm followed by 
40μm cell strainer. 
2.2.5 Skin 
Both ears were removed and cut into small pieces before incubating with 2mg/ml 
Collagenase IV (Sigma Aldrich), 2mg/ml Hyaluronidase (Sigma Aldrich) and 100 
U/ml DNase (Invitrogen) for 40min at 37°C, shaking at 180rpm. After digestion, 2ml 
of complete RPMI was added to stop the reaction and the tissues were dissociated 
in gentleMACS C-tubes (Miltenyi Biotec) using the gentleMACs dissociator 
manufacturer program B.01 twice. Samples were then mashed through a 100μm 
cell strainer to obtain a cell suspension.  
2.2.6 Gingiva 
Gingival digest protocol was adapted from Mizraji et al., (2013)307. Briefly, the whole 
palette was collected and minced in PBS 2% FCS then digested using 2mg/ml 
Collagenase II (Lorne Laboratories) and 1mg/ml DNase I (Sigma Aldrich) for 20min, 
37°C, shaking at 200rpm. 5mM EDTA was added and the gingivae were incubated 
for a further 10min. The samples were then filtered through a 70μm cell strainer.  
2.2.7 Uterus 
The uterus was digested using Multi Dissociation Kit 1 (Miltenyi Biotec) as per the 
manufacturer’s instructions. Briefly, tissue was minced then incubated with 2.5ml 
incomplete RPMI (without added FCS or antibiotics), 100µl Enzyme D, 50µl Enzyme 
R and 12.5µl Enzyme A at 37°C, shaking at 200rpm for 20mins. Tissues were 
dissociated in gentleMACS C-tubes (Miltenyi Biotec) using the gentleMACs 
dissociator manufacturer program C then incubated for a further 20mins and the 
dissociation repeated. Samples were then mashed through a 70μm cell strainer to 
obtain a cell suspension. 
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2.2.8 Bone Marrow 
Bone marrow cells were obtained by cutting the ends off the femoral and tibia bones 
and flushing PBS through using a 26G needle. Cells were then pelleted by 
centrifugation at 400xg for 5min at 4°C. Cells were then RBC lysed using 1ml RBC 
lysis buffer (eBioscience) incubated at room temperature for 2.5min before washing 
in PBS. 
2.3 Generation of bone marrow-derived dendritic cells 
(BMDCs) 
BMDCs were generated by culturing bone marrow cells obtained from femoral and 
tibia bones in 10ng/ml GM-CSF (Peprotech) and 20ng/ml IL-4 (Peprotech). Total 
bone marrow suspensions were cultured without RBC lysis. Cells were plated into 
10cm non-treated tissue culture plates and fed on days 3 and 6 of culture. BMDCs 
were harvested using 4mM EDTA incubated for 10min at 37°C. To activate BMDCs 
50ng/ml LPS was added to the culture overnight. For flow cytometry analysis, 
BMDCs were gates as shown in Figure 2-1.  
 
Figure 2-1 Gating strategy for BMDCs 
Representative plots from WT BMDCs cultured without LPS. 
2.4 BMDC-T-Cell Co-Culture 
BMDCs were either stimulated with 50ng/ml LPS or left unstimulated overnight then 
pulsed with 5μg/ml OVA323-339 peptide (Sigma-Aldrich) for 90mins. Lymph nodes 
from OT-II mice were pooled and the tissues disrupted using the end of a 2.5ml 
syringe in a 40μm cell strainer to produce a single cell suspension. Cells were 
pelleted by centrifugation at 380xg for 5min at 4°C then re-suspended in PBS. Using 
the same process spleens from OT-II mice were also pooled then re-suspended in 
RBC lysis buffer (1ml per spleen) and incubated at room temperature for 2.5mins 
Chapter 2 Materials and Methods 
 
  54 
then washed in PBS. Lymph node and spleen cells were pooled then CD4+ T cells 
purified by negative selection using EasySepTM Mouse CD4+ T Cell Isolation Kit 
(Stemcell Technologies) according to the manufacturer’s instructions. This provided 
CD4+ T cells of a 95-97% purity. The isolated CD4+ T cells were then labelled with 
1μM CFSE (Life Technologies) for 20mins at 37°C. Unbound dye was removed by 
washing cells twice in complete RPMI. Peptide-loaded BMDCs were cultured with 
the CFSE-labelled CD4+ OT-II T cells in a ratio of 1:10 (using approx. 0.7x106 T cells 
per well) in a total volume of 1ml in 24 well plates. Cells were harvested for flow 
cytometry analysis on day 1 and day 3 of culture.  
2.5 Flow Cytometry 
To control for background staining, fluorescence minus one (FMO) controls were 
used as indicated in the figures. For β2 integrin α chain staining, CD18 KO mice 
were used as a negative control.  
2.5.1 Extracellular Staining 
Cells were pelleted by centrifugation at 400xg for 5min at 4°C then re-suspended in 
PBS and transferred into round-bottomed 96 well plates for staining. Typically, 1x106 
cells were used for BMDCs and 5x106 cells for ex vivo cell suspensions. Cells were 
washed in PBS, incubated in viability dye for 30mins at 4°C prior to extracellular 
staining then washed again in PBS. Cells were then re-suspended in 50μl Fc block 
(made in-house using supernatant from 2.4G2 cell line) and incubated with 
appropriate antibodies in FACS Buffer (PBS 2% FCS, 1mM EDTA) for 30min at 4°C, 
with the exception of CCR7 staining that was done at 37°C for 15min. Antibodies 
used are listed in Table 2-2. Cells were washed in PBS then re-suspended in 200μl 
FACS Buffer before running on BD LSRII, BD LSR Fortessa or BD FACSCelesta. 
Data was analysed using FlowJo software (Treestar).  
2.5.2 Intracellular Staining 
For detection of intracellular cytokines, cells were stimulated with 10ng/ml PMA 
(Sigma Aldrich), 500ng/ml ionomycin (Sigma Aldrich) and GolgiPlug 1:1000 (BD 
Biosciences) for 4h at 37°C. Cells were fixed in 100μl Cytofix/Cytoperm (BD 
Biosciences) at 4°C for 20min then washed with 100μl Perm/Wash (BD 
Biosciences). Cells were then stained with appropriate antibodies in Perm/Wash for 
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1h at room temperature. Cells were washed in PBS then re-suspended in 200μl 
FACs Buffer before acquisition. 
For intracellular staining of transcription factors, cells were fixed using 100µl Foxp3 
Transcription Factor Fixation/Permeabilization buffer (eBioscience) for 1h at room 
temperature. Cells were then washed with 100µl permeabilization buffer 
(eBioscience) and stained with appropriate antibodies in permeabilization buffer for 
1h at room temperature. Cells were washed in PBS then re-suspended in 200μl 
FACS Buffer before acquisition. 
2.5.3 Apoptosis Marker Staining 
For staining with Annexin V and 7AAD, single cell suspensions were washed in PBS 
following extracellular staining, then stained in Annexin V Binding Buffer (Biolegend) 
with Annexin V and 7AAD antibodies in a total volume of 100µl for 15mins at room 
temperature. 200µl of annexin buffer was then added to samples prior to running.  
2.5.4 Phosphoflow 
For staining of phosphorylated proteins, 50µl of single cell suspensions containing 
4x106 cells from the spleen, and each lungs sample was re-suspended in a total of 
200µl, were exposed to 50µl of stimulus for the appropriate time in incomplete RPMI 
at 37°C. Cells were immediately fixed by adding 60µl of 4% paraformaldehyde 
(Sigma Aldrich) (final concentration of 1.5%) and incubating at room temperature 
for 10mins, then washed twice using FACS buffer. The cells were then 
permeabilised with 100µl of ice-cold 100% methanol at 4°C for 30mins, then washed 
twice in FACS buffer. Extracellular and intracellular markers were then stained using 
appropriate antibodies in FACS buffer for 2h at room temperature. Cells were 
washed in FACS buffer then re-suspended in 200μl FACS Buffer before acquisition.  
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Table 2-2 Antibodies used for flow cytometry 
Marker Fluorochrome Clone Conc. Used Manufacturer 
7AAD - - 5µl/sample BD Biosciences 
Annexin V APC - 5µl/sample Biolegend 
B220 (CD45R) APC RA3-7B2 1:200 BD Biosciences 
Bcl2 FITC Bcl/10C4 1:100 Biolegend 
BrdU FITC B44 1:10 BD Biosciences 
CCR7 (CD197) PE Cy7 4B12 1:100 eBioscience 
CD11a APC M17/4 1:200 Biolegend 
CD11b PE Cy7 M1/70 1:200 eBioscience 
CD11b Superbright 600 M1-70 1:200 eBioscience 
CD11c PerCP Cy5.5 N418 1:200 eBioscience 
CD11c APC eFluor780 N418 1:200 eBioscience 
CD121a (IL-1βR) APC JAMA-147 1:200 Biolegend 
CD127 (IL-7R) BV510 A7R34 1:200 Biolegend 
CD18 PE M18/2 1:200 Biolegend 
CD19 eFluor 450 eBio103 1:200 eBioscience 
CD24 PE Cy7 M1/69 1:200 BD Biosciences 
CD25 APC Cy7 PC61 1:200 Biolegend 
CD27 PE Dazzle594 LG.3A10 1:200 Biolegend 
CD27 BV421 LG.3A10 1:200 Biolegend 
CD3 AlexaFluor 700 17A2 1:200 BioLegend 
CD3 BV785 17A2 1:100 BioLegend 
CD4 eFluor 450 RM4-5 1:200 eBioscience 
CD4 PerCP Cy5.5 GK1.5 1:200 Biolegend 
CD40 APC 1C10 1:200 eBioscience 
CD44 PerCP Cy5.5 IM7 1:200 eBioscience 
CD44 APC IM7 1:200 eBIoscience 
CD44 eFluor 780 IM7 1:400 eBioscience 
CD45 PE 30-F-11 1:200 BD Biosciences 
CD45RB APC/Cy7 C36-16A 1:200 Biolegend 
CD54 (ICAM-1) PE/Cy7 YN1/1.74 1:200 Biolegend 
CD54 (ICAM-1) FITC 3E2 1:200 BD Biosciences 
CD62L PE Mel-14 1:200 BD Biosciences 
CD64 BV421 X54-5/7.1 1:200 Biolegend 
CD69 PerCP Cy5.5 H1.2F3 1:200 eBioscience 
CD8  PE Cy7 53-6.7 1:200 eBioscience 
CD80 FITC 16-10A1 1:200 BD Biosciences 
CD86 PE GL1 1:200 BD Biosciences 
Fas (CD95) PE Cy7 Jo2 1:200 BD Biosciences 
Gr1 (Ly-6G) APC IA8 1:200 Biolegend 
IFNγ PE/Cy7 XMG1.2 1:100 BioLegend 
IL-17A PE TC11-18H10 1:100 BD Biosciences 
IL-17A BV605 TC11-18H10 1:100 BD Biosciences 
IL-17F PE eBIO 18F10 1:100 eBioscience 
IL-23R PE 12B2B64 1:200 Biolegend 
Ki67 PE/Cy7 16A8 1:100 BioLegend 
MHC II APC Cy7 M5114 1:200 eBioscience 
NK1.1 AF700 PK136 1:200 Biolegend 
NK1.1 e450 PK136 1:200 eBioscience 
pSTAT3 (pY705) AlexaFluor 647 4/P-Stat3 5µl/sample BD Biosciences 
pSTAT5 (pY694) PE 47/Stat5 5µl/sample BD Biosciences 
RORγt APC AFKJS-9 1:100 eBiosciences 
Tbet PE Cy7 4B10 1:100 eBiosciences 
TCRβ APC H57-597 1:200 BD Biosciences 
TCRβ PerCP Cy5.5 H57-597 1:200 eBioscience 
TCRγδ FITC UC7-13D5 1:200 eBioscience 
TCRγδ BV650 GL3 1:200 BD Biosciences 
Viability eFluor 506 - 1:1000 eBioscience 
Vγ1.1 (Vγ1) BV421 2.11 1:200 BD Biosciences 
Vγ2 (Vγ4) FITC UC3-10A6 1:200 BioLegend 
Vγ2 (Vγ4) PE UC3-10A6 1:200 Biolegend 
Vγ3 (Vγ5) APC 536 1:200 BioLegend 
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2.6 Fluorescence-Activated Cell Sorting (FACS) 
For isolation of γδ T cells for RT-PCR analysis, cells from CD18 KO spleens were 
first pre-enriched for T cells using EasySepTM Mouse T Cell Isolation Kit (Stemcell 
Technologies), providing CD3+ cells of 90% purity with 10-40% expressing TCRγδ. 
Cells were then sorted using a FACS Aria IIU or FACS Aria III (BD Biosciences). 
Samples were sorted in FACS buffer gated on live, CD3+TCRγδ+ then Vγ1-Vγ4- cells 
into PBS supplemented with 50% FCS.  
2.7 BrdU Labelling and Staining 
Mice were injected intraperitoneally with 1mg bromodeoxyuridine (BrdU) (Sigma 
Aldrich) in 200µl of PBS. From the day following injection, mice were fed 0.8mg/ml 
BrdU in the drinking water supplemented with 20% sucrose to make it more 
palatable. Fresh drinking water containing BrdU was given every other day and mice 
were culled after 7 days.  
Tissues from BrdU-treated mice were processed as described in the cell isolation 
section, and then stained as described for viability and extracellular markers. After 
washing in PBS, cells were fixed using 100µl cytofix/cytoperm (BD Biosciences) for 
20mins on ice. Cells were washed in 100µl permwash (BD Biosciences) then 
incubated in 100µl cytoperm permeabilization buffer plus (BD Biosciences) for 
10mins on ice. After washing in 200µl permwash, samples were re-fixed in 100µl 
cytofix/cytoperm for 5mins on ice and washed again in permwash. To expose the 
incorporated BrdU, cells were incubated with 100µl of DNase (Sigma Aldrich) for 1h 
at 37°C. Samples were then washed in permwash and stained with anti-BrdU and 
any other intracellular antibodies for 1h at room temperature. After washing again 
with permwash, cells were re-suspended in 200μl FACS Buffer for acquisition. 
2.8 ELISAs 
Cytokine concentrations were measured by enzyme-linked immunosorbent assay 
(ELISA) from serum and tissue supernatant samples. Serum was isolated from 
mouse blood by allowing the blood to clot at room temperature for up to 6h then 
samples were centrifuged at 133,000rpm for 5min and the serum removed. Tissue 
supernatants were collected by incubating the spleen, lungs or uterus in 2-300µl of 
complete RPMI at 37°C for 4h then the tissue was removed.  
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For all ELISAs, absorbance was measured at 450nm and 570nm using a Sunrise 
Absorbance Reader (Tecan). The reading A570 was subtracted from A450 and the 
background was removed by subtracting the blank reading from all samples. 
Cytokine concentration was determined by extrapolating the unknowns from a 
standard curve using GraphPad Prism software. The limits of detection were: IL-
17A 62.5pg/ml, IL-1β 16pg/ml, IL-7 6.3pg/ml and IL-23 8pg/ml.  
2.8.1  IL-17A 
For detection of IL-17A, Costar 96 well high-binding assay plates (Corning) were 
coated with 50µl of 1µg/ml IL-17A capture antibody (BD Biosciences) in PBS 
overnight at 4°C. Plates were washed twice in PBS-T (PBS 0.05% Tween-20) then 
blocked with 200µl of 1% BSA (Sigma Aldrich) in PBS for 2h at room temperature. 
Plates were washed twice in PBS-T then 50µl of samples and standards added for 
2h at room temperature. The top standard was added at 2000pg/ml and 2-fold serial 
dilutions performed across the plate. Plates were washed 3 times in PBS-T then 
50µl of 1µg/ml IL-17A biotin detection antibody (BD Biosciences) in 0.5% BSA/PBS 
was added and incubated for 1h at room temperature. Plates were washed 3 times 
in PBS-T then 50µl of Extravidin-peroxidase (Sigma Aldrich) diluted 1:10,000 in PBS 
was added per well for 45mins at room temperature. Plates were washed 4 times in 
PBS-T then 50µl of SureBlueTMB substrate (KPL) was incubated in the dark. Once 
the blue colour developed, typically in 10min, the reaction was stopped by adding 
50µl of 10% H2SO4.  
2.8.2 IL-1β and IL-23 
Levels of IL-1β and IL-23 were detected using Mouse IL-1β ELISA MAXTM Deluxe 
and Mouse IL-23 ELISA MAXTM Deluxe kits (Biolegend), respectively, according to 
the manufacturer’s instructions.  
2.8.3 IL-7 
Levels of IL-7 were detected using Mouse IL-7 Quantikine ELISA kit (R&D Systems) 
according to the manufacturer’s instructions.  
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2.9 Adoptive Transfer of Cells 
2.9.1 OT-II T cell and BMDC Transfer 
BMDCs and CD4+ OT-II T cells were prepared as described in sections 1.3 and 1.4. 
2x106 CD4+ OT-II T cells were transferred intravenously into WT recipients. BMDCs 
were stimulated with 50ng/ml LPS overnight then pulsed with 5μg/ml OVA323-339 
peptide (Sigma-Aldrich) for 90mins. On the day following the T cell transfer, 1.5x106 
BMDCs were injected subcutaneously into one footpad of recipient mice and the 
contralateral was left as a control. The popliteal lymph nodes were then analysed 1 
or 3 days following the BMDC transfer.  
2.9.2 Total T Cell Transfer 
T cells were isolated from CD18 KO spleens using EasySepTM Mouse T Cell 
Isolation Kit (Stemcell Technologies) according to the manufacturer’s instructions. 
T cells were then labelled with 1μM CFSE (Life Technologies) in PBS for 20mins at 
37°C. Unbound dye was removed by washing cells twice in complete RPMI. 
Labelled T cells were re-suspended in PBS then 2x106 cells were transferred 
intravenously into WT or CD18 KO hosts. Mice were culled 1, 4 or 8 days following 
the T cell transfer. 
2.10 Static Adhesion Assay 
ICAM-1 (6μg/ml, R&D Systems), Fibronectin (10μg/ml, R&D Systems) or PBS were 
coated onto Costar 96 well high-binding assay plates (Corning) overnight at 4°C. 
The following day, the plate was washed twice in PBS then blocked with 1% milk in 
PBS for 1h 15mins at 37°C. The plate was again washed twice in PBS then put on 
ice. BMDCs were re-suspended at 0.4x106 cells/ml in adhesion medium (RPMI, 
0.1%BSA, 20mM HEPES pH 7.25 and 2mM MgCl2) then 400µl was added per well 
in duplicate or triplicate and incubated on ice for 8mins to allow cells to settle. The 
plate was then incubated at 37°C for 15mins for cells to adhere before being placed 
upside down in 2.5L of PBS 2mM MgCl2 for 50mins at RT to remove any un-adhered 
cells. Liquid was removed from the wells, leaving 50μl. Adherent cells were then 
lysed with 3mg/ml p-Nitrophenyl Phosphate (PNPP) (Calbiochem) in 1% Tx-
100/50mM acetate buffer pH5 incubated at 37°C for 60mins then 50μl of 1M NaOH 
was added to stop the reaction. Absorbance was measured at 405nm using a 
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Sunrise Absorbance Reader (Tecan). A total plate was also prepared by pelleting 
400µl of BMDCs at 0.4x106 cells/ml by centrifugation at 300xg for 1min then re-
suspending cells in 200μl PBS. 50μl of cells were added to the total plate in triplicate 
then they were lysed, and absorbance read as with the experimental plate. The 
absorbance from the total plate was used to calculate the percentage adhesion for 
each sample.  
2.11 Polymerase Chain Reaction (PCR) 
All PCR and cDNA reactions were carried out using an S1000 thermal cycler 
(BioRad) as detailed in the sections following 
Table 2-3 Primers used for PCR 
Primer Sequence 5’ to 3’ 
Dock2 forward GAC CTT ATG AGG TGG AAC CAC AAC C 
Dock2 reverse GAT CCA AAG ATT CCC TAC AGC TCC AC 
Vγ1 forward ATGCTGCTCCTGAGATGGC 
Vγ1 reverse TTATGAACGTTGATCATCACAGGAC 
Vγ2 forward TTGGTACCGGCAAAAAACAAATCA 
Vγ2 reverse CAATACACCCTTATGACATCG 
Vγ4 forward ATGAAGAACCCTGGCTCACAAG 
Vγ5 forward ATGTCAACCTCTTGGCTTTTTCTTC 
Vγ6 forward ATATATGTTTAAACGCCGCCACCATGGGGCTTCTGCTACAAGTC 
Vγ6 reverse ATATATGCGGCCGCTTAGGATTTCTTCTCATTGCCACAG 
Vγ7 forward ATGCTGTGGGCTCTGGC 
Vg common reverse TTAGGATTTCTTCTCATTGCCACAG 
Vδ1 forward AATAGCAATTCTACTGATGGTGG 
Vδ2 forward AGTCCTCAGTCTCTGACAATC 
Vδ3 forward CCAGATTCAATGGAAAGTAC 
Vδ4 forward GTACAAACAGCAAGGAGGGCAGG 
Vδ5 forward CCAGACAGTGGCAAGCGGCACTG 
Vδ6 forward TCAAGTCCATCAGCCTTGTC 
Vδ reverse CGAATTCCACAATCTTCTTG 
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2.11.1 Genomic DNA Preparation 
The protocol for isolation of genomic DNA was adapted from Truett et al., 2000308. 
Clips of 1-2mm were cut from mouse ear or tail and incubated in 100µl alkaline lysis 
reagent (25mM NaOH, 0.2mM EDTA, pH 12) for 45mins at 95°C. 100µl of 
neutralisation reagent (40mM Tric-HCl) was then added and samples were stored 
at -20°C prior to use.  
2.11.2 RNA Purification 
RNA was purified from single cell suspensions using RNeasy Mini Kit (Qiagen) 
according to manufacturer’s instructions and eluted in 30µl of RNase-free water. 
Quantification of RNA was carried out using Nanodrop 1000 spectrophotometer 
(Thermo Fisher Scientific). Samples were stored at -20°C prior to use.  
2.11.3 cDNA Synthesis 
Synthesis of cDNA was carried out using High-Capacity RNA-to-cDNA Kit (Applied 
Biosystems) according to the manufacturer’s instructions. The quantity of RNA used 
for the cDNA reaction was normalised to the maximum that could be used 
(concentration in 9µl) of the sample with the lowest quantity of RNA. Samples were 
incubated for 60mins at 37°C, 95°C for 5mins, then held at 4°C. Resulting cDNA 
samples were stored at -20°C.   
2.11.4 Dock2Hsd PCR 
The PCR to detect the mutated form of Dock2 (Dock2Hsd) was adapted from 
Mahajan et al., (2017)309 with primer sequences from Yasuda et al., (2014)310, listed 
in Table 2-3. Each reaction contained 1X ThermoPrime ReddyMix PCR Master Mix 
(Thermo Fisher Scientific), 5µM primers, 50mM MgCl2 (Thermo Fisher Scientific), 
2µl genomic DNA, made up to 25µl with nuclease-free water. Initial denaturation for 
3min at 94°C, followed by 35 cycles of 94°C 30s, 54°C 45s, 72°C 45s and then final 
extension for 2min at 72°C. The expected band size for the Dock2Hsd copy number 
variant is 305bp.  
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2.11.5 Vγ/Vδ Chain RT-PCR 
Expression of Vγ and Vδ chains was determined from sorted γδ T cells by reverse 
transcription PCR (RT-PCR). Primer sequences (Table 2-3) for Vγ1, Vγ4, Vγ5 and 
Vγ7 were kindly provided by Pierre Vantourout (Kings College London) and for Vγ6 
by Leticia Monin Aldama (Francis Crick Institute, London). Sequences for Vγ2 and 
all Vδ chains obtained from Andrew et al., (2005)311. Primers were purchased from 
Integrated DNA Technologies (IDT). Each reaction contained 2µl template cDNA, 
1X Phusion HF buffer (Thermo Fisher Scientific), 0.2mM dNTPs (Invitrogen), 0.3µM 
primers, 0.02U/µl Phusion DNA polymerase (Thermo Fisher Scientific), 3% DMSO, 
2mM MgCl2 (Thermo Fisher Scientific) for Vγ6 reaction only, made up to 20µl with 
nuclease-free water. The protocol for gene amplification was initial denaturation for 
30s at 98°C, followed by 35 cycles of 98°C 10s, x°C 30s, 72°C 30s and then final 
extension for 10min at 72°C. The annealing temperatures (x°C) are listed in Table 
2-4.  
Table 2-4 Annealing Temperatures for Vγ and Vδ RT-PCR 
Gene Temperature (°C) 
Vγ1 66 
Vγ2 55 
Vγ4 66 
Vγ5 50 
Vγ6 66 
Vγ7 68 
Vδ1 60.5 
Vδ2 60.5 
Vδ3 55 
Vδ4 60.5 
Vδ5 55 
Vδ6 60.5 
 
2.12 Agarose Gel Electrophoresis 
Gel electrophoresis was used to separate DNA fragments. Gels were 1% UltraPure 
agarose (Invitrogen), 1X SYBR safe gel stain (Invitrogen) in 1X Tris Acetate-EDTA 
(TAE) buffer (Thermo Fisher Scientific). Gels were run at 120V for 30mins and 
fragments visualised using Gel DocTM XR+ system (BioRad).  
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2.13 Statistical Analysis 
Data represents mean + standard deviation, or where individual data points are 
shown the mean is displayed. All statistical analyses were performed using 
GraphPad Prism software. Student t test for comparison of 2 groups, one-way 
ANOVA for comparison of one variable for more than 2 groups and two-way ANOVA 
for comparison of two variables for more than 2 groups. P values shown as *p<0.05, 
** p<0.01, ***p<0.005, ****p<0.0001. 
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Chapter 3 Characterisation of β2 integrin-
mediated regulation of dendritic cells and the 
impact on interactions with T cells 
3.1 Introduction 
DCs are innate leukocytes responsible for linking innate and adaptive immunity. The 
main function of DCs is to present antigen to T cells, resulting in either activation of 
an immune response or induction of tolerance312,313. This activation or inhibition is 
dependent on factors present in the DC microenvironment. In the presence of pro-
inflammatory cytokines such as TNF-α or microbial factors such as pathogen-
associated molecular patterns (PAMPs) DCs are likely to activate other immune 
cells165. The induction of tolerance tends to occur both in the presence of anti-
inflammatory cytokines such as IL-10 and under steady state conditions (absence 
of pathogens or cytokines) when self-antigen is presented by immature DCs165,314. 
This balance between immune activation versus the induction of tolerance is 
particularly important in the context of autoimmune disease, where there is an 
inappropriate inflammatory response due to loss of tolerance to self-antigens. An 
increased knowledge of DC regulation is therefore required to improve our 
understanding of what controls DC activation. This will allow the manipulation of DC-
induced activation versus tolerance, which can be used to improve responses to 
infection/cancer or dampen responses in autoimmune disease.  
One way in which DCs are regulated is through their integrin receptors. In particular, 
the β2 integrins are a family of leukocyte-specific adhesion molecules expressed on 
DCs. β2 integrins all express the β2 chain (CD18) hybridised to one of four α chains: 
CD11a (αL), CD11b (αM), CD11c (αX) or CD11d (αD), all of which are expressed on 
DCs27,37,60,315. β2 integrins have been shown to negatively regulate TLR-mediated 
responses: Macrophages and DCs from CD18 deficient mice were hyperresponsive 
to stimulation by TLR2, 4 and 9, shown by enhanced production of IL-6 and IL-12182. 
Specific knockout of CD11b also resulted in an enhanced production of TNF, IL-6 
and IFNβ in macrophages treated with agonists for TLR3, 4 and 9183. However, there 
is contrasting evidence that supports the role of CD11b in positive regulation of 
TLR4 responses shown by Ling et al., that CD11b KO BMDCs had impaired 
cytokine production in response to LPS185. It has also been shown that β2 integrins 
can regulate DCs in the absence of TLR stimulation. In mice that lack functional β2 
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integrin receptors (beta2TTT/AAA integrin knock-in mice), BMDCs expressed higher 
levels of activation markers irrespective of their maturity state73. This was also true 
for knock-in DCs in vivo, as they expressed higher levels of CD86 both in the 
absence and presence of an inflammatory stimulus73. This evidence supports the 
important role for β2 integrins in regulating DC responses. 
In addition to their role in regulating DC activation, β2 integrins are also implicated 
in the migration of DCs. BMDCs generated from mice with functionally-deficient β2 
integrin receptors expressed higher levels of the chemokine receptor CCR7, which 
mediates DC migration to LNs73. These beta2TTT/AAA integrin knock-in mice also 
displayed an increased percentage of DCs in the spleen, peripheral and mesenteric 
lymph nodes under steady state conditions73. The increase was due to a higher 
proportion of CD103+ and CD11b+ migratory DCs. This data suggests that in the 
absence of functional β2 integrins, DCs are more migratory and therefore integrins 
may play a role in restricting DC migration in vivo. Other work has suggested that 
DC migration to LNs is independent of β2 integrins. The transfer of WT and integrin-
deficient LPS-matured BMDCs (lacking β1, β2, β3 and β7) showed equivalent 
migration to LNs and similar localisation within the T cell zone72. Based on this data, 
β2 integrins can influence the migration of DCs, although potentially in a context-
dependent manner, and may differ for immature versus mature DCs. 
There is clear evidence showing that β2 integrins directly influence the activation of 
DCs and may influence their migration. In addition to this, β2 integrins expressed on 
DCs have been implicated in modulating the subsequent priming of T cells. The 
transfer of peptide-loaded BMDCs induces a Th1 response, demonstrated by IFNγ 
production, and this was enhanced when β2 integrin signalling-deficient BMDCs 
were transferred compared to WT73. In line with this, the co-culture of DCs with 
constitutively active CD11a induced lower levels of CD4 T cell proliferation than WT 
DCs and reduced IFNγ production and T-bet expression, indicative of an impaired 
Th1 response88. Similarly, magnesium-induced activation of β2 integrins on DCs 
impaired their ability to induce T cell proliferation and this effect was found to be 
CD11b-dependent97. Taken together, this data demonstrates that alterations in β2 
integrins on DCs can influence the outcome of the subsequent T cell response.  
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There is clear evidence that β2 integrins play an important role in the regulation of 
dendritic cell function, but it is not yet understood which subunits are responsible for 
this regulation and how these individually impact the subsequent T cell response. 
The aims of this chapter were: 
1. To determine which of the β2 integrins (CD11a, CD11b, CD11c or CD11d) 
regulate DC activation in vitro.  
2. Examine whether this β2 integrin-mediated regulation of DCs also occurs in 
vivo. 
3. Assess the impact of β2 integrin loss on DC interactions with T cells and 
subsequent T cell priming.  
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3.2 Results 
3.2.1 CD11a and CD11c KO BMDCs display enhanced activation 
markers and reduced ligand binding 
It has previously been shown that the absence of functional β2 integrin receptors 
leads to elevated activation marker expression on BMDCs, but the specific subunits 
responsible for this altered phenotype are unknown73. To determine the loss of 
which β2 integrin subunit/s mediate this activated phenotype, BMDCs were 
generated from WT, CD11a KO, CD11b KO, CD11c KO and CD11d KO mice. The 
BMDCs were either left unstimulated (resting/immature DCs) or stimulated with LPS 
overnight (activated/mature DCs) before assessing cell surface marker expression 
by flow cytometry.  
First, integrin expression on BMDCs was measured to check whether the absence 
of one β2 integrin receptor had an impact on expression of the others. The β2 integrin 
family members have a level of redundancy due to their overlapping ligand 
repertoire, therefore another subunit may be upregulated to compensate for integrin 
loss. Levels of the common β2 chain (CD18), α chains (CD11a, CD11b and CD11c) 
and the β2 ligand ICAM-1 were measured. CD11d expression was not measured, 
as there are no murine antibodies currently available.  
Expression of CD18 was significantly reduced in all immature β2 integrin KO 
BMDCs, as expected, and in mature CD11a and CD11c KO BMDCs compared to 
WT (Figure 3-1). It is unclear why the levels of CD18 on mature CD11b and CD11d 
KO BMDCs are equivalent to WT, as CD11b is expressed highly on BMDCs, 
therefore it was expected the loss of this subunit would reduce CD18 expression. 
Levels of CD11a were similar in all genotypes other than CD11a KO BMDCs in the 
absence of stimulus, suggesting that CD11a expression is not altered by loss of 
other integrin subunits in resting BMDCs. However, after activation with LPS, CD11a 
expression was significantly increased in CD11b and CD11c KO BMDCs. This may 
suggest that in the absence of CD11b or CD11c, CD11a is upregulated as a 
compensatory mechanism in response to TLR4-mediated signalling. Surprisingly, 
expression of CD11b was significantly downregulated in all β2 integrin KO BMDCs, 
regardless of activation status. Over 90% of WT BMDCs express CD11b316 and my 
data implies that this expression may be partially controlled by other β2 integrins. In 
Chapter 3 Characterisation of β2 integrin-mediated regulation of dendritic 
cells and the impact on interactions with T cells 
 
  68 
contrast to this, the expression of CD11c remained unchanged in the absence of 
CD11a, CD11b or CD11d.  
The β2 integrin ligand ICAM-1 is expressed on DCs and can mediate their 
interactions with T cells73. Levels of ICAM-1 were significantly higher on CD11a KO 
BMDCs regardless of maturation status and were upregulated on mature CD11c 
KO BMDCs. This could indicate a feedback loop between the receptor (CD11a or 
CD11c) and ligand (ICAM-1) expression. The increased expression of ICAM-1 is 
likely to mediate the binding of DCs to β2 integrins expressed on T cells and may 
partially overcome the loss of interactions that occur due to the absence of β2 
integrins on DCs that would normally bind to ICAM-1 on T cells. Additionally, the 
expression of ICAM-1, CD18 and the α subunits were unchanged by LPS-induced 
maturation.  
It can be concluded that the loss of any one β2 integrin subunit in BMDCs results in 
a significant reduction in CD11b expression. Additionally, the expression of ICAM-1 
was elevated in CD11a and CD11c KO BMDCs. These changes must be taken into 
consideration when interpreting the results from experiments using BMDCs, as 
altered expression of integrin subunits other than the one that is targeted by the KO 
could contribute to any changes found in their phenotype and/or function. 
Chapter 3 Characterisation of β2 integrin-mediated regulation of dendritic 
cells and the impact on interactions with T cells 
 
  69 
 
Figure 3-1 Expression of CD11b is reduced on all β2 integrin-deficient BMDCs and the loss 
of CD11a or CD11c induces upregulation of ICAM-1.  
WT, CD11a KO, CD11b KO, CD11c KO and CD11d KO BMDCs were cultured with or without 
50ng/ml LPS overnight then cell surface marker expression was measured by flow cytometry. Cells 
were gated on MHC II+. (A) Representative plots of WT BMDCs -LPS. (B) Expression of β2 
integrins and ICAM-1 on BMDCs. Values shown are relative to WT -LPS from individual 
experiments. WT n=8, CD11a/b/c/d KO n=4. Data from a minimum of 2 independent experiments. 
Data represents mean + SD. Statistical differences were determined using a two-way ANOVA. 
*p<0.05, ** p<0.01, ***p<0.005, ****p<0.0001.  
Chapter 3 Characterisation of β2 integrin-mediated regulation of dendritic 
cells and the impact on interactions with T cells 
 
  70 
After identifying that β2 integrin-deficient BMDCs lack expression of the expected 
integrin subunit but also show reduced levels of CD11b, the activation status of the 
cells was then analysed. The aim was to characterise which β2 integrin subunit/s 
are responsible for regulating BMDC activation. DCs present peptide to CD4 T cells 
via MHC II, which in combination with co-stimulatory signals via receptors such as 
CD40, CD80 and CD86 induces T cell activation. Assessment of these markers on 
β2 integrin-deficient BMDCs showed no statistically significant difference in the 
expression of MHC II in any β2 integrin KO BMDCs compared to WT (Figure 3-2). 
However, there were differences found in co-stimulatory molecule expression on 
CD11a and CD11c KO BMDCs: CD40 was upregulated in mature CD11a KO 
BMDCs compared to WT. CD80 expression was higher in both resting and activated 
CD11a and CD11c KO BMDCs. Higher levels of CD86 were also found in mature 
CD11a and CD11c KO as well as immature CD11a KO BMDCs. Interestingly, 
expression of CD80 was decreased in immature but not mature CD11b KO BMDCs, 
though none of the other markers of activation were differentially expressed in the 
CD11b KO BMDCs. The chemokine receptor CCR7 is upregulated on mature DCs 
to induce their homing to LNs. Expression of CCR7 was significantly upregulated on 
mature CD11a KO BMDCs but no differences were found on any other BMDCs 
compared to WT.  
In summary, the absence of CD11a or CD11c in BMDCs resulted in enhanced 
expression of co-stimulatory molecules CD40, CD80 and CD86. This suggests that 
these β2 integrin receptors are responsible for negatively regulating BMDC 
activation through control of co-stimulatory gene expression. Importantly, there was 
no difference in the activation marker expression on BMDCs lacking CD11b alone, 
therefore it is unlikely that the reduced expression of CD11b on the other integrin-
deficient BMDCs has an impact on their activation.  
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Figure 3-2 Increased expression of activation markers on CD11a and CD11c KO BMDCs.  
WT, CD11a KO, CD11b KO, CD11c KO and CD11d KO BMDCs were cultured with or without 
50ng/ml LPS overnight then cell surface marker expression was measured by flow cytometry. Cells 
were gated on MHC II+. Values shown are relative to WT -LPS from individual experiments. WT 
n=8, CD11a/b/c/d KO n=4. Data from a minimum of 2 independent experiments. Data represents 
mean + SD. Statistical differences were determined using a two-way ANOVA. *p<0.05, ** p<0.01, 
***p<0.005, ****p<0.0001. 
BMDCs lacking CD11a or CD11c expressed higher levels of co-stimulatory 
molecules that are important for mediating the activation of T cells. In addition to co-
stimulation of T cells, the physical interaction between DCs and T cells is essential 
for mediating T cell activation. It is well characterised that CD11a expressed on T 
cells binds to ICAM-1 on APCs during immunological synapse formation, when T 
cells are activated via MHC II-TCR interactions75. It is likely that the reverse of this 
interaction also occurs, where integrin expression on the APC binds to ICAM-1 on 
the T cell88,97. DC integrin expression may, therefore, influence the outcome of the 
DC-T cell interaction and subsequently affect T cell activation/proliferation. It was 
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previously discovered that BMDCs lacking functional β2 integrin receptors displayed 
reduced binding to ICAM-1 and formed weaker contacts with T cells73. To determine 
which of the β2 integrin subunits mediate adhesion to ICAM-1, BMDCs from WT, 
CD11a KO, CD11b KO, CD11c KO and CD11d KO mice were used in a static 
adhesion assay to measure their ability to bind to ICAM-1 (β2 integrin ligand), with 
fibronectin (β1 integrin ligand) as a positive control.  
In the absence of CD11a or CD11c, immature BMDC binding to ICAM-1 was 
significantly reduced compared to WT (Figure 3-3A). There was no difference in the 
adhesion of CD11b, CD11c or CD11d KO BMDCs to ICAM-1. In mature BMDCs, 
the lack of CD11a significantly reduced binding to ICAM-1, whereas in the absence 
of CD11b or CD11c increased adhesion was seen compared to WT. Fibronectin is 
predominantly a β1 integrin ligand so was used as a positive control, although it can 
also bind some β2 integrins. The binding of immature CD11a KO BMDCs to 
fibronectin was decreased whereas CD11b and CD11c KO BMDCs showed 
significantly increased adhesion to fibronectin. Activation of these BMDCs with LPS 
abolished the differences in adhesion to fibronectin and no differences were found 
in the binding of immature or mature CD11d KO BMDCs to fibronectin.  
Based on these results, it can be concluded that CD11a and CD11c are important 
for BMDC adhesion to ICAM-1. This reduced adhesion of BMDCs to ICAM-1 in the 
absence of CD11a or CD11c may impact on the strength and duration of interactions 
with T cells, and ultimately on the outcome of the T cell response.  
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Figure 3-3 Decreased binding of CD11a and CD11c KO BMDCs to ICAM-1.  
WT, CD11a KO, CD11b KO, CD11c KO and CD11d KO BMDCs were cultured with or without 
50ng/ml LPS overnight then binding to ICAM-1, fibronectin and milk blocking only measured by a 
static adhesion assay. Values calculated are relative to the total cells added per well. WT, 
CD11a/b/c KO n=4. WT, CD11d KO n=6. Data is pooled from a minimum of 2 independent 
experiments. Data represents mean + SD. Statistical differences were determined using a two-way 
ANOVA. *p<0.05, ** p<0.01, ***p<0.005, ****p<0.0001. 
3.2.2 CD11a KO BMDCs induce an enhanced T cell response 
The loss of CD11a or CD11c expression in BMDCs resulted in an increased 
expression of co-stimulatory molecules but they displayed a reduced adhesion to 
ICAM-1. This could result in an increase in T cell activation if there are sufficient 
interactions between the integrin-deficient BMDCs and T cells. On the other hand, 
if the adhesion of BMDCs to T cells is impaired then the activation of T cells may be 
reduced, regardless of the increased levels of co-stimulatory molecules. To address 
these questions, the impact of β2 integrin loss on the ability of BMDCs to prime T 
cells was assessed. BMDCs generated from WT, CD11a KO, CD11b KO, CD11c 
KO and CD11d KO mice were cultured with CD4+ OT-II T cells, then T cell 
proliferation (by CFSE dilution) and activation (expression of CD25, CD69 CD62L 
and CD44) were measured by flow cytometry after 1 or 3 days in culture.  
The co-culture of CD4+ OT-II T cells with either immature or mature BMDCs for 3 
days induced their proliferation (Figure 3-4A). The peaks of CFSE expression 
allowed the detection of 4 divisions of the T cells. The percentage of T cells that 
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divided 1-4 times was variable between groups, but the majority of the T cells had 
divided 2 or 3 times (Figure 3-4B). The percentage of T cells that did not divide was 
similar across the cultures using immature BMDCs (Figure 3-4C). However, the co-
culture of T cells with mature BMDCs showed a significant decrease in the 
percentage of undivided T cells when cultured with CD11a KO BMDCs compared 
to WT, but no difference when cultured with BMDCs deficient for CD11b, CD11c or 
CD11d. The proportion of T cells that divided 2 or 3 times were compared, because 
the majority of T cells that divided were in these gates (30-50%). There was no 
difference in the percentage of T cells that had undergone 2 or 3 divisions when 
cultured with immature BMDCs (Figure 3-4C). In the cultures with mature BMDCs, 
there was a significant increase in the percentage of T cells that divided 2 and 3 
times when cultured with CD11a KO BMDCs compared to WT. No difference was 
found when T cells were cultured with mature CD11b, CD11c or CD11d KO BMDCs.  
The loss of CD11a expression on BMDCs resulted in increased proliferation of CD4 
T cells in vitro. This suggests that CD11a plays a role in inhibiting DC-induced 
proliferation of CD4 T cells.  
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Figure 3-4 Increased T cell proliferation of OT-II T cells cultured with CD11a KO BMDCs.  
WT, CD11a KO, CD11b KO, CD11c KO and CD11d KO BMDCs were cultured overnight with or 
without 50ng/ml LPS then pulsed with 5μg/ml OVA323-339 peptide for 90mins before culturing with 
CD4+ OT-II T cells in vitro at a ratio of 1:10. (A) Gating strategy for cell divisions based on CFSE 
fluorescence after 3 days. Representative plots from culture with WT BMDCs shown. (B) 
Percentage of OT-II T cells that divided 1-4 times. (C) Percentage of OT-II T cells that did not 
divide, underwent 2 or 3 divisions.  n=5, data pooled from 2 independent experiments. Data 
represents mean + SD. Statistical differences were determined using a two-way ANOVA. *p<0.05, 
** p<0.01, ***p<0.005, ****p<0.0001. 
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In addition to measuring increased proliferation of T cells induced by CD11a-
deficient BMDCs the expression of the early T cell activation markers CD25 and 
CD69 were assessed. After 1 day of culture, there was no significant difference in 
the expression of CD25 or CD69 on T cells cultured with immature BMDCs, 
regardless of genotype (Figure 3-5A). When cultured with mature CD11a KO 
BMDCs, T cells expressed significantly higher levels of both CD25 and CD69 
compared to WT on day 1. CD25 expression was lower on T cells that were cultured 
with mature CD11b KO BMDCs compared to WT BMDCs but expression of CD69 
was not significantly different. Similarly, both CD11c KO and CD11d KO BMDCs 
induced expression levels of CD25 and CD69 in T cells to the same extent as WT.  
The differentiation of T cells from naïve into effector phenotype was determined by 
expression of CD44 and CD62L: CD44loCD62Lhi (naïve) and CD44hiCD62Llo 
(effector) T cells were quantified on days 1 and 3 of culture (Figure 3-5B). After 1 
day in culture with immature WT BMDCs there was a large population of naïve 
(60%) and a smaller population of effector T cells (<20%) (Figure 3-5C). After 3 days 
of culture there was a reduced population of naïve T cells (40%) and expansion of 
effector T cells (>20%). The culture of T cells with immature CD11a KO BMDCs 
resulted in a significant decrease in the percentage of naïve T cells after both 1 and 
3 days, whereas those with CD11b KO BMDCs retained significantly more naïve T 
cells compared to WT. Co-culture with immature CD11c or CD11d KO BMDCs 
resulted in the same proportions of naïve and effector T cells as with WT BMDCs. 
In cultures with mature BMDCs, there was a significant decrease in the percentage 
of naïve T cells after 1 and 3 days of culture with CD11a KO BMDCs and after 3 
days with CD11c KO BMDCs compared to WT. Conversely, culture with CD11b KO 
BMDCs resulted in a higher percentage of naïve T cells and in cultures with CD11d 
KO BMDCs the percentage of naïve and effector T cells was similar to WT.  
Overall, these results show that in vitro, CD11a KO BMDCs induce increased 
proliferation, expression of activation markers CD25/CD69 and differentiation of 
CD4 T cells into an effector phenotype. This indicates that despite their reduced 
ability to adhere to ICAM-1, CD11a KO BMDCs are able to sufficiently interact with 
T cells to induce activation and proliferation. Further experiments are required to 
quantify the dynamics of this interaction and confirm that the enhanced T cell 
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activation by CD11a KO BMDCs is due to their increased co-stimulatory molecule 
expression. 
 
Figure 3-5 Increased activation of OT-II T cells cultured with CD11a KO BMDCs.  
WT, CD11a KO, CD11b KO, CD11c KO and CD11d KO BMDCs were cultured overnight with or 
without 50ng/ml LPS then pulsed with 5μg/ml OVA323-339 peptide for 90mins before culturing with 
CD4+ OT-II T cells in vitro in a ratio of 1:10. (A) Mean expression of T cell activation markers CD25 
and CD69 after 1 day of culture. Dotted line represents mean expression on T cells prior to culture. 
(B) Gating strategy for naïve (CD44loCD62Lhi) and effector (CD44hiCD62Llo) T cells. Representative 
plot from T cells prior to co-culture (day 0). (C) Percentages of naïve and effector T cells following 1 
and 3 days of co-culture. n=5, data pooled from 2 independent experiments. Data represents mean 
+ SD. Statistical differences were determined using a one-way ANOVA. *p<0.05, ** p<0.01, 
***p<0.005, ****p<0.0001. 
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Having determined that CD11a KO BMDCs induce greater activation of CD4 T cells 
in vitro, the ability of CD11a KO BMDCs to stimulate CD4 T cell responses in vivo 
was then assessed. To investigate this, CD4+ OT-II T cells (that express the 
congenic marker CD45.1) were transferred into WT mice i.v. and then, the following 
day, either WT or CD11a KO peptide-loaded BMDCs were injected into the footpad. 
The T cell response was measured in the draining (popliteal) LN 3 days post-transfer 
of BMDCs.  
A population of OT-II (CD45.1+) T cells was found in the LN draining the site where 
BMDCs were transferred, but not in the contralateral LN (Figure 3-6A). There was 
a significant increase in the percentage and number of transferred T cells in the 
draining LN of mice injected with CD11a KO BMDCs compared to WT BMDCs. 
However, when the expression of activation markers was analysed on these T cells 
there was a significant decrease in both CD25 and CD69 on T cells from mice 
injected with CD11a KO BMDCs. The expression of CD62L was similar on T cells 
that were stimulated with either genotype of BMDCs but CD44 expression was also 
lower with CD11a KO BMDCs compared to WT.  
The in vitro co-culture of CD11a KO BMDCs with OT-II T cells resulted in greater T 
cell proliferation, enhanced expression of CD25/CD69 and an enhanced effector 
phenotype (CD62LloCD44hi). The interaction of these same cells in vivo resulted in 
an increased number of T cells when mice were injected with CD11a KO BMDCs 
compared to WT. This suggests that CD11a KO BMDCs are able to induce greater 
T cell recruitment and/or proliferation in vivo. This could be confirmed by labelling 
the cells with CFSE prior to transfer, to allow quantification of proliferation. However, 
there was not the expected increase in activation marker expression in these T cells 
as was seen in vitro (Figure 3-5). Instead, expression of T cell CD25, CD69 and 
CD44 were all lower in mice injected with CD11a KO BMDCs compared to WT. As 
CD25 and CD69 are markers of early T cell activation, it is possible that the CD11a 
KO BMDCs may have induced higher expression of these markers prior to the 3-
day timepoint. Further analysis of T cell activation over several time-points using 
CFSE-labelled T cells would be required to determine if T cell activation and 
proliferation in vivo is enhanced following priming by CD11a KO BMDCs.  
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Figure 3-6 CD11a KO BMDCs induce higher numbers of CD4 T cells in vivo but these T cells 
show reduced activation marker expression.  
CD4+ OT-II T cells were transferred into mice i.v. then challenged the following day with OVA-
peptide loaded WT or CD11a KO BMDCs s.c. in the footpad. 3 days following BMDC injection the 
draining LN (popliteal) from the injection site and the contralateral side were analysed by flow 
cytometry. Cells were gated on CD4+CD45.1+. (A) Percentage and numbers of transferred T cells. 
(B) Activation marker expression on transferred T cells. n=5, data from 1 experiment. Data 
represents mean + SD. Statistical differences were determined using a two-way ANOVA. *p<0.05, 
** p<0.01, ***p<0.005, ****p<0.0001.  
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3.2.3  Increased percentage of DCs in CD11a and CD11c KO mice 
but no difference in activation marker expression 
The results so far indicate that CD11a and CD11c subunits are responsible for 
regulating the activation status of in vitro-generated BMDCs. The next question was 
whether the loss of CD11a or CD11c expression results in enhanced activation of 
DCs in vivo. To test this, DCs were stained ex vivo from β2 integrin-deficient mice. 
Cells were isolated from the spleen, mesenteric LN (mLN) and peripheral LN (pLN; 
inguinal, brachial and axillary LNs pooled) of WT, CD11a KO, CD11b KO, CD11c 
KO and CD11d KO mice then analysed by flow cytometry to determine the 
expression of activation markers on the DCs.  
CD11c is commonly used as a marker for DCs when analysing murine tissues by 
flow cytometry, but due to the use of CD11c KO mice this strategy could not be 
used. To overcome this, a series of dump gates were used to remove all possible 
cell types other than cDCs (macrophages/monocytes, B cells, T cells, neutrophils, 
NK/NK T cells, pDCs) then cells were gated on MHC II+ and these were regarded 
as the DCs (Figure 3-7A). Using this gating strategy, the population of DCs analysed 
were consistently of 80-90% purity, based on CD11c expression in WT and β2-
deficient mice that expressed CD11c.  
Analysis of DCs from the spleen, mLN and pLN showed an increased percentage 
of DCs in the lymphoid organs of CD11a and CD11c KO mice compared to WT, but 
no difference in CD11b or CD11d KO mice (Figure 3-7B). However, the absolute 
numbers of DCs in the lymph nodes and spleen of the β2 integrin KO mice were 
similar to WT (Figure 3-7C). The similar number of DCs found across β2 integrin-
deficient mice indicates that DC migration to the spleen and LNs is unaffected by 
integrin loss. This supports the idea that β2 integrins are not required for DC 
migration, as found previously72. There was a proportional increase in DCs from 
CD11a and CD11c KO mice, this may suggest there is a reduced number of another 
immune cell population causing this difference. Indeed, analysis of the total cell 
number in the spleen and LNs of β2 integrin-deficient mice demonstrated a reduced 
cellularity in the organs of CD11a and CD11c KO mice but not CD11b or CD11d KO 
compared to WT (Figure 3-8). It is therefore likely that proportional differences in 
DCs found in CD11a and CD11c KO mice are due to a reduced number of another 
cell population. αβ T cells require CD11a for entry into LNs68, therefore the lower 
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cell number in CD11a KO mLN and pLN is likely due to a reduced number of T cells. 
It is unclear what causes the lower cell number in the LNs of CD11c KO mice or in 
the spleen. A more global analysis of leukocyte populations present in these mice 
would be required to answer this question. Overall there was no difference in the 
number of DCs in vivo from β2 integrin-deficient mice.  
 
Figure 3-7 Increased percentage of DCs in lymphoid organs of CD11a and CD11c KO mice.  
Cells were isolated from the spleen, mesenteric LN (mLN) and peripheral LN (pLN: inguinal, 
brachial and axillary pooled) from WT, CD11a KO, CD11b KO, CD11c KO and CD11d KO mice. 
DCs were analysed by flow cytometry. (A) Gating strategy to define DCs. (B) Percentage and 
numbers of DCs. Spleen - WT/CD11a KO/CD11b KO/CD11c KO n=12, CD11d KO n=6. LN – 
WT/CD11a KO/CD11b KO/CD11c KO n=16, CD11d KO n=4. mLN – WT/CD11aKO/CD11b 
KO/CD11c KO n=10, CD11d KO n=4. Data pooled from 2-7 independent experiments. Data 
represents mean + SD. Statistical differences were determined using a two-way ANOVA. *p<0.05, 
** p<0.01, ***p<0.005, ****p<0.0001. 
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Figure 3-8 Decreased total cellularity in CD11a and CD11c KO spleen and lymph nodes. 
 Cells were isolated from the spleen, mesenteric LNs (mLN), peripheral LNs (inguinal, axillary and 
brachial pooled; pLN) of WT, CD11a KO, CD11b KO, CD11c KO and CD11d KO mice. Total cell 
numbers calculated are shown. n=16, data pooled from 6 independent experiments. Data 
represents mean + SD. Statistical differences were determined using a one-way ANOVA. *p<0.05, 
** p<0.01, ***p<0.005, ****p<0.0001. 
Following analysis of DC numbers in β2 integrin-deficient mice, the activation status 
of these DCs was then measured. Analysis of surface marker expression on DCs 
ex vivo showed that overall there were no significant differences in the expression 
of MHC II, the co-stimulatory molecules CD80, CD86, CD40 or the chemokine 
receptor CCR7. There was the exception of CD11c KO DCs from the spleen that 
expressed higher levels of CD86 compared to WT, and CCR7 expression was 
increased on CD11d KO DCs from the mLN. Although statistically significant, these 
differences were small. 
Based on these results, it can be concluded that the increased expression of 
activation markers on BMDCs in the absence CD11a and CD11c in vitro is not 
replicated on in vivo DCs.  
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Figure 3-9 DCs from integrin-deficient mice show equivalent expression of activation 
markers.  
Cells were isolated from the spleen, mesenteric LN (mLN) and peripheral LN (LN: inguinal, brachial 
and axillary pooled) from WT, CD11a KO, CD11b KO, CD11c KO or CD11d KO mice. Surface 
marker expression on DCs (identified as per the gating strategy outlined in figure 7A) was analysed 
by flow cytometry. Spleen - WT/CD11a KO/CD11b KO/CD11c KO n=12, CD11d KO n=6. pLN – 
WT/CD11a KO/CD11b KO/CD11c KO n=13, CD11a, CD11d KO n=7. mLN – WT/CD11a 
KO/CD11b KO/CD11c KO n=10, CD11d KO n=4. Data pooled from 2-6 independent experiments. 
Data represents mean + SD. Statistical differences were determined using a two-way ANOVA. 
*p<0.05, ** p<0.01, ***p<0.005, ****p<0.0001.  
3.2.4 CD4 T cells from CD11a and CD11c KO mice display 
enhanced activation and cytokine production ex vivo 
In addition to understanding how the loss of β2 integrin expression affects DCs, I 
also wanted to understand what impact this may have on the subsequent T cell 
response. The results from earlier in vitro experiments showed that CD11a KO 
BMDCs expressed higher levels of co-stimulatory molecules (Figure 3-2) and when 
co-cultured with T cells induced increased levels of T cell activation and proliferation 
(Figure 3-4, Figure 3-5). There was no difference in the activation status of DCs ex 
vivo, however this may be due to high variability in the data. This variability could be 
explained by the mixed population of DCs that were analysed (cDC1 and cDC2) 
compared with the less heterogeneous population of BMDCs generated in vitro. It 
is also possible that the increased proportion of DCs identified in CD11a and CD11c 
KO mice may affect T cell responses due to an increased ratio of DCs to T cells. To 
assess whether levels of T cell activation are enhanced in vivo in integrin-deficient 
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mice, the expression of activation markers was assessed on CD4 T cells ex vivo. 
Cells were isolated from the spleen, mLN and pLN of WT, CD11a KO, CD11b KO, 
CD11c KO and CD11d KO mice, and then analysed by flow cytometry to determine 
the expression of activation markers on the CD4 T cells. The gating strategy is 
shown in Figure 3-10A.  
On CD4 T cells isolated from the spleen of CD11a and CD11c KO mice there was 
a decreased expression of CD62L and increased expression of CD44 compared to 
WT (Figure 3-10B). The expression of CD25 was significantly lower on CD4 T cells 
from the CD11a KO spleen but no difference in CD69 expression across all 
genotypes. On T cells from the mLN, there was also a higher percentage of CD44+ 
in CD11a and CD11c KO mice compared to WT, but there was no difference in 
expression of CD62L, CD25 or CD69 (Figure 3-10C). In the pLN, CD11a KO mice 
displayed decreased expression of CD62L on CD4 T cells, accompanied by 
increased levels of CD44, CD25 and CD69 relative to WT mice (Figure 3-10D). For 
T cells from CD11c KO mice the only difference in the pLN was a small but 
significant increase in CD44. There was no difference in the expression of any of 
the activation markers measured on CD4 T cells from CD11b or CD11d KO mice, 
in any of the tissues studied.  
This data suggests that the loss of CD11a or CD11c expression in mice results in 
an increased activation status of CD4 T cells. This finding of enhanced T cell 
activation was true in all 3 lymphoid organs investigated (spleen, mLN and pLN), 
though there were subtle differences in marker expression between tissues. Further 
work is required to determine if this increased activation is an intrinsic property of 
the β2 integrin-deficient CD4 T cells or due to alterations in another cell population. 
Based on the ex vivo data showing no difference in DC numbers or their activation 
marker expression, this effect is unlikely to be DC-dependent.  
Chapter 3 Characterisation of β2 integrin-mediated regulation of dendritic 
cells and the impact on interactions with T cells 
 
  85 
 
Figure 3-10 Increased activation marker expression on CD11a and CD11c KO CD4 T cells. 
Cells were isolated from WT, CD11a KO, CD11b KO, CD11c KO or CD11d KO mice and surface 
marker expression on CD4 T cells was analysed by flow cytometry. (A) Gating strategy from WT 
spleen, representative of other genotypes and tissues. Activation marker expression on CD4+ T 
cells from the spleen (B), mesenteric lymph nodes (mLN) (C) and peripheral lymph nodes (pLN: 
inguinal, brachial and axillary pooled) (D). Spleen - n=12 (cKO), n=11 (WT, abdKO), n=6 (18KO), 4 
expt.  mLN – n=9 (cKO), n=8 (WT bdKO), n=6 (aKO), 3 expt. LNs – n=9, 3 expt. Data represents 
mean + SD. Statistical differences were determined using a one-way ANOVA. *p<0.05, ** p<0.01, 
***p<0.005, ****p<0.0001 
After identifying that the absence of CD11a or CD11c results in enhanced T cell 
activation in vivo, the next question was whether integrin loss had an effect on the 
CD4 T cell functional response. To address this, cells from the spleen of WT and β2 
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integrin-deficient mice were analysed by flow cytometry following in vitro stimulation 
with PMA/ionomycin to assess their potential to produce cytokines.  
CD4 T cells from CD11a and CD11c KO mice showed enhanced production of both 
IFNγ and IL-17 compared to WT mice (Figure 3-11). Whereas cytokine levels were 
similar in T cells from WT, CD11b and CD11d KO mice. This indicates that, in 
addition to their increased activation status in CD11a and CD11c KO mice, CD4 T 
cells show an enhanced ability to produce IFNγ and IL-17.  
 
Figure 3-11 Increased production of IFNγ and IL-17 by CD4 T cells from CD11a and CD11c 
KO mice. 
Cells isolated from the spleen of WT, CD11a KO, CD11b KO, CD11c KO and CD11d KO mice 
were stimulated in vitro with PMA/ionomycin and levels of IFNγ and IL-17 were measured by flow 
cytometry. Cells were gated on CD4+. Percentage of CD4+ cells that expressed IFNγ or IL-17 are 
shown. IFNγ n=6, IL-17 n=4, data pooled from 2-3 independent experiments. Data represents 
mean + SD. Statistical differences were determined using a one-way ANOVA *p<0.05, ** p<0.01, 
***p<0.005, ****p<0.0001.  
3.2.5 Dock2 mutation found in CD11a KO, CD11c KO and CD11d 
KO mice 
A publication by Mahajan et al. was brought to the attention of the lab in August 
2016. The authors described an additional genetic mutation found in their line of 
sialic acid-deficient mice, in a gene called Dock2. The mutation in the Dock2 gene 
was a frameshift mutation that causes the production of nonsense RNA, leading to 
a loss of functional Dock2 expression. They traced this mutation to a line of ‘WT’ 
C57BL/6NHsd mice from Harlan Sprague Laboratories in the US (now Envigo 
Biosciences) and suggested the mutation in Dock2 spontaneously arose in the 
C57BL/6NHsd colony. As the C57BL/6NHsd line is routinely used for backcrossing, it 
is likely that many GM strains generated in the US may exhibit phenotypes due to 
this unknown deficiency in the Dock2 gene, in addition to the actual targeted gene 
of interest. This mutation in the Dock2 gene is referred to as Dock2Hsd.  
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It was decided to screen the β2 integrin-deficient mice for Dock2Hsd as they were 
originally generated in US labs and may have been backcrossed onto C57BL/6NHsd 
mice affected by the Dock2 mutation. DNA from β2 integrin-deficient mice was 
analysed for expression of Dock2Hsd by PCR. Note that this PCR protocol detects 
Dock2Hsd in genomic DNA, however it does not discriminate between heterozygous 
and homozygous expression.  
For CD11a and CD11b KO lines, the original breeders (2 males and 2 females that 
were purchased from Jackson Laboratories) were analysed. The CD11c KO mice 
were a gift from Professor Christie Ballantyne (Baylor College of Medicine, Texas, 
USA). Ear clips were not kept from the original breeders so DNA from the first litter 
of mice that were then bred to continue the line were examined. Both the CD11d 
and CD18 KO lines originated from cryopreserved embryos purchased from 
Jackson Laboratories, so DNA from the mice born following implantation of these 
embryos was analysed.  
The expression of Dock2Hsd was identified in the CD11a KO, CD11c KO and CD11d 
KO mice, but was absent from CD11b KO, CD18 KO and WT control (Figure 3-12A). 
The implantation of cryopreserved embryos resulted in the birth of 3 mice for the 
CD11d KO line and only 1 for the CD18 KO line. Due to this low number, one of 
each line was bred with a C57BL/6 purchased from Harlan UK (negative for 
Dock2Hsd). To assess whether the CD11d KO line retained the expression of 
Dock2Hsd and to confirm the absence in the CD18 KO line, DNA from the breeders 
of these lines was examined. The expression of Dock2Hsd was found in 7 out of the 
12 CD11d KO breeders, whereas all of the CD18 KO breeders were negative for 
Dock2Hsd (Figure 3-12B). 
This indicates that CD11a KO, CD11c KO and some of the CD11d KO mice I used 
for previous experiments had a mutation in the Dock2 gene in addition to their 
integrin deficiency. The expression of Dock2Hsd is probably homozygous in the 
CD11a and CD11c KO lines, whereas many of the CD11d KO mice are likely to be 
heterozygous. This is because the CD11a and CD11c KO mice were obtained as 
live breeding pairs, whereas the CD11d KO was from an implanted embryo that was 
bred with a WT. Based on these findings, a careful re-examination of the data was 
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required to determine which immune phenotypes were due to the β2 integrin 
deficiency and which were due to loss of Dock2 function.  
 
Figure 3-12 Mutated form of Dock2 (Dock2Hsd) is expressed in CD11a, CD11c and CD11d KO 
mouse strains.  
DNA from digested ear clips of CD11a KO, CD11b KO, CD11c KO, CD18 KO or C57BL/6 (WT) 
mice. Dock2Hsd was amplified by PCR and the resulting fragments were separated by gel 
electrophoresis on a 1% agarose gel (1X TAE 1X SYBR safe). The expected band size of the 
mutated form of Dock2 is 305bp. (A) Analysis of DNA from CD11a KO and CD11b KO line original 
breeders, CD11c KO line first litter, CD11d KO and CD18 KO lines original mice obtained from 
embryos. (B)  Analysis of DNA from CD11d KO and CD18 KO line breeders.   
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3.2.6 Determination of immune phenotypes in CD11a and CD11c 
KO mice due to loss of Dock2 or integrin expression 
Dock2 is a guanine nucleotide exchange factor that regulates membrane 
polarisation and cytoskeletal dynamics. It is expressed exclusively in 
haematopoietic cells, therefore the mutation in this gene is particularly relevant for 
mice used to study immune cells. The main immune phenotypes that have been 
characterised due to Dock2Hsd are an increase in memory CD8 T cells, loss of 
marginal zone B cells, iNKT cells and pDCs309.  
Both Dock2 and β2 integrins play important roles in leukocyte migration. It was, 
therefore, imperative to determine which effects described earlier in this chapter 
were due to the β2 integrin deficiency and which phenotypes were due to the 
mutation in Dock2. In order to answer these questions, mice from the CD11a and 
CD11c KO lines (where the most significant differences were seen in DCs and CD4 
T cells) were crossed to create CD11a/CD11c hets (Figure 3-13). These mice were 
heterozygous for the expression of both CD11a and CD11c but retained 
homozygous expression of Dock2Hsd. The phenotype of cells from these integrin 
hets was compared with the homozygous integrin KO Dock2Hsd mice (CD11a KO & 
CD11c KO), mice that express WT integrins/Dock2 (WT) and mice with WT 
integrins/Dock2Hsd (Dock2).  
 
Figure 3-13 Mice used to determine effects downstream of β2 integrin-deficiency or 
Dock2Hsd.  
C57BL/6 (WT) mice were purchased from Harlan, CD11a KO mice were purchased from Jackson 
Labs, and CD11c KO mice gifted from Christie Ballantyne (Baylor College of Medicine, Texas, 
USA). CD11a/CD11c het mice were bred in-house by crossing CD11a and CD11c KO strains. 
Dock2 mice were bred in-house from the offspring of crossed F1 generation from CD11c KO mice 
crossed with WT C57BL/6 (see Figure 1-21). The integrin and Dock2 genotypes are shown. 
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Before assessing the immune phenotypes, β2 integrin expression was first assessed 
on total splenocytes from WT, CD11a KO, CD11c KO and CD11a/CD11c het mice. 
The aim was to assess the altered integrin expression in CD11a/CD11c het mice to 
determine if they had the expected intermediate level of integrin expression. The 
expression of CD18 was significantly lower on cells from CD11a KO mice compared 
to WT, CD11c KO and CD11a/CD11c hets (Figure 3-14). CD11a was expressed to 
a similar extent on cells from WT and CD11c KO mice, but was absent in CD11a 
KO mice, as expected. The expression of CD11a on cells from CD11a/CD11c hets 
was higher than the CD11a KO mice but lower than the CD11c KOs, indicative of 
heterozygous expression. The Dock2 mice showed lower expression of CD11a than 
the CD11c KO mice but no difference compared to WT. The expression of CD11c 
was significantly increased on cells from CD11a and CD11a/CD11c hets than WT, 
CD11c KO or Dock2 mice. There was no significant difference in the mean 
expression of CD11c between WT and CD11c KO mice, suggesting that there was 
a high level of background staining or due to a low number of CD11c+ cells present 
in the spleen.  
As expected, the expression of both CD11a and CD11c in the CD11a/CD11c het 
mice was higher than their respective homozygous KO mice. The expression of 
CD18, CD11a and CD11c was similar on cells from WT mice regardless of their 
Dock2 expression (WT and Dock2 groups).  
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Figure 3-14 Expression of β2 integrins in integrin-deficient dock2 mutant mice.  
Splenocytes from WT, CD11a KO, CD11c KO, CD11a/CD11c het and Dock2 mice were analysed 
by flow cytometry for expression of β2 integrins and ICAM-1. Data shown is geometric mean from 
total live single cells. WT, CD11a KO, CD11c KO, CD11a/CD11c het n=9, data from 3 independent 
experiments. Dock2 n=3 from 1 experiment. Data represents mean + SD. Statistical differences 
were determined using a one-way ANOVA *p<0.05, ** p<0.01, ***p<0.005, ****p<0.0001. 
The CD11a/CD11c deficient Dock2Hsd mice displayed higher integrin expression 
than the KO mice but, in some cases, reduced compared to WT. There are two 
possible functional consequences of this altered integrin expression, either the 
intermediate level of CD11a/CD11c expression will be: 1) sufficient for cell function 
so the het mice will appear as WT or 2) insufficient to restore integrin function so the 
het mice will display the same phenotype as KO.  
Next, I wanted to confirm the mutation in Dock2 resulted in the expected altered 
immune phenotype that has been reported. One of the major immune cell 
phenotypes that occurs in mice with Dock2Hsd is the loss of marginal zone B cells 
(MZ B cells)309,317. To confirm that Dock2Hsd resulted in a loss of MZ B cells in the 
integrin-deficient mice, splenic B cells were analysed from WT, CD11a KO, CD11c 
KO, CD11a/CD11c het and Dock2 mice.  
The total B cell population in the spleen can be identified by gating on CD19+ cells, 
then MZ B cells are identified as CD21/35hi CD23lo 318 (Figure 3-15A). The Dock2 
mice (which have WT integrin expression but express Dock2Hsd; see Figure 3-13) 
were obtained from in-house breeding of the CD11a/CD11c KO lines to remove 
expression of Dock2Hsd. This was done by crossing the CD11a or CD11c KO mice 
with WT C57BL/6, then the F1 generation were crossed, and this resulted in the 
generation of some mice that had WT integrin expression but expressed Dock2Hsd. 
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However, the PCR to test for Dock2Hsd does not discriminate between mice that are 
heterozygous or homozygous, therefore it was known that the mice in the Dock2 
group expressed Dock2Hsd, but they may have 1 or 2 copies of the mutated gene. 
Analysis of MZ B cells from the Dock2 mice revealed that 2 out of the 3 mice had a 
population of MZ B cells but the other mouse was deficient (Figure 3-15B). This 
suggests that mouse number 3 was homozygous for Dock2Hsd whereas mice 1 and 
2 were heterozygous. This Dock2Hsd homozygote mouse appears to have a 
population of CD23hi B cells that is absent in the WT and het mice, though this was 
not investigated further. In the WT spleen, MZ B cells represented around 7% of the 
total B cell population (Figure 3-15C). Whereas in CD11a KO, CD11c KO and 
CD11a/CD11c het mice the MZ B cells were completely absent. Both the 
percentage and numbers of MZ B cells were significantly decreased in all of the 
integrin-deficient mice compared to WT.  
Analysis of the MZ B cell populations confirmed that, as expected, the homozygous 
mutation in Dock2 found in the CD11a KO, CD11c KO and CD11a/CD11c het mice 
resulted in a complete loss of MZ B cells in the spleen. The data also revealed that 
in the Dock2 group (mice with Dock2Hsd but WT integrin expression), 2 out of 3 mice 
were likely heterozygous for Dock2Hsd. This must be taken into consideration when 
interpreting the results from experiments using the Dock2 group of mice (Figures 3-
16 to 20).  
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Figure 3-15 Loss of marginal zone B cells in mice with dock2 mutation.  
Splenocytes from WT, CD11a KO, CD11c KO or CD11a/CD11c het mice were analysed by flow 
cytometry. (A) Cells were gated on CD19+ (total B cells) then CD21/35hi CD23lo (marginal zone B 
cells). (B) Plots and the absolute numbers of marginal zone B cells from replicates of Dock2 mice. 
(C) Representative plots showing marginal zone B cells, percentages and numbers of CD19+ cells 
and marginal zone B cells. n=9, data pooled from 3 independent experiments. Data represents 
mean + SD. Statistical differences were determined using a one-way ANOVA. *p<0.05, ** p<0.01, 
***p<0.005, ****p<0.0001. 
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Having confirmed CD11a and CD11c KO mice possess the Dock2Hsd mutation at 
the genomic level and display the expected immune phenotype of marginal zone B 
cell loss, I next analysed their DC phenotype. In the initial experiments in this 
chapter, DCs were generated in vitro to determine which β2 integrin subunits are 
responsible for regulating the activation state of BMDCs. First, β2 integrins and 
ICAM-1 expression were assessed on the BMDCs and it was found that BMDCs 
lacking CD11a or CD11c expressed reduced levels of CD18 and CD11b but 
expressed higher levels of ICAM-1 than WT (Figure 3-1). This same analysis was 
carried out using BMDCs generated from WT, CD11a KO, CD11c KO, 
CD11a/CD11c het and Dock2 mice to determine whether these effects were due to 
the loss of β2 integrin expression or due to Dock2-deficiency.  
The expression of both CD18 and CD11b was significantly lower on BMDCs from 
β2 integrin KO mice compared to WT, but expression on BMDCs generated from 
Dock2 mice was equivalent to WT (Figure 3-16). This was true regardless of the 
maturation status of the BMDCs. This indicates that, as expected, the 
downregulation of CD18 and CD11b on CD11a/CD11c-deficient BMDCs is due to 
the loss of integrin expression and not the absence of functional Dock2. As 
expected, CD11a KO and CD11c KO BMDCs lacked expression of CD11a and 
CD11c respectively. The CD11a/CD11c het BMDCs expressed CD11a and CD11c, 
but at significantly lower levels than WT. There was no difference in the expression 
of either CD11a or CD11c on Dock2 BMDCs compared to WT. The expression of 
ICAM-1 was higher on immature CD11a KO and CD11a/CD11c het BMDCs 
compared to WT. However, following maturation, all integrin-deficient and Dock2 
BMDCs expressed increased ICAM-1 compared to WT.  
This data confirms the expected loss/reduced expression of CD11a and CD11c on 
BMDCs based on their genotype. The mutation in the Dock2 gene did not impact on 
β2 integrin expression but did contribute to the upregulation of ICAM-1 on mature 
BMDCs.  
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Figure 3-16 Altered expression of β2 integrins on BMDCs is independent of Dock2.  
BMDCs generated from WT, CD11a KO, CD11c KO, CD11a/CD11c het and Dock2 mice were 
cultured with or without 50ng/ml LPS overnight then cell surface marker expression was measured 
by flow cytometry. Values shown are relative to WT -LPS from individual experiments. WT, CD11a 
KO, CD11c KO, CD11a/CD11c het n=9, data pooled from 3 independent experiments. Dock2 n=3, 
data from 1 experiment. Data represents mean + SD. Statistical differences were determined using 
a one-way ANOVA. *p<0.05, ** p<0.01, ***p<0.005, ****p<0.0001. 
After confirming the reduced β2 integrin expression on BMDCs was independent of 
Dock2, the expression of co-stimulatory molecules and the chemokine receptor 
CCR7 were assessed. The previous results (Figure 3-2) demonstrated that in the 
absence of CD11a or CD11c, BMDCs express higher levels of CD40, CD80 and 
CD86. The expression of CCR7 was increased only on mature CD11a KO BMDCs. 
All of the immature BMDCs expressed similar levels of the markers analysed (Figure 
3-17). However, mature BMDCs from CD11a KO, CD11c KO and CD11a/CD11c 
het mice expressed significantly higher levels of CD40, CD80 and CD86 than WT 
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mice. The expression of these co-stimulatory molecules was equivalent in WT and 
Dock2 BMDCs. In contrast to the previous experiments, there was no significant 
difference in CCR7 expression across any of the groups.  
The aim with comparing the phenotype of cells from CD11a/CD11c het mice with 
CD11a and CD11c KO, was that intermediate levels of integrin expression may be 
sufficient to rescue any effects that occur due to integrin loss. Based on this idea, 
the expectation was that CD11a/CD11c hets would display a similar phenotype to 
the Dock2 and WT groups. In contrast to this, the enhanced expression of co-
stimulatory molecules on CD11a and CD11c KO BMDCs was maintained in the 
CD11a/CD11c hets. This data indicates that reduced β2 integrin expression is 
sufficient to induce the enhanced expression of co-stimulatory molecules on BMDCs 
and importantly, this effect is due to the loss of integrin expression and independent 
of the mutation in Dock2. 
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Figure 3-17 Elevated expression of co-stimulatory molecules on CD11a and CD11c KO 
BMDCs is independent of Dock2Hsd. 
BMDCs generated from WT, CD11a KO, CD11c KO, CD11a/CD11c het and Dock2 mice were 
cultured with or without 50ng/ml LPS overnight then cell surface marker expression was measured 
by flow cytometry. Values shown are relative to WT from individual experiments. WT, CD11a KO, 
CD11c KO, CD11a/CD11c het n=9, data pooled from 3 independent experiments. Dock2 n=3, data 
from 1 experiment. Statistical differences were determined using a two-way ANOVA. Data 
represents mean + SD. *p<0.05, ** p<0.01, ***p<0.005, ****p<0.0001. 
The enhanced activation of β2 integrin-deficient DCs generated in vitro was found 
to be an integrin-dependent effect. The next question was whether the increased 
proportions of DCs in secondary lymphoid tissues of CD11a and CD11c KO mice 
(Figure 3-7) is also an integrin-dependent effect. To test this, DCs were identified by 
ex vivo analysis in the CD11a/c het mice. 
An increased percentage of DCs was identified in the spleen of CD11c KO mice and 
CD11a/CD11c het compared to WT, but there was no difference in the CD11a KO 
or Dock2 mice. There was variability in the data from CD11a KO mice (indicated by 
the large error bar), which may explain why the percentage of DCs was not 
significantly different in this group. No significant differences were seen between 
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any groups in the mLN or pLN analysis. Calculation of the absolute numbers of DCs 
showed a greater number of DCs in the spleen of CD11a KO, CD11c KO and 
CD11a/CD11c het mice compared to WT, but no difference in the Dock2 mice. 
Similar to the percentage data, the numbers of DCs did not differ in the mLN and 
pLN.  
As found with the BMDC data, the CD11a/CD11c het group displayed the same 
phenotype as the CD11a and CD11c KO mice, but not the WT or Dock2. This 
indicates that intermediate expression of CD11a/CD11c is sufficient to cause an 
increase in DCs. As the increase in splenic DCs in CD11a, CD11c KO mice and 
CD11a/CD11c hets was not found in WT or Dock2 mice it can be concluded that the 
expression of Dock2Hsd does not influence DC numbers in vivo. 
 
Figure 3-18 Increased proportions and numbers of DCs in vivo is due to the β2 integrin 
defect.  
Cells were isolated from WT, CD11a KO, CD11c KO, CD11a/CD11c het or Dock2 mutant mice 
then DCs analysed by flow cytometry. As per the gating strategy in (Figure 3-7A). WT, CD11a KO, 
CD11c KO, CD11a/CD11c het n=9, data pooled from 3 independent experiments. Dock2 n=3, data 
from 1 experiment. Data represents mean + SD. Statistical differences were determined using a 
two-way ANOVA. *p<0.05, ** p<0.01, ***p<0.005, ****p<0.0001. 
The enhanced activation of BMDCs and increased proportion of DCs ex vivo from 
CD11a and CD11c KO mice have now been confirmed as integrin-dependent 
effects, and not due to the expression of Dock2Hsd. To determine the potential effect 
the increased number of DCs may have on the subsequent T cells response, the 
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phenotype of CD4 T cells was assessed in β2 integrin deficient mice earlier in this 
chapter (Figure 3-10). Before looking at T cell activation, the percentages and 
numbers of CD4 T cells were first analysed. It is known that CD11a plays a major 
role in αβ T cell extravasation into LNs68 and Dock2 also plays a role in regulating 
this process319. Therefore, the deficiency in both integrin and Dock2 may contribute 
to altered T cell populations in lymphoid organs. The percentages and numbers of 
CD4 T cells were assessed in the WT, CD11a KO, CD11c KO, CD11a/CD11c het 
and Dock2 mice to determine the effect of integrin deficiency vs loss of Dock2 on 
the overall CD4 T cell population present in the spleen and LNs.  
The percentage of CD4 T cells in the spleen was decreased in CD11a KO mice 
compared to WT but remained equivalent in CD11c KO, CD11a/CD11c het and 
Dock2 mice (Figure 3-19). In the mLN, all of the CD11a/CD11c deficient mice 
displayed a lower percentage of CD4 T cells but the deficiency of Dock2 alone had 
no effect. In the peripheral LNs, the proportion of CD4 T cells was significantly 
reduced in CD11a KO and to a lesser extent in CD11c KO mice. However, this effect 
was lost in the CD11a/CD11c het LNs and, again, mice with the Dock2 mutation 
displayed a similar percentage of CD4 T cells to WT mice.  
Despite a decreased percentage in the spleen of CD11a KO mice, the number of 
CD4 T cells was similar across all of the groups. On the contrary, in the mLN and 
pLNs there was a β2 integrin-dependent defect in the number of CD4 T cells. Mice 
with the mutated form of Dock2 and reduced expression of CD11a/CD11c showed 
a significantly lower number of CD4 T cells, whereas mice with Dock2Hsd and WT 
integrin expression had numbers equivalent to WT.  
In summary, the loss of CD11a and/or CD11c expression leads to a reduced number 
of CD4 T cells in the mLN and peripheral LNs of mice but the absence of functional 
Dock2 has no effect on CD4 T cell distribution.  
Chapter 3 Characterisation of β2 integrin-mediated regulation of dendritic 
cells and the impact on interactions with T cells 
 
  100 
Figure 3-19 Reduced numbers of T cells in LNs is due to the β2 integrin defect. 
Cells were isolated from the spleen, mesenteric lymph nodes (mLN) and peripheral lymph nodes 
(LNs) of WT, CD11a KO, CD11c KO, CD11a/CD11c het or Dock2 mutant mice. Cells were gated 
on CD3+CD4+ then T cell numbers and percentages calculated. WT, CD11a KO, CD11c KO, 
CD11a/CD11c het n=9, 3 expt; Dock2 mutant n=3, 1 expt. Data represents mean + SD. Statistical 
differences were determined using a two-way or one-way ANOVA. *p<0.05, ** p<0.01, ***p<0.005, 
****p<0.0001. 
After identifying that Dock2Hsd does not impact the number of CD4 T cells in spleen 
and LNs, the phenotype of these cells was then analysed. Previous experiments 
showed an increase in the expression of activation markers on CD4 T cells in mice 
lacking CD11a or CD11c (Figure 3-10).  
In the spleen, CD4 T cells from CD11a KO, CD11c KO and CD11a/CD11c het mice 
displayed increased expression of CD44 compared to WT (Figure 3-20A), as was 
found previously in the CD11a and CD11c KO mice (Figure 3-10). Expression of 
CD44 on T cells from the Dock2 mice was variable but not significantly different from 
WT. In contrast to the previous findings, there was no difference in the expression 
of CD62L on CD4 T cells from CD11a or CD11c deficient mice. Similarly, the 
expression of CD25 and CD69 was equivalent on CD4 T cells regardless of their 
genotype. 
In the mLN, there were no differences in the expression of CD62L, CD25 or CD69 
(Figure 3-20B). The percentage of CD44+ CD4 T cells was greater only in the CD11c 
KO mice, as found previously (Figure 3-10). However, unlike the initial experiments, 
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CD11a KO T cells expressed CD44 at the same levels as WT. In pLNs, the data 
also showed inconsistencies with the previous experiments, where an increase in 
CD44 expression was identified in the absence of CD11a and CD11c, and CD11c 
KO mice showed higher expression of CD25 and reduced CD62L. CD4 T cells from 
all mice with the Dock2 mutation, regardless of β2 integrin expression, expressed 
similar levels of CD44 and CD25 to those from WT mice (Figure 3-20C). The 
percentage of CD62L+ T cells was similar between WT and β2 integrin-deficient CD4 
T cells but higher on T cells from Dock2 mice. In contrast to the initial experiments, 
there was also a significant increase in the percentage of CD69+ CD4 T cells from 
CD11a KO mice compared to WT. No difference was seen in CD69 expression on 
the other groups.  
It is unclear why the activation state of CD4 T cells from CD11a and CD11c KO mice 
was not consistent with the previous experiments. The altered expression of CD44 
in the spleen appears to be an integrin-dependent effect, and this is potentially true 
in the mLN as well. However, this was not accompanied by the expected decrease 
in CD62L expression, and levels of CD44 were unaltered in the pLN. It is therefore 
difficult to make firm conclusions about the effect of β2 integrin deficiency versus 
loss of Dock2 on the phenotype of CD4 T cells in vivo. Further analysis, including 
cytokine profiling, would be required to confirm the specific roles for integrins and 
Dock2 in CD4 T cell activation in vivo. 
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Figure 3-20 Loss of β2 integrins and Dock2 have inconsistent effects on CD4 T cell 
phenotype.  
Cells were isolated from WT, CD11a KO, CD11c KO, CD11a/CD11c het and Dock2 mice and 
analysed by flow cytometry. Cells were gated on CD3+CD4+ then activation marker expression 
was assessed on CD4 T cells from the spleen (A), mesenteric LN (mLN) (B) and peripheral LN 
(pLN) (C). WT, CD11a KO, CD11c KO, CD11a/CD11c het n=9, data pooled from 3 independent 
experiments; Dock2 n=3, data from 1 experiment. Data represents mean + SD. Statistical 
differences were determined using a one-way ANOVA. *p<0.05, ** p<0.01, ***p<0.005, 
****p<0.0001. 
In summary, it was identified that CD11a KO, CD11c KO and CD11d KO mouse 
strains possessed an additional mutation in the Dock2 gene. The CD11a and CD11c 
KO mice displayed a loss of MZ B cells due to the expression of Dock2Hsd, whereas, 
the β2 integrin-deficiency was responsible for the enhanced co-stimulatory molecule 
expression on BMDCs, increased population of DCs in vivo and reduced number of 
CD4 T cells in LNs.  
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3.2.7 Generation and Characterisation of β2 integrin KO mice with 
WT expression of Dock2 
Upon the discovery that CD11a KO, CD11c KO and CD11d KO mouse strains had 
a mutation in the Dock2 gene in addition to the intended β2 integrin deficiency, the 
mice were then bred to restore WT expression of Dock2. For the CD11d KO line, 
only some of the mice expressed Dock2Hsd and were likely heterozygous, whereas 
others expressed Dock2WT. Breeders were selected that did not express Dock2Hsd 
so that all future offspring would not possess this mutation. For the CD11a and 
CD11c KO lines all of the mice were affected by the Dock2 mutation, therefore it 
was assumed that the mice were homozygous for Dock2Hsd. To restore WT 
expression of Dock2, CD11a and CD11c KO mice were crossed with WT mice 
(C57BL/6 mice purchased from Envigo) (Figure 3-21). This produced an F1 
generation of mice that were heterozygous for both their respective β2 integrin and 
Dock2Hsd. The F1 generation were then crossed and breeders from their offspring 
were selected that had WT expression of Dock2, and either heterozygous or 
homozygous expression of the relevant integrin subunit. From the F3 generation 
breeders were then selected that lacked expression of Dock2Hsd and were 
homozygous KO for the β2 integrin receptor to continue the line.  
 
Figure 3-21 Breeding strategy for CD11a and CD11c KO mouse strains to remove Dock2Hsd. 
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In order to confirm the findings that marginal zone B cell loss (Figure 3-15) and 
enhanced CD4 T cell activation (Figure 3-10, Figure 3-11) in CD11a and CD11c KO 
mice were due to Dock2Hsd, the phenotype of β2 integrin α-chain deficient mice, all 
with WT expression of Dock2, was then compared to WT and total β2-deficient mice 
(CD18 KO).  
First, the total cell numbers obtained from the spleen, mLN and pLN of these mice 
were calculated and compared with the mice affected by Dock2Hsd. The total cell 
counts from the original strains affected by Dock2Hsd showed a significant decrease 
in the number of cells in the spleen, mLN and pLN of CD11a and CD11c KO mice 
compared to WT (Figure 3-22A). Note, this data is the same as Figure 3-8, with the 
CD18 KO group added. Interestingly, in total β2 integrin KO mice (CD18 KO) the cell 
number was also lower in the mLN and pLN, but numbers were greatly increased in 
the spleen compared to WT mice. Despite some of the CD11d KO mice expressing 
Dock2Hsd (probably heterozygous), there was no difference in cell numbers from 
these mice or in the CD11b KOs. However, in the integrin-deficient mice with WT 
expression of Dock2 there was no difference in the number of splenic cells in any of 
the α-chain KO mice compared to WT, and in the mLN and pLN the decreased 
number was only seen in the CD11a KO and CD18 KO but not in the CD11c KO 
mice.  
This suggests that the decreased cellularity of the spleen of CD11a and CD11c KO 
mice was due to Dock2Hsd. This reduction in cellularity may therefore be attributed 
to the loss of MZ B cells. Similarly, the reduced cellularity of CD11c KO LNs was 
also due to Dock2Hsd, though the reason for this remains unknown. However, the 
decreased cell number in the mLN and pLN of CD11a KO mice was due to the loss 
of CD11a expression. This is to be expected due to the essential role for CD11a in 
leukocyte extravasation into the LNs. 
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Figure 3-22 Reduced total cell numbers in the spleen of CD11a KO, spleen and LNs of 
CD11c KO mice were due to Dock2Hsd. 
Cells were isolated from the spleen, mesenteric LN (mLN) and peripheral LN (pLN) of WT, CD11a 
KO, CD11b KO, CD11c KO, CD11d KO, and CD18 KO mice and total cell numbers calculated. 
Counts from mice affected by Dock2Hsd (A) and with WT Dock2 expression (B). n=16, data pooled 
from 6 independent experiments. Data represents mean + SD. Statistical differences were 
determined using a one-way ANOVA. *p<0.05, ** p<0.01, ***p<0.005, ****p<0.0001. 
I previously showed that CD11a KO and CD11c KO mice displayed one of the most 
striking immune phenotypes associated with Dock2Hsd, the loss of MZ B cells309,317. 
To confirm the expression of Dock2WT in integrin-deficient mice rectified this defect, 
MZ B cells were analysed from α-chain and β2 KO mice that expressed Dock2WT. 
The population of MZ B cells in the spleen was restored in Dock2 WT integrin-
deficient mice (Figure 3-23A). In the CD11c KO mice, the MZ B cell population was 
in fact increased, both by percentage and number, compared to the WT spleen 
(Figure 3-23B). Similar numbers of MZ B cells were seen in WT, CD11a KO, CD11b 
KO, CD11d KO and CD18 KO mice.  
The presence of MZ B cells in CD11a and CD11c KO mice confirms the impairment 
was due to Dock2Hsd and the breeding strategy (outlined in Figure 3-21) successfully 
restored Dock2 function in the integrin-deficient strains. Further to this, the loss of 
CD11c expression in the absence of Dock2Hsd resulted in an increased number of 
MZ B cells, suggesting a potential role for CD11c in regulating MZ B cells.  
Chapter 3 Characterisation of β2 integrin-mediated regulation of dendritic 
cells and the impact on interactions with T cells 
 
  106 
 
Figure 3-23 Confirmation that loss of marginal zone B cells in CD11a KO and CD11c KO 
mice was due to the mutation in Dock2.  
Cells were isolated from the spleen of WT, CD11a KO, CD11b KO, CD11c KO, CD11d KO and 
CD18 KO mice (all WT for Dock2) then cells were analysed by flow cytometry. MZ B cells were 
gated on CD19+ CD21/35hi CD23lo. (A) Representative plots of marginal zone B cells as a 
percentage of CD19+ cells. (B) Percentages and numbers of marginal zone B cells. n=9, data 
pooled from 3 independent experiments. Data represents mean + SD. Statistical differences were 
determined using a one-way ANOVA. *p<0.05, ** p<0.01, ***p<0.005, ****p<0.0001. 
Following confirmation that Dock2Hsd removal from CD11a and CD11c KO mice 
strains resulted in the expected return of MZ B cells, the CD4 T cell population was 
then analysed. Data obtained from experiments using the CD11a/CD11c het mice 
suggested that the loss of CD11a and/or CD11c expression, but not Dock2, caused 
a reduction in the number of CD4 T cells in LNs (Figure 3-19). To confirm these 
findings, CD4 T cells were analysed from β2 integrin-deficient mice with Dock2WT 
expression. There was no difference in the number of CD4 T cells in the spleen of 
CD11a KO, CD11b KO, CD11c KO or CD11d KO mice compared to WT, but 
numbers were increased in CD18 KO mice (Figure 3-24A). In both the mLN and 
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pLN, there was a significant decrease in CD4 T cell numbers in CD11a KO and 
CD18 KO mice compared to WT. Equivalent numbers of CD4 T cells were found in 
the mLN and pLN of WT, CD11b KO and CD11d KO mice.  
There were inconsistencies in activation marker expression on CD4 T cells between 
the initial experiments carried out in integrin-deficient mice with Dock2Hsd (Figure 
3-10) and experiments using CD11a/CD11c het mice (Figure 3-20). The initial data 
showed that CD4 T cells from the tissues of CD11a and CD11c KO mice displayed 
a more activated phenotype, but this was not apparent in the repeat experiments. 
To clarify this contradictory data, the expression of activation markers was assessed 
on CD4 T cells from the spleen of β2 integrin-deficient mice with Dock2WT 
expression. There was a reduced expression of CD25 on CD4 T cells from CD11a 
and CD18 KO mice compared to WT, whereas higher expression was seen on cells 
from CD11d KO mice (Figure 3-24B). CD11a KO CD4 T cells also displayed lower 
levels of CD69, whereas CD69 expression was upregulated on cells from CD11c 
and CD11d KO mice compared to WT. Fewer CD4 T cells expressed CD62L in the 
CD18 KO spleen, but no difference was found on T cells from any other integrin-
deficient mice. CD44 expression was similar across all genotypes.  
In the initial experiments using integrin-deficient mice expressing Dock2Hsd, CD4 T 
cells from the spleen of CD11a and CD11c KO mice produced significantly higher 
levels (~2-fold) of IFNγ and IL-17 following in vitro re-stimulation (Figure 3-11). To 
determine whether the mice with Dock2WT retained this phenotype, the levels of 
IFNγ and IL-17 were measured in response to PMA/ionomycin in CD4 T cells from 
integrin-deficient mice expressing Dock2WT. The percentage of CD4 T cells 
producing IFNγ was similar across the β2 integrin-deficient mice, except for the 
CD11d KO cells that showed a small but significant increase compared to WT 
(Figure 3-24C). In contrast to this, there was increased production of IL-17 in CD4 
T cells from CD11a and CD18 KO mice, but the CD11b, CD11c and CD11d KO T 
cells produced similar levels to WT. The increase in IL-17 production was similar in 
magnitude (~2-fold) to that seen in CD11a KO mice expressing Dock2Hsd. 
This suggests that the absence of CD11a but not CD11c leads to a decreased 
number of CD4 T cells in LNs and enhanced production of IL-17 by T cells in the 
spleen. Loss of β2 integrin expression does not have consistent effects on CD4 T 
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cell activation marker expression, but additional experiments are required to 
examine this further. Finally, the enhanced IFNγ production by CD4 T cells in CD11a 
KO mice was due to the Dock2Hsd mutation. 
 
Figure 3-24 Reduced numbers of CD4+ T cells in CD11a/CD18 KO mice and enhanced IL-17 
production in the spleen due to the integrin-deficiency.  
Cells were isolated from the spleen, mesenteric LN (mLN) and peripheral LN (pLN) of WT, CD11a 
KO, CD11b KO, CD11c KO, CD11d KO and CD18 KO mice (all WT for Dock2). (A) Cells were 
gated on CD3+CD4+ then T cell numbers calculated. (B) Percentage of splenic CD4 T cells 
expressing activation markers. (C) Production of IFNγ and IL-17 from splenic CD4 T in cells 
following in vitro re-stimulation with PMA/ionomycin. n=6, data pooled from 2 independent 
experiments. Data represents mean + SD. Statistical differences were determined using a one-way 
ANOVA. *p<0.05, ** p<0.01, ***p<0.005, ****p<0.0001, #p<0.01 when CD18 KO group excluded.  
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3.3 Discussion 
In summary, I set out with the aim to determine which β2 integrin family members 
regulate DCs and how this impacts the subsequent T cell response. However, this 
was confounded by the discovery that the integrin-deficient mouse strains used 
contained an additional mutation in a gene called Dock2. I have now identified the 
major phenotypes due to Dock2Hsd are a loss of MZ B cells and reduced number of 
CD4 T cells in the LNs of CD11c KO mice. The loss of both of these cell types is 
likely to have contributed to the reduced total cell number in the spleen of CD11a 
and CD11c KO mice, and in the LNs of CD11c KO mice affected by Dock2Hsd. 
Importantly, the increased activation of in vitro generated BMDCs and increased 
proportion of DCs found in vivo in CD11a KO and CD11c KO mice, were due to the 
loss of integrin expression. Further work is ongoing in the lab to follow up on the 
mechanism(s) by which CD11a and CD11c integrin subunits regulate the various 
aspects of DC phenotype and function. 
3.3.1 Implications of the Dock2 mutation identified in several 
strains of β2 integrin-deficient mice 
DCs are antigen presenting cells that play an essential role in mediating the 
induction of an immune response or tolerance of immune cells to specific antigens. 
It is essential to better understand the mechanisms regulating DCs and their ability 
to induce immune activation versus tolerance, to identify potential therapeutic 
targets for diseases where there is a loss of tolerance, such as autoimmunity. In 
recent years it has become apparent that β2 integrins are important regulators of 
immune activation, particularly in DCs. CD18 KO BMDCs showed enhanced 
cytokine production in response to TLR stimulation182 and the loss of β2 integrin 
receptor function increased co-stimulatory molecule expression on DCs under 
steady state conditions73. DCs lacking functional β2 integrins induced greater Th1 
responses73 whereas DCs expressing a constitutively active form of CD11a inhibited 
the generation of Th1 cells shown by reduced T-bet expression and IFNγ 
production88. These studies demonstrate that β2 integrins are important for the 
negative regulation of DC function and limiting the priming of T cell responses. 
However, it has not yet been determined which of the subunits and associated 
signalling pathways are responsible for this regulation.  
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The aim of this chapter was to determine which β2 integrin subunit(s) regulate DCs 
in vitro and in vivo, and to assess the impact that integrin loss on DCs has on their 
ability to prime T cells. These questions were answered using β2 integrin-deficient 
mice that lack a specific subunit: CD11a, CD11b, CD11c or CD11d. My initial 
findings indicated that CD11a and CD11c KO mice have significant differences in 
DC and T cell activation compared to WT: CD11a and CD11c KO BMDCs 
expressed higher levels of co-stimulatory molecules and displayed reduced 
adhesion to ICAM-1. Ex vivo analysis of spleen and LNs found an increased 
percentage of DCs in CD11a and CD11c KO mice, and increased activation and 
cytokine production in CD4 T cells. Together, these initial findings suggested that 
integrin subunits CD11a and CD11c mediate regulation of DC phenotype that, in 
turn, keeps T cell activation in check.  
While this work was underway, a publication highlighted that an additional mutation 
in a gene called Dock2 was present in several genetically modified mouse strains 
including Siae and Cmah KO mice309. They proposed this mutation originated from 
the C57BL/6Hsd colony at Harlan in the USA. As these mice were used for 
backcrossing of newly generated genetically modified strains, other mouse colonies 
may express the mutated form of Dock2, termed Dock2Hsd. Using PCR to test for 
the Dock2Hsd gene it was found that CD11a, CD11c and CD11d KO mice expressed 
the mutated form of Dock2 but CD11b KO and CD18 KO mice did not. The Dock2Hsd 
allele is a functional mutation that results in a failure of protein translation, therefore 
mice possessing the Dock2Hsd mutation pheno-copy Dock2 KO mice. The presence 
of Dock2Hsd in addition to the intended β2 integrin defect called into question whether 
the immune phenotypes described in the early sections of this chapter (Figures 3-1 
– 3-11) were due to the loss of integrin subunits or Dock2.  
Both Dock2 and integrins play important roles in cytoskeletal rearrangement, cell 
adhesion and migration. Given that the functions of β2 integrins and Dock2 in 
immune cells are similar, it was imperative that any effects resulting from Dock2Hsd 
were identified, and that the findings describing CD11a and CD11c as mediating the 
negative regulation of DC and T cell phenotypes were confirmed.  
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3.3.1.1 Uncovering Dock2-related phenotypes using CD11a/CD11c hets 
The initial approach taken to uncover which altered immune phenotypes were 
caused by Dock2Hsd and which were due to the β2 integrin loss, was to cross the 
CD11a and CD11c KO mice to create CD11a/c hets. These mice still expressed 
homozygous Dock2Hsd but were heterozygous for both CD11a and CD11c. The 
CD11a/CD11c het mice expressed intermediate levels of both of these integrin 
receptors and it was hypothesised that this level of expression would be sufficient 
to restore integrin function. If this hypothesis was correct then BMDCs generated 
from CD11a/CD11c hets would express co-stimulatory molecules at the same levels 
as WT, and the increased expression of T cell activation markers seen in CD11a 
and CD11c KO mice would be lost. Comparison of immune phenotypes in mice that 
were CD11a or CD11c homozygous KO or heterozygous for CD11a/CD11c 
expression with WT mice that either expressed WT Dock2 or Dock2Hsd allowed the 
separation of effects that were integrin-dependent or Dock2-dependent.  
However, it was identified in the Dock2 group (WT integrin expression but non-
functional Dock2), only one of the three mice was homozygous for Dock2Hsd and the 
other two were likely heterozygous based on the presence of MZ B cells in the 
spleen. As mice that were heterozygous for Dock2Hsd did not display an absence of 
MZ B cells it is likely that this trait is recessive. In the analysis of DCs, both in vitro 
and ex vivo, the hom and het Dock2Hsd mice clustered closely together and 
appeared similar to the WT mice. The fact that the increased co-stimulatory 
molecule expression on BMDCs and increased number of DCs found in the spleen 
were not seen in the Dock2 mice, despite variability in the expression of Dock2Hsd, 
further confirms the increased activation of DCs as an integrin-dependent and not a 
Dock2-dependent effect.  
3.3.1.2 Reduced cell numbers in CD11a and CD11c KO mice due to Dock2Hsd 
To confirm the findings from experiments using CD11a/CD11c het and integrin WT 
Dock2Hsd mice, cells from CD11a and CD11c KO mice bred to restore Dock2WT were 
analysed to confirm which effects were due to the integrin deficiency (figures 21-
23). There was a decreased total cell number in the spleen of CD11a and CD11c 
KO mice with Dock2Hsd however, in the same strains with Dock2WT expression the 
cell counts were equivalent to WT. A potential explanation for this is that the reduced 
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total cell number in the spleen was due to the loss of MZ B cells. MZ B cells absent 
from the spleen in CD11a and CD11c KO Dock2Hsd mice were restored upon the 
removal of the Dock2 mutation. There was also no defect found in the numbers of 
any other leukocyte population examined from the spleen of CD11a and CD11c KO 
mice with restored Dock2 function (CD4 T cells, CD8 T cells, γδ T cells, NK cells, 
neutrophils, macrophages, DCs, eosinophils; McIntyre & Morrison unpublished 
data). Taken together, this data suggests that Dock2Hsd caused a decreased total 
cell number in the spleen of CD11a and CD11c KO mice due to the loss of MZ B 
cells. In CD11c KO mice expressing Dock2WT, the numbers of MZ B cells were in 
fact increased compared to WT mice. This finding was surprising as it has previously 
been shown that B cell development is unaffected by the loss of functional β2 integrin 
receptors320. The equivalent number of MZ B cells in CD18 KO mice compared to 
WT is in agreement with this finding, but further work is required to determine why 
the loss of CD11c alone results in an increased number of MZ B cells.  
In addition to changes in B cell populations there were also differences found in CD4 
T cells. The number of CD4 T cells was reduced in the LNs of mice deficient in 
CD11a and CD11c that expressed Dock2Hsd. When the mice were bred to remove 
Dock2Hsd, this defect in CD4 T cells was lost from the CD11c KO but remained in 
the CD11a KO mice. Dock2 is known to play a role in T cell migration, as in Dock2 
KO mice the homing of CD4 T cells to the mLN and inguinal LNs was impaired319. 
The reduced number of CD4 T cells in CD11a and CD11c KO mice with Dock2Hsd 
is in agreement with these findings. The equivalent number of CD4 T cells found in 
the LNs of WT and WT Dock2Hsd mice is likely due to the fact that 2/3 of the Dock2 
mice were heterozygous for Dock2Hsd. This would mean that one WT copy of Dock2 
is sufficient to mediate CD4 T cell migration into secondary lymphoid tissues. A 
reduced number of CD4 T cells was found in the mLN and pLN of CD11a KO mice 
regardless of their Dock2 expression. It has previously been established that CD11a 
is involved in the migration of T cells into LNs by mediating firm adhesion of 
lymphocytes to endothelial cells68, therefore it is unsurprising that the decrease in 
CD4 T cells in CD11a KO mice is integrin-dependent. When comparing the average 
number of CD4 T cells from Dock2Hsd CD11a KO mice (mLN 5.5x105, pLN 3.1x105) 
with the Dock2WT CD11a KO (mLN 1.3x106, pLN 4.5x105), the number of LN CD4 T 
cells increased with the restoration of Dock2 function. This indicates that the 
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absence of Dock2 expression had an additive effect on the impairment in CD4 T cell 
migration seen in CD11a KO mice.  
3.3.1.3 Loss of Dock2 and β2 integrins contributed to changes in CD4 T cells 
The phenotype of CD4 T cells was also characterised in β2 integrin-deficient mice 
to determine whether the increased activation of T cells by CD11a KO DCs in vitro 
may also occur in vivo. Initial experiments showed increased activation of CD4 T 
cells in the absence of CD11a or CD11c expression, although these findings were 
not consistent when these same mice were compared to CD11a/CD11c hets, or 
when WT mice were compared to integrin-deficient mice with restored Dock2WT 
expression. There is evidence linking both Dock2 and β2 integrins to CD4 T cell 
activation. Dock2 is induced downstream of CD28 co-stimulatory signal to activate 
Rac, which is required for effective T cell activation321 and in vivo transfer of antigen-
specific Dock2 KO CD4 T cells show impaired activation in response to DC 
immunisation, based on CD25 and CD69 expression322. In β2 integrin signalling-
deficient mice, T cell activation was reduced following immunisation but unchanged 
during homeostasis320.  
In the experiment using mice expressing Dock2Hsd there was a consistent increase 
in the percentage of CD44+ CD4 T cells in the spleen of CD11a and CD11c KO 
mice, but this difference was lost when Dock2WT expression was restored. This 
suggests that enhanced activation of CD4 T cells was due to Dock2. However, as 
the absence of Dock2 is linked to reduced T cell activation322 and the Dock2Hsd mice 
had a global loss of Dock2 function, the mechanism could be mediated by another 
cell population as opposed to a cell-intrinsic effect on T cells. There was a significant 
decrease in CD25 expression on CD4 T cells from both CD11a and CD18 KO mice. 
Expression of CD25 (IL-2Rα) is upregulated during activation of conventional T cells 
but it is also expressed highly on regulatory T cells (Tregs)323,324. It has been shown 
that CD18-deficient mice have a reduced number of CD4+CD25+ Tregs325,326, 
therefore the reduced expression of CD25 may be due to the Treg deficiency in 
these mice, although a defect in activation of conventional CD4 T cells cannot be 
ruled out.  
In contrast to this, CD4 T cells from CD11d KO mice expressed higher levels of 
CD25 and CD69 than WT. To my knowledge, the loss of CD11d expression has not 
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previously been linked to an increased activation of CD4 T cells. CD11d is generally 
expressed on myeloid cells and not T cells, therefore this effect may be due to the 
loss of CD11d altering another cell population that ultimately increases CD4 T cell 
activation. It has been shown that CD11d-deficient T cells have an impaired 
proliferative response to staphylococcal enterotoxins58, suggesting that CD11d is 
required for an optimal T cell response. However, the CD11d KO mice used in the 
published study were the original strain donated to Jackson Labs and, therefore, the 
altered T cell response may be due to expression of Dock2Hsd.  
In the CD11d KO colony only some mice expressed Dock2Hsd. This indicates that of 
the mice that tested positive, the expression was likely heterozygous. In the initial 
experiments comparing DC and T cell phenotypes in β2 integrin-deficient mice, there 
were no significant findings identified in the CD11d KO mice. Given that the absence 
of splenic MZ B cells and reduced number of CD4 T cells in LNs were not seen in 
WT Dock2Hsd mice with heterozygous expression, it is probable that there were no 
apparent changes in immune cell phenotype in the CD11d KO mice that were due 
to Dock2Hsd because of the presence of at least one WT allele.  
3.3.1.4 Altered DC phenotypes were independent of Dock2Hsd and due to 
defects in β2 integrin expression 
It is clear the loss of both Dock2 and integrins contributed to changes in B and T cell 
populations in the β2 integrin α-chain deficient mice. Yet, the main aim of this chapter 
was to explore the regulatory function of β2 integrins in DCs. This was based on the 
previous report that the loss of β2 integrin-mediated signalling results in enhanced 
activation of BMDCs and an increase in mature migratory DCs in vivo73. The 
generation of BMDCs from Dock2Hsd mice with differing expression of CD11a and/or 
CD11c showed an upregulation of CD40, CD80 and CD86 in cells deficient in 
CD11a and/or CD11c but not those with WT integrin expression. Similarly, the 
increased number of DCs in the spleen of CD11a- and CD11c-deficient mice was 
also found to be β2 integrin-dependent. The study that demonstrated β2 integrin loss 
alters DCs used beta2TTT/AAA knock-in mice that have a mutated kindlin-3 binding 
site downstream of CD18, causing a loss of receptor function73. Importantly, these 
mice express Dock2WT. Therefore, the increased co-stimulatory molecule 
expression by BMDCs is due to the loss of β2 integrin expression. Taken together, 
this data shows that in the absence of CD11a or CD11c expression DCs show an 
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increased level of activation in vitro, suggesting that CD11a and CD11c are involved 
in the negative regulation of DCs.  
I did not find any evidence to suggest that the DC phenotypes I described in β2 
integrin-deficient mice were related to the mutation in Dock2. However, Dock2 has 
previously been reported to influence the development and function of DC 
populations. A reduced number of plasmacytoid DCs (pDCs) has been described in 
the spleen and LNs of Dock2-deficient mice309,327. Dock2 is essential for pDC 
migration, in Dock2 KO mice pDCs are reduced in the spleen and LNs despite 
normal development in the bone marrow, and in in vitro assays were unable to 
migrate towards chemokine stimuli327. However, this is not true for cDCs as they 
express Dock180 in addition to Dock2 which have redundant functions, and the 
defects in the pDC population in Dock2 KO mice were not present in cDCs327. The 
majority of pDCs express B220328, and in the ex vivo DCs analysis B220+ cells were 
removed within the dump gate. The DC data from β2 integrin-deficient mice only 
included cDCs and was therefore not impacted by the reduction in pDCs caused by 
Dock2Hsd. 
Finally, it is worth noting that the identification of Dock2Hsd in CD11a KO, CD11c KO 
and CD11d KO mice is an important finding that must be taken into consideration 
when interpreting any results published previously using these mice. In addition to 
the lack of MZ B cells and reduced numbers of pDCs, mice expressing Dock2Hsd 
have increased numbers of splenic CD8 T cells with a memory phenotype309. 
Indeed, a higher number of central memory CD8 T cells was also described in 
CD11a KO mice that were obtained from Jackson, so will express Dock2Hsd 329. This 
alteration in CD8 T cells may not be a CD11a-dependent effect, as interpreted by 
the authors, but instead due to Dock2Hsd. Using Dock2 KO mice it was shown that 
Dock2-deficient T cells have impaired TCR clustering330. This decreased TCR 
clustering was also described in CD8 T cells from CD11a KO mice, where they 
attributed this effect to the absence of CD11a expression, however it is likely that 
these mice expressed Dock2Hsd 331. My data shows the increased expression of 
CD44 on CD4 T cells in the spleen of CD11a and CD11c KO mice and loss of MZ 
B cells was due to Dock2Hsd and not the integrin-defect. Importantly, the altered 
phenotype of BMDCs and DCs ex vivo were β2 integrin-dependent. The loss of MZ 
B cells and pDCs, increase in memory CD8 T cells in mice affected by Dock2Hsd will 
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likely also have an indirect effect on other leukocyte populations. For example, pDCs 
can drive T cell responses, activate NK cells and recruit other immune cells through 
chemokine production332. Therefore, there will be knock-on effects on the phenotype 
and function of other leukocyte subsets. These findings highlight the importance of 
using multiple approaches to validate findings and not relying completely on 
genetically-deficient mouse models.  
3.3.2 Regulation of DCs by β2 integrins  
My data demonstrates that, regardless of the mutation in Dock2, CD11a and CD11c 
act as negative regulators of DC activation. This conclusion can be made based on 
the following evidence: (i) BMDCs with reduced or absent CD11a and CD11c 
expressed higher levels of co-stimulatory molecules, whereas in integrin-sufficient 
BMDCs expression was unchanged whether from Dock2WT or Dock2Hsd mice. (ii) 
These findings are in line with previously published data, where mice with signalling-
deficient β2 integrin receptors showed an increased percentage of DCs in the spleen 
and BMDCs generated from these mice expressed higher levels of co-stimulatory 
molecules73.  
Initial experiments carried out used β2 integrin-deficient in vitro generated BMDCs. 
First, integrin expression was assessed on the BMDCs to determine whether the 
loss of one β2 integrin subunit affects the expression of the others. β2 integrin family 
members have overlapping ligand repertoires and as a result there is a level of 
redundancy of function between the receptors. It is therefore possible that in the 
absence of one β2 integrin, another may be upregulated to help compensate for the 
loss. Other than the loss of integrin expression expected based on the genetic KO, 
the only difference seen was in the levels of CD11b. CD11b expression was 
downregulated in CD11a, CD11c and CD11d KO BMDCs. However, as there were 
no significant differences in the activation or priming of T cells by CD11b KO BMDCs 
it is unlikely that the reduced CD11b expression in the other genotypes is 
contributing to the effects seen. 
It was previously shown that in BMDCs expressing non-functional β2 integrin 
receptors there was an enhanced expression of MHC II, CD40, CD80 and CD8673. 
From the results in the β2 α-chain KO mice, the increased co-stimulatory molecule 
expression can be attributed specifically to the loss of CD11a and CD11c, 
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suggesting that these integrins are involved in the regulation of signalling pathways 
associated with co-stimulatory molecule gene expression. The transcription factor 
PU.1 induces the transcription of CD80 and CD86 in BMDCs333 and can be activated 
by GM-CSF334 and Akt335. It was previously shown that GM-CSF-induced activation 
of the MAPK pathway, including pAkt, was enhanced in β2 signalling-deficient 
BMDCs73. Therefore, enhanced signalling through pAkt in the absence of CD11a 
and CD11c may activate PU.1 to induce greater transcription of CD80/CD86. There 
was no difference in MHC II expression in the absence of any of the individual CD11 
subunits. This could be explained by the differential signalling pathways that control 
the expression of MHC II compared to CD80/CD86. The transcription of MHC II is 
activated by the transactivator protein CIITA, which can be induced by STAT5336. In 
the absence of β2 integrin signalling, BMDCs showed comparable levels of 
pSTAT573, indicating that β2 integrin-mediated regulation occurs independently of 
STAT5. There was no difference in the activation of BMDCs from CD11b mice, in 
agreement with the findings of Ling et al., who reported similar expression of MHC 
II, CD40, CD80 and CD86 in WT and CD11b KO immature BMDCs 185. However, in 
contrast to my findings the authors also demonstrated reduced expression of MHC 
II, CD80 and CD86 after LPS-stimulation in CD11b KO BMDCs. The concentration 
of LPS they used was 20 times greater than I used in this study (1μg/ml compared 
to 50ng/ml) and the duration of stimulation was longer at 24h, which may explain 
the inconsistency in results.  
Following identification of increased co-stimulatory molecule expression on CD11a 
and CD11c KO BMDCs, the effect on the subsequent T cell response was then 
tested. In co-cultures of BMDCs with CD4 T cells there was increased proliferation 
and activation of T cells when cultured with CD11a KO but not CD11c KO BMDCs 
compared to WT, despite both CD11a and CD11c KO BMDCs displaying increased 
expression of co-stimulatory molecules. Although there were differences in the 
levels of co-stimulatory molecules between CD11a and CD11c KO BMDCs. The 
expression of CD40 was not significantly upregulated on CD11c KO BMDCs 
compared to WT, and in the absence of LPS the levels of CD86 were similar in 
CD11c KO and WT BMDCs. This indicates that there are subtle differences in co-
stimulatory molecule expression on CD11c KO BMDCs, potentially explaining the 
enhanced T cell response with CD11a KO but not CD11c KO BMDCs.  
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The interactions between CD11a KO BMDCs and CD4 T cells in vivo resulted in an 
increase in the number of T cells in the draining LN, but these T cells displayed 
lower levels of activation marker expression. This is in contrast to the in vitro data 
where the absence of CD11a on BMDCs caused an increase in T cell activation. 
The higher number of OT-II T cells in the LN of mice that received CD11a KO 
BMDCs suggests that these cells induced greater recruitment or proliferation of the 
transferred CD4 T cells. CFSE staining of the transferred OT-II T cells could be used 
to investigate this in the future. A potential explanation for the reduced expression 
of CD25, CD69 and CD44 is that the CD11a KO BMDCs induced an earlier 
activation of the T cells, so after 3 days these receptors may already be 
downregulated. Whereas the WT BMDCs may activate the T cells at a slower rate, 
therefore at the 3 day timepoint the expression of activation markers may be at their 
peak. A time-course of analysis would be required to address this issue. 
Alternatively, the phenotype of the BMDCs may be changed when they are 
transferred in vivo, thereby losing their capacity to induce enhanced T cell 
responses. Recovering enough BMDCs from the draining LN after transfer makes 
this difficult to study.  
When integrin-deficient DCs were stained ex vivo for activation marker expression 
the altered co-stimulatory molecule expression found in the BMDCs was not 
replicated, with the exception of higher CD86 expression on splenic DCs from 
CD11c KO mice. There was a high variability in the data from DCs stained ex vivo, 
demonstrated by large error bars, therefore it was not possible to detect any subtle 
effects. This discrepancy between in vitro and in vivo DCs, may be due to factors 
within the microenvironment in vivo that affect expression of these markers. In 
particular for CD40 the difference in expression was only seen when DCs were 
activated with LPS, suggesting an inflammatory insult may be required to detect any 
differences in this marker. In addition, the generation of BMDCs produces a mixed 
population of DCs and macrophages337 compared to the analysis of DCs ex vivo, 
where monocyte-derived cells were excluded. In the in vivo setting DCs were 
analysed by gating out other leukocytes then gating on MHC II+ cells, therefore the 
purity of DCs analysed may have impacted the results, discussed in detail below. 
There is also evidence that BMDCs display a transcriptional signature related to 
subsets of migratory DCs found in vivo337, so the enhanced expression of co-
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stimulatory molecules may be subset-specific and consequently not detected by 
analysis of total DCs in vivo.  
It was previously found that when β2 integrin receptors are functionally impaired, 
DCs in the spleen expressed higher levels of CD8673. An increase in CD86 
expression was also identified in splenic DCs from CD11c KO mice, indicating that 
the effect seen in the signalling-deficient mice may be due to the specific loss of 
CD11c. However, it must be taken into consideration that the markers used to 
identify the DCs were different. In the beta2TTT/AAA KI mice, the integrin receptors 
have impaired signalling but are still expressed on the cell surface, therefore CD11c 
was used as marker to identify DCs. The use of CD11c KO mice meant that an 
alternative gating strategy had to be used to identify DCs from the β2 integrin α-
chain KO mice. This was done by using ‘dump’ markers to exclude 
monocytes/macrophages (CD64), pDCs (B220), B cells (CD19/B220), NK/NK T 
cells (NK1.1), neutrophils (Gr1) and T cells (TCRβ). Cells were then gated on MHC 
II+ and these were considered DCs. Using this method, the DCs were of 80-90% 
purity based on the percentage of CD11c+ identified in WT, CD11a KO, CD11b KO 
and CD11d KO mice. This means that 10-20% of the cells are not DCs as they did 
not express CD11c. Potential sources of contamination would be cell types that 
were not removed by the dump gate and are known to express MHC II. This 
includes: ILCs338, stromal cells339 and γδ T cells262. The addition of CD45 to the 
panel would remove any stromal cells and replacement of TCRβ with CD3 would 
allow the exclusion of γδ T cells in addition to αβ T cells. Further optimisation of the 
gating strategy for DCs in β2 integrin-deficient mice will clarify whether the findings 
from BMDCs generated in vitro are not replicated with in vivo DCs, or if the effects 
were lost due contamination of other cell populations.  
One of the main unanswered questions is why the loss of CD11a and CD11c results 
in enhanced DC activation but not CD11b or CD11d. This could potentially be 
explained by the differential expression of the receptors on DCs, distinct ligand 
binding or downstream signalling pathways. BMDCs expressed CD11a, CD11b and 
CD11c (Figure 3-1), but CD11d was not measured due to the lack of a commercially 
available murine CD11d antibody. It could be hypothesised that higher expression 
of CD11a and CD11c than CD11b would indicate the functional significance of these 
subunits in BMDCs. Contrary to this, CD11b was expressed highest by BMDCs 
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(95%), followed by CD11a (70-80%) and then CD11c (65%) (relative expression 
shown in Figure 3-1). This suggests that the negative regulation of DCs by CD11a 
and CD11c is not governed by cellular expression levels of the receptors.  
An alternative explanation is that CD11a and CD11c share a ligand specificity that 
differs from CD11b and CD11d. CD11a has the most restricted β2 integrin ligand 
repertoire, only recognising the ICAM family (ICAM-1-5) and CD11c has also been 
shown to bind ICAM-1103. CD11b and CD11d have a high degree of structural 
homology and can recognise a similar diverse ligand repertoire including ICAM-3, 
VCAM-1, fibronectin, fibrinogen and other matrix proteins22–25. But unlike CD11b, 
CD11d does not display affinity for ICAM-124. CD11b and CD11c also share a high 
degree of structural homology and the ability to bind ICAM-125, meaning there is not 
an obvious ligand that conveys specificity for CD11a and CD11c. However, ICAM-
1 can exist in different isoforms, which consist of a combination of immunoglobulin 
(Ig) domains numbered 1-5340. The ability of ICAM-1 to bind CD11a is isoform-
dependent341 and CD11a binds to Ig domain 1 whereas CD11b binds to Ig domain 
3342. The CD11c-binding Ig domain has not been characterised, but there may be a 
specific isoform/s of ICAM-1 that demonstrate specificity for CD11a and CD11c over 
CD11b. In my adhesion assay data, CD11a and CD11c were the major mediators 
of BMDC binding to ICAM-1, suggesting it may be specifically integrin binding to 
ICAM-1 that regulates DCs.  
Downstream of β2 integrin receptor binding signalling pathways are activated by the 
intracellular cytoplasmic tails. The β2 integrin α chains differ in length and sequence, 
with different phosphorylation residues on their cytoplasmic regions343. The specific 
signalling molecules that bind individual α chains are not well characterised, unlike 
the CD18 chain, but shared downstream signalling molecules may explain the 
negative regulation of DCs by CD11a and CD11c, with different pathways induced 
compared to CD11b and CD11d.  
In addition to the reason for DC regulation being specific to CD11a and CD11c 
receptors, the mechanism of this regulation is also unknown. BMDC cultures 
contained GM-CSF and IL-4, therefore it is likely that the β2 integrin-mediated 
regulation of DCs occurs downstream of signalling from the receptors for these 
cytokines. It was previously shown that in the absence of β2 integrin signalling, GM-
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CSF treatment of BMDCs enhanced phosphorylation of Syk, p38, Erk and Akt but 
not STAT573. This suggests that under homeostatic conditions, β2 integrin receptor 
signalling may induce inhibitors of the MAPK and PI3K pathways. This could occur 
through the targeting of GM-CSF-induced signalling molecules for degradation via 
phosphorylation that enables degradation by ubiquitination, as was demonstrated 
for the signalling adapters TRIF and MyD88 in macrophages downstream of 
CD11b183. Thus, in the absence of β2 integrins, signalling molecules downstream of 
GM-CSF are unconstrained.  
3.4 Conclusions 
In conclusion, I have identified that the loss of CD11a and CD11c leads to enhanced 
co-stimulatory molecule expression on BMDCs generated in vitro. These findings 
demonstrate that CD11a and CD11c function as negative regulators of DC 
activation. The presence of an additional mutation in the Dock2 gene in CD11a, 
CD11c and CD11d KO mouse strains contributed to altered immune phenotypes in 
addition to the β2 integrin-deficiency. Loss of Dock2 expression caused a loss of MZ 
B cells and in CD11c KO mice reduced CD4 T cell numbers in LNs. Whereas the 
defect in CD4 T cells in CD11a KO mice was due to the loss of both Dock2 and 
CD11a. The enhanced expression of co-stimulatory molecules on DCs in vitro and 
increased percentage of DCs in vivo in CD11a and CD11c KO mice was 
independent of Dock2. These findings have provided new information on how 
integrins regulate DCs, with the identification of the specific β2 integrin receptor 
subunits, CD11a and CD11c as negative regulators of DCs. Further studies can now 
focus on the potential ligands for these receptors and the mechanism of this 
regulation.  
 
 
  122 
Chapter 4 Characterisation of γδ T cells in β2 
integrin-deficient mice 
4.1 Introduction 
β2 integrin receptors play an essential role in αβ T cell migration and function. CD11a 
is the β2 integrin most highly expressed on T cells and plays a major role in cell 
adhesion of CD4 and CD8 T cells. The binding of CD11a to ICAM-1 expressed on 
antigen presenting cells mediates the formation of the immune synapse, an 
important interaction for the differentiation and activation of T cells 75,304. In a similar 
interaction, CD8 T cells adhere to target cells via CD11a and this interaction is 
necessary for effective cell killing through release of cytotoxic granules 77,87. CD11a-
ICAM-1 contacts are also required for αβ T cell migration, both extravasation from 
the bloodstream into tissues and for entry into lymph nodes via the high endothelial 
venule 64,68.  
β2 integrins are also expressed on γδ T cells however, their role is much less 
understood than on αβ T cells. Previous studies suggest that unlike αβ T cells, the 
migration of γδ T cells to sites of inflammation is not dependent on β2 integrins. 
Models of experimental autoimmune encephalitis (EAE) and psoriasis carried out in 
β2 integrin-deficient mice demonstrated that γδ T cells were able to effectively 
migrate to the primary site of inflammation, central nervous system and skin 
respectively, despite lacking the adhesion receptor 295,296. There has also been work 
demonstrating that mice deficient in β2 integrins can develop inflammation 
associated with an increase in γδ T cells. In a model of reduced CD18 expression 
(CD18hypoPL/J) mice spontaneously develop skin inflammation, with IL-17-
producing γδ T cells found in the skin lesions and draining lymph nodes 296. CD11a 
KO mice can develop periodontal disease as they age, which is also associated with 
an increased number of IL-17-producing γδ T cells in the oral mucosa 302. There is 
additional evidence of expanded γδ T cells in integrin-deficient mice without signs 
of inflammation. An increased number of γδ T cells has been described in the 
cervical lymph nodes and spleen of CD18 KO mice 297,303.  
Despite several studies demonstrating an expansion of γδ T cells in the absence of 
β2 integrins, the mechanism of this expansion has not been identified. Furthermore, 
the number of γδ T cells in other mucosal tissues, where they perform essential 
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functions such as the lungs and intestines, were not investigated. To address this, I 
used total β2 integrin deficient mice, CD18 KO, to assess γδ T cells more globally 
under steady-state conditions. It is worth noting that some strains of CD18 KO mice 
have been reported to develop a spontaneous dermatitis5, however the colony 
housed at our mouse facility are on a C57BL/6 background which are resistant to 
the development of skin inflammation344. 
4.1.1 Hypothesis and Aims 
Given that several mouse models indicate the loss of β2 integrin expression leads 
to an increased number of γδ T cells, my hypothesis is that β2 integrins are a novel 
regulator of γδ T cells. 
The overall aim of this chapter was to examine how the absence of β2 integrins 
alters the phenotype and localisation of γδ T cells under steady state conditions. 
This is further divided into 4 sub-aims: 
1. At which lymphoid/mucosal sites are γδ T cell numbers increased in CD18 
KO mice? 
2. Is the increased number of γδ T cells due to a global expansion or specific 
subset/s? 
3. Which β2 integrin family member/s (CD11a/b/c/d) is responsible for the 
phenotype? 
4. Does β2 integrin expression differ on subsets of γδ T cells? 
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4.3 Results 
4.3.1 CD18 KO mice have a tissue-restricted increase in γδ T cells 
The first aim was to determine which lymphoid and mucosal sites display an 
increase in γδ T cell numbers in CD18 KO mice compared to WT. Cells were isolated 
from the spleen, blood, lungs, uterus, skin (ears), small intestine lamina propria (LP), 
small intestine epithelium (Ep), colon, Peyer’s patches, mesenteric lymph nodes 
(mLN), peripheral lymph nodes (pLN; inguinal, brachial and axillary pooled), gingiva 
(oral mucosa), thymus and bone marrow. These were analysed by flow cytometry 
to determine the percentage and number of γδ T cells present in each tissue. 
Evaluation of αβ T cells was provided as a comparator population. A defined gating 
strategy was used to determine cell populations (Figure 4-1). 
 
Figure 4-1 Flow cytometry gating strategy to identify αβ and γδ T cells.  
(A) Gating strategy used to identify αβ and γδ T cells for data shown in figures 4-2 and 4-3 with the 
exception of small intestine, colon, mLN and Peyer’s patches, which were gated as shown in (B). 
(C) Gating strategy used to identify αβ and γδ T cells for figures 4-4 onwards. Examples shown in 
(A & C) from CD18 KO spleen are representative of WT and of other tissues. Example shown in 
(B) from WT mLN is representative of CD18 KO and other intestinal tissues.   
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The comparison between WT and CD18 KO mice revealed that with the exception 
of the skin, colon and thymus, there was a substantial increase in the percentage of 
CD3+ γδ T cells in CD18 KO mice (Figure 4-2). This was accompanied by the 
expected decrease in proportion of αβ T cells. Enumeration of the absolute cell 
numbers (Figure 4-3) revealed that the actual differences in γδ and αβ T cells were 
site-specific. Notably, the absolute number of γδ T cells were greater only in the 
spleen, blood, lungs and uterus (Figure 4-3). In the skin, small intestine, colon, 
Peyer’s patches, lymph nodes, gingiva, thymus and bone marrow there was no 
difference in the number of γδ T cells. In addition, the number of αβ T cells was 
decreased in the colon, Peyer’s patches, mLN, pLN, thymus and bone marrow. It 
has already been established that αβ T cell migration is dependent on β2 integrins, 
in particular they require these integrin receptors to enter lymph nodes via high 
endothelial venules68. It is therefore unsurprising that CD18 KO mice show a 
decreased number of αβ T cells in several lymphoid tissues including the mLN, pLN 
and Peyer’s patches.  
This comprehensive tissue analysis indicates that in the absence of CD18 there is 
an increased number of γδ T cells in a restricted number of sites, namely the spleen, 
blood, lungs and uterus.   
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Figure 4-2 Increased proportion of γδ T cells in multiple tissues of CD18 KO mice.  
Cells were isolated from various tissues of WT and CD18 KO mice then analysed by flow 
cytometry. Percentage of αβ and γδ T cells as a proportion of CD3+ are shown, as per the gating 
strategy in Fig 1-1A. Spleen, blood, lungs, skin, pLN, gingiva, thymus, bone marrow n=10. Uterus, 
Peyer’s patches n=9. Small intestine LP WT n=9, CD18 KO n=8. Small intestine Ep WT n=9, CD18 
KO n=8. Colon and mLN n=6. Male and female mice were used, aged 6-14 weeks. Data are 
pooled from a minimum of 3 independent experiments; each symbol representing an individual 
mouse. Statistical differences were determined using a two-way ANOVA *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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Figure 4-3 Increase in the number of γδ T cells in the spleen, blood, lungs and uterus of 
CD18 KO mice.  
Cells were isolated from various tissues of WT and CD18 KO mice then analysed by flow 
cytometry. Absolute number of αβ and γδ T cells per tissue are shown. For blood numbers were 
calculated per 100µl. Spleen, blood, lungs, uterus, skin n=18. Gingiva and bone marrow n=10. 
Small intestine LP WT n=9, CD18 KO n=8. Small intestine Ep WT n=8, CD18 KO n=9. Colon and 
mLN n=6. Peyer’s patches n=9. pLN WT n=18 CD18 KO n=16. Thymus n=20. Male and female 
mice were used, aged 6-14 weeks. Data from a minimum of 3 independent experiments; each 
symbol represents an individual mouse. Statistical differences were determined using a two-way 
ANOVA *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Given that there was an increase in the number of γδ T cells found in the blood and 
also lungs, a highly vascularised organ, there could be contaminating cells in the 
lung samples that were circulating in the blood. To minimise contamination by 
leukocytes present in the vasculature, the lungs were perfused prior to removal. This 
will not completely remove all circulating cells present in the lung vasculature but 
does provide an appropriate comparator. Thus, to confirm that the cells analysed 
were present in lung tissue, γδ T cells recovered from perfused lung tissue were 
compared to unperfused. Both the percentage and number of γδ T cells isolated 
from unperfused or perfused lung tissue were similar (Figure 4-4). The same 
significant increase in γδ T cells can be seen when comparing CD18 KO to WT. 
There was no significant difference between the number of γδ T cells from 
unperfused and perfused lungs, regardless of the genotype, suggesting that the γδ 
T cells analysed are likely to reside in the lung tissue. Ideally, immunofluorescent 
microscopy could provide information on the location of γδ T cells within the lungs 
and visualise their position in relation to blood vessels and lung tissue. 
Unfortunately, although staining of lung sections for TCRγδ was attempted, due to 
technical issues it was unsuccessful. Alternatively, intravenous administration of 
labelled antibody (e.g. anti-CD45) prior to analysis of the lungs would confirm 
whether or not the γδ T cells are in the circulation (staining positive) or the tissue 
(staining negative). 
 
Figure 4-4 Perfusion of lungs does not affect the percentage/number of γδ T cells analysed. 
Cells were isolated from the lungs of WT and CD18 KO mice either immediately, or following 
perfusion with 2mM EDTA. WT/CD18 KO unperfused and WT perfused n=8, CD18 KO perfused 
n=7. 3 independent experiments; each symbol represents and individual mouse. Statistical 
differences were determined using a two-way ANOVA. ns not significant, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.  
As noted above, analysis of individual tissues from CD18 KO mice identified that γδ 
T cell numbers are increased in the spleen, blood, lungs and uterus compared to 
WT. In order to assess the impact this has on the overall number of γδ T cells from 
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WT and integrin-deficient mice, the total number of γδ T cells was calculated by 
plotting the average number from all organs analysed. It was found that overall 
CD18 KO mice had a 6.5 times greater number of γδ T cells at 1.1x107, compared 
to 1.7x106 in WT mice (Figure 4-5). This was predominantly due to heightened 
numbers within the spleen, with CD18 KO mice displaying a 50-fold increase in γδ 
T cells in this organ. Similarly, in the lungs there was also a 50-fold increase in γδ T 
cells, whereas the increase was lower in the blood and uterus (8- and 4-fold 
respectively).  
 
Figure 4-5 CD18 KO mice have 6.5 times more γδ T cells than WT.  
Data from Figure 1-3 represented as the average number of γδ T cells per tissue, used to calculate 
the total number in WT and CD18 KO mice. For the blood the total number was calculated based 
on mouse blood volume 58.5ml/kg and an average weight of 25g345.  
In summary, the loss of CD18 expression leads to a 6.5-fold increase in the number 
of γδ T cells. This was due to higher numbers in a restricted number of sites; the 
spleen, blood, lungs and uterus. There were no differences in γδ T cell numbers 
found in the 10 other tissues examined.  
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4.3.2 Loss of β2 integrin expression causes a specific increase in 
Vγ6Vδ1+ IL-17-producing γδ T cells 
After establishing that the increase in γδ T cells found in β2 integrin-deficient mice 
is not restricted to the spleen and cervical LNs as previously reported 297,303, the 
next question was whether the expanded γδ T cells in CD18 KO mice were 
phenotypically different from those in WT mice. There are a number of cell surface 
markers, cytokines and transcription factors that are commonly used to characterise 
γδ T cells. The ability to produce either IFNγ or IL-17 broadly divides γδ T cells into 
two subsets. These subsets have different functions in response to infectious 
challenge and in diseases such as cancer can either promote or protect against 
tumour progression. Previous studies have identified that IFNγ-producing γδ T cells 
are CD62Lhi CD44lo CD45RB+ CD27+ and express T-bet, whereas IL-17-producing 
γδ T cells are CD62Llo CD44hi CD45RB- CD27- and express RORγt 199,206,207.  
Initial experiments evaluated the expression of surface markers. The majority of γδ 
T cells from the spleen of CD18 KO mice expressed CD44 but lacked expression of 
CD62L, CD27 and CD45RB (Figure 4-6A). Whereas those from a WT spleen mainly 
expressed CD62L, CD27 and CD45RB but lacked CD44. Both expression of the 
TCR and its co-receptor CD3 were higher on γδ T cells from CD18 KO compared to 
WT. High expression of these markers on γδ T cells has previously been shown to 
identify a population of IL-17-producing cells that express Vγ6 346. Combined, this 
implies that there may be an increase in Vγ6+ γδ T cells in the CD18 KO spleen. 
This was further supported by the analysis of transcription factors T-bet and RORγt 
(associated with IFNγ and IL-17 production respectively), which showed an 
increased proportion of CD18 KO γδ T cells expressed RORγt in comparison with 
WT. There was no difference in the expression of T-bet (Figure 4-6A).  
Based on the expression of surface markers and transcription factors, CD18 KO γδ 
T cells display a phenotype associated with IL-17 production. To investigate if this 
was the case, splenocytes from WT and CD18 KO mice were stimulated with 
PMA/ionomycin and their cytokine production was analysed. γδ T cells from CD18 
KO mice produced higher levels of IL-17 and less IFNγ (Figure 4-6C). Despite this 
percentage difference, calculation of the number in the whole spleen showed that 
IL-17+ γδ T cells were increased but there was no difference in the IFNγ+ γδ T cells.  
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Figure 4-6 CD18 KO γδ T cells express high levels of CD44, CD3, TCRγδ, RORγt and IL-17.  
Analysis of γδ T cells from the spleen of WT and CD18 KO mice by flow cytometry. (A) 
Representative plots of cell surface markers and transcription factors. (B) Percentages and number 
of IL-17+ and IFNγ+ γδ T cells following in vitro stimulation with PMA/ionomycin for 4h. n=9. Data 
representative of 3 independent experiments. Statistical differences were determined using a two-
way ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
As γδ T cells from CD18 KO mice showed an increased ability to produce IL-17 
following in vitro stimulation, the next question was whether CD18 KO mice display 
higher levels of IL-17 in vivo. The quantity of IL-17 was measured by ELISA in the 
serum and tissue supernatants (media from the whole tissue incubated for 4h) 
isolated from WT and CD18 KO mice. The levels of IL-17 were increased in the 
serum and spleen of CD18 KO mice compared to WT but there was no difference 
in the lungs or uterus. This suggests that circulating IL-17 is increased in CD18 KO 
mice, however, it is apparent that IL-17 production is not enhanced at all the sites 
where an increase in γδ T cell numbers was found.  
The ELISA data showed that CD18 KO mice have increased levels of IL-17 in the 
serum and spleen, but this does not confirm that γδ T cells are the source of the IL-
17. The ability of γδ T cells from the lungs and uterus (where an increased number 
of γδ T cells was found) to produce IL-17 had also not been assessed. To determine 
which cells produce IL-17 in the tissues of WT and CD18 KO mice, and therefore 
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assess the potential contribution of γδ T cell-derived IL-17 to the levels measured in 
supernatant samples, cells were re-stimulated in vitro with PMA/ionomycin and the 
phenotype of IL-17-producing cells was analysed. The gating strategy is shown in 
Figure 4-7B.  
In the spleen, lungs and uterus of WT mice, the predominant IL-17 producers were 
a population of non-T cells (CD3-) (Figure 4-7C). Conversely, in CD18 KO mice the 
main source of IL-17 was γδ T cells, with a significant increase found in the 
percentage of IL-17+ cells that were TCRγδ+ compared to WT. In all tissues this was 
accompanied by a significant decrease in the percentage of IL-17-producing non-T 
cells. This shows that γδ T cells in the spleen and lungs have an enhanced potential 
to produce IL-17 despite similar levels of IL-17 detected by ELISA. Interestingly, in 
the CD18 KO spleen there was also a decreased proportion of CD4 T cells and in 
the uterus a decrease in CD45- cells within the IL-17+ population compared to WT.  
When the total number of IL-17-producing cells were calculated and compared 
across tissues, a significant increase in the number of IL-17+ cells was detected in 
the spleen but not lungs or uterus of CD18 KO mice compared to WT (Figure 4-7D). 
This shows that although there appears to be an increased number of IL-17-
producing cells in the lungs and uterus, this is not significant when compared 
alongside the spleen, indicating that there is a greater increase in IL-17+ cell 
numbers in the spleen. This may explain why there is an increase in IL-17 levels in 
the spleen but not lungs or uterus of CD18 KO mice. 
Overall, this data indicates that in CD18 KO mice the predominant cell type capable 
of producing IL-17 is γδ T cells. Consequently, it is likely that the increased levels of 
IL-17 found in vivo are due to enhanced production by γδ T cells.  
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Figure 4-7 Increased levels of IL-17 in the serum and spleen of CD18 KO mice in vivo and in 
γδ T cells in vitro.  
(A) Levels of IL-17 were measured by ELISA from serum isolated from the blood of WT and CD18 
KO mice, and from tissue supernatants collected by incubating the whole tissue in complete media 
for 4h at 37°. Dotted line indicates the limit of detection (62.5pg/ml). Serum n=11, spleen n=9, 
uterus and lungs n=8. Each symbol represents an individual mouse, with mean shown. (B&C) The 
phenotype of IL-17+ cells were analysed by flow cytometry, gating strategy (B) percentage of IL-17+ 
cells of indicated phenotype. (D) Total number of IL-17+ cells. Data represents mean + SD. n=9. 
Data pooled from 3 independent experiments. Statistical differences were determined using a two-
way ANOVA. ns not-significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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I have identified that there is an increase in IL-17A-producing γδ T cells in β2 integrin-
deficient mice, specifically in the spleen, blood, lungs and uterus. The next question 
was whether the expanded population occurred due to the enhancement of one or 
more subsets of γδ T cells. Murine γδ T cells can be categorised according to the 
Vγ chain expressed as part of the TCR, each of which is associated with a specific 
wave of thymic development, tissue-homing properties and cytokine profile196. 
These are numbered Vγ1-7 (Heilig and Tonegawa nomenclature 224), with IL-17 
production predominantly by Vγ4+ and Vγ6+ cells (Figure 1-5, Table 1-1). In order to 
determine any Vγ chain bias in the expanded population, cells isolated from various 
tissues of WT and CD18 KO mice were analysed by flow cytometry for expression 
of Vγ chains that have commercially available antibodies (Vγ1, Vγ4 and Vγ5). Based 
on the data above (increased number of IL-17+ γδ T cells in CD18 KO mice) it was 
hypothesised that the expanded population is likely to be either Vγ4+, Vγ6+, or a 
combination of both. 
In line with prior studies, the majority of the γδ T cells in the WT spleen, blood and 
lungs were Vγ1+ or Vγ4+ (Figure 4-8A). Over 70% of the γδ T cells in these tissues 
were accounted for in WT mice using the available Vγ1, Vγ4 and Vγ5 antibodies. In 
contrast, CD18 KO mice showed a decrease in the proportion of Vγ1+ and Vγ4+ cells, 
with Vγ1-Vγ4-Vγ5- cells representing over 85% of the γδ T cell repertoire in the 
spleen, blood and lungs. In the WT uterus 90% of γδ T cells were Vγ1-Vγ4-Vγ5-. 
This is expected as the predominant subset in the uterus expresses Vγ6 198. In the 
CD18 KO uterus the percentage of Vγ1-Vγ4-Vγ5- γδ T cells was increased to 98%. 
In the small intestine over 50% of the repertoire was unidentified in WT mice. The 
likely explanation is that the majority of these cells are Vγ7+, the predominant subset 
located in the intestine 202,347. Interestingly in CD18 KO mice the lamina propria 
displayed an increase in the Vγ1-Vγ4-Vγ5- population similar to the spleen, blood, 
lungs and uterus whereas in the epithelium there was no difference in repertoire 
between the WT and CD18 KO mice. In the skin of both WT mice and CD18 KO 
mice, all γδ T cells could be accounted for and, as expected, 95% were Vγ5+.  
Despite changes in the proportions of multiple γδ T cell subsets in CD18 KO mice, 
calculation of the absolute numbers of each subset revealed that only the Vγ1-Vγ4-
Vγ5- γδ T cells were significantly altered (Figure 4-8B). The number of this subset 
was increased in the same tissues that we found the total γδ numbers raised in 
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(spleen, blood, lungs and uterus; Figure 1-3) and surprisingly also in the small 
intestine lamina propria.  
 
Figure 4-8 Increased number of Vγ1-4-5- γδ T cells in the spleen, blood, lungs, uterus and 
small intestine lamina propria of CD18 KO mice.  
Cell were isolated from WT and CD18 KO mice lymphoid/mucosal tissues then analysed by flow 
cytometry. Samples were gated on CD3+TCRγδ+ then Vγ1+, Vγ4+, Vγ5+ or Vγ1-4-5-. (A) Percentage 
of total γδ T cells expressing each TCR chain. Number in white indicates percentage of Vγ1-Vγ4- 
cells shown in the grey segment. Representative plots shown. (B) Absolute numbers of each γδ 
subset. n=10, 4 independent experiments. Each symbol represents an individual mouse, with mean 
shown. Statistical differences were determined using a two-way ANOVA. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.   
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The increased number of γδ T cells found in CD18 KO mice do not express Vγ1, 
Vγ4 or Vγ5. The remaining subsets are Vγ2, Vγ6 and Vγ7. Vγ2 is expressed at the 
transcript level in all γδ T cells, however the transcripts are either out of frame or do 
not correlate with expression on the cell surface225,226. Vγ7+ γδ T cells are the 
predominant subset in the intestines and tend to produce IFNγ 202,347. The expanded 
Vγ1-Vγ4-Vγ5- were therefore expected to express Vγ6. To test this, RNA was 
isolated from CD18 KO splenocytes sorted on Vγ1-Vγ4- cells then RT-PCR was 
performed for Vγ and Vδ chains (Figure 4-9A&B).  
The PCR results showed that CD18 KO Vγ1-Vγ4- cells express the Vγ6 chain but 
not Vγ7 (Figure 4-9C), confirming my hypothesis. The flow cytometric analysis of Vγ 
chain expression was also confirmed, as expression of Vγ1, Vγ4 and Vγ5 could not 
be detected. All γδ T cell receptors exist as dimers of a γ and δ chain. Vγ6 is an 
invariant TCR that pairs with Vδ1198. PCR analysis for the six Vδ chains 
demonstrated that the Vγ1-Vγ4- CD18 KO γδ T cells predominately express mRNA 
for Vδ1.  
In summation, the current data supports the concept that the increased population 
of Vγ1-Vγ4- γδ T cells in CD18 KO mice are Vγ6+Vδ1+ cells. In the rest of the thesis, 
γδ T cells from the spleen, blood, lungs and uterus that were gated on Vγ1-Vγ4- or 
from the thymus gated on Vγ1-Vγ4-Vγ5- will be referred to as Vγ6.  
Chapter 4 Characterisation of γδ T cells in β2 integrin-deficient mice 
 
  137 
 
Figure 4-9 Expanded γδ T cell population in CD18 KO mice expresses Vγ6 and Vδ1.  
CD18 KO splenocytes were sorted by FACS for CD3+TCRγδ+, Vγ1-Vγ4- cells then RNA isolated 
and RT-PCR performed. (A) Gating strategy used for sorting. Representative gels showing 
expression of Vγ and Vδ chain mRNA from positive controls (B) and Vγ1-Vγ4- cells (C). For positive 
controls for Vγ1, Vγ2, Vγ4, Vγ6, and all Vδ chains total spleen RNA was used, for Vγ5 total skin 
RNA, and for Vγ7 small intestine RNA. Results are representative of 4 mice.  
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CD18 KO mice have an increased number of Vγ6+Vδ1+ γδ T cells in the spleen, 
blood, lungs and uterus. Next, I wanted to confirm that the raised levels of IL-17 
identified by flow cytometry in the total γδ population and serum/spleen cytokine 
levels by ELISA, were due specifically to enhanced IL-17 production by Vγ6+ cells. 
To address this, splenocytes from WT and CD18 KO mice were stimulated ex vivo 
with PMA/ionomycin and the expression of IL-17A and IL-17F were assessed by 
flow cytometry.  
As expected, both Vγ4+ and Vγ6+ cells from WT mice produced IL-17A but Vγ1+ γδ 
T cells did not (Figure 4-10A&B). Surprisingly some production of IL-17A was 
detected by Vγ1+ γδ T cells from CD18 KO mice, with 15% of Vγ1+ cells producing 
IL-17A. However, the majority of this cytokine was produced by the Vγ6+ cells, with 
80% of these cells staining positive for IL-17A. There was a significant increase in 
the percentage of Vγ6+ γδ T cells that were IL-17A+ in CD18 KO mice compared to 
WT. In the samples from CD18 KO mice 15% of Vγ1+ cells produced IL-17A 
compared to 0.9% of WT Vγ1+ cells, but this was not statistically significant (Figure 
4-10B). The levels of IL-17F were very low, with less than 5% of cells expressing 
the cytokine, and no differences were found in expression between WT and CD18 
KO γδ T cells. This data indicates that the increase in levels of IL-17 seen in the 
CD18 KO total γδ T cell population is predominantly due to production by Vγ6+ γδ T 
cells. 
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Figure 4-10 Increased IL-17 production by Vγ1-Vγ4- γδ T cells in CD18 KO mice. 
Splenocytes were isolated from WT and CD18 KO mice and cytokine production by γδ T cells was 
assessed by flow cytometry, following ex vivo stimulation with PMA/ionomycin for 4h. Cells were 
gated on CD3+TCRγδ+ then Vγ1+, Vγ4+, or Vγ1-4- (Vγ6+). (A) Representative plots of Vγ subset IL-
17A and IL-17F. (B) Percentage of each γδ subset expressing IL-17A or IL-17F. n=6, 2 
independent experiments. Data represents mean; each symbol represents and individual mouse. 
Statistical differences were determined using a two-way ANOVA.  *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
In summary, the phenotype of γδ T cells from CD18 KO mice is different to WT as 
they are predominantly CD62Llo CD44hi CD45RB- CD27- RORγt+. This is due to the 
specific increase in the Vγ6Vδ1-expressing subset of γδ T cells that show an 
enhanced production of IL-17A.  
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4.3.3 Increase in γδ T cells is due to the loss of CD11a expression 
The β2 integrin receptors are a family of four adhesion molecules. I have identified 
that mice lacking expression of the common β2 chain have an increased number of 
IL-17-producing Vγ6+ γδ T cells, therefore I next wanted to identify which of the β2 
integrin family member/s are responsible for this phenotype. To do this, γδ T cell 
numbers and cytokine production was analysed from mice that lack the individual α 
chains: CD11a KO, CD11b KO, CD11c KO and CD11d KO.  
Flow cytometric analysis revealed that there was a greater number of γδ T cells in 
the spleen, blood and lungs of CD11a KO mice compared to WT (Figure 4-11A). 
Whereas there were no differences detected in CD11b KO, CD11c KO or CD11d 
KO mice (Figure 4-11A). Consistent with this, the percentage of γδ T cells that 
produced IL-17 was also only increased in the CD11a KO mice, with the proportion 
of IFNγ-producers in all of the α-chain KO mice remaining unchanged (Figure 
4-11B&C). The absolute number of IL-17+ γδ T cells was also higher in CD11a KO 
mice compared to WT, but in contrast to the findings in the CD18 KO, the number 
of IFNγ+ γδ T cells also showed a significant increase in the CD11a KO mice. These 
data suggest that the expansion of IL-17-producing γδ T cells found in CD18 KO 
mice is due to the loss of CD11a expression.  
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Figure 4-11 Increased number of IL-17-producing γδ T cells in CD18 KO mice is due to the 
loss of CD11a.  
Cells were isolated from the spleen, blood and lungs of WT, CD11a KO, CD11b KO, CD11c KO 
and CD11d KO mice then analysed by flow cytometry. (A) Absolute numbers of γδ T cells. Levels 
of IL-17 and IFNγ from γδ T cells in the spleen were measured following ex vivo stimulation with 
PMA/ionomycin for 4h, representative plots (B), percentages and absolute numbers (C). n=9, 3 
independent experiments; each symbol represents an individual mouse. Statistical differences 
were determined using a one-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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4.3.4 The effect of location and subset on β2 integrin and ICAM-1 
expression on γδ T cells 
After discovering the loss of CD11a expression results in increased γδ T cells, 
presumably Vγ6+ cells as found in CD18 KO mice. I next assessed β2 integrin 
expression on different subsets of γδ T cells in WT mice. The hypothesis was that 
CD11a expression may be higher on Vγ6+ γδ T cells, suggesting this integrin may 
be of more functional importance than on the other subsets. The expression of 
CD11a, CD11b and CD11c was examined in the spleen, lungs and uterus (tissues 
where an increase in γδ T cell numbers was found) and in the pLN (site with no 
difference in γδ T cell numbers). CD11d expression could not be measured as there 
are currently no murine antibodies available.  
Over 90% of γδ T cells expressed CD11a in all of the tissues examined (Figure 
4-12A). In the spleen and pLN, all subsets expressed equivalent levels of CD11a. 
Conversely, in the lungs and uterus, Vγ6+ γδ T cells expressed higher levels of 
CD11a than the Vγ1+ and Vγ4+ subsets. When comparing the mean expression of 
CD11a on Vγ6 γδ T cells across tissues there was a significant increase in both the 
lungs and uterus compared to spleen and pLN, as well as in the uterus compared 
to the lungs (Figure 4-12B). 
In most tissues γδ T cells expressed very low levels of CD11b and CD11c, with the 
exception of the pLN where all subsets showed some expression of CD11b (Figure 
4-12A&B). The majority of γδ T cells in the pLN were CD11b negative, but a small 
population of cells were CD11b+. This population was greater in Vγ4+ and Vγ6+ than 
Vγ1+ γδ T cells. The expression of CD11b was significantly higher on Vγ4+ and Vγ6+ 
cells in the pLN compared to spleen and lungs. The levels of CD11c were 
significantly increased on all subsets of γδ T cells from the spleen compared to pLN 
and lungs, although the percentage of CD11c+ cells was less than 5. The functional 
relevance of low level CD11b and CD11c expression by γδ T cells in the pLN 
remains unknown. 
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Figure 4-12 CD11a is expressed higher on Vγ1-Vγ4- γδ T cells in the lungs and uterus. 
Expression of CD11a, CD11b and CD11c on γδ T cell subsets was measured by flow cytometry. 
Cells were gated on CD3+TCRγδ+ then Vγ1+, Vγ4+, or Vγ1-4- (Vγ6+). (A) Representative plots 
shown in. Grey with dotted line represents expression on CD18 KO γδ T cells. (B) Geometric mean 
of integrin expression. n=8, 3 independent experiments. Data represents mean + SD. Statistical 
differences were determined using a two-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001.   
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CD11a was expressed higher on Vγ6+ γδ T cells that reside in the lungs and uterus, 
and loss of CD11a leads to Vγ6 expansion. The main ligand for CD11a is ICAM-1 
(CD54), which is expressed on endothelial cells and leukocytes. Therefore, it is likely 
that the absence of interaction between CD11a and ICAM-1 is involved in mediating 
the expansion of γδ T cells in CD18 KO mice. It has been shown that γδ T cells in 
the spleen express ICAM-1348, however comparison of ICAM-1 expression across 
tissues and subsets has not been done previously.  
ICAM-1 expression was initially assessed on total γδ T cells from different tissues 
in WT mice (Figure 4-13A). Expression of ICAM-1 was readily detectable on γδ T 
cells in all tissues examined but expression was significantly lower on γδ T cells in 
the lungs compared to the spleen, pLN and uterus.  
Expression of ICAM-1 was then analysed on γδ T cell subsets from WT and KO 
mice. In the spleen, where in WT mice Vγ1 and Vγ4 subsets predominate but in 
CD18 KO mice there is a large proportion of Vγ6+ cells, there was a significant 
increase in Vγ1+ and Vγ4+ γδ T cell expression of ICAM-1 in CD18 KO compared to 
WT (Figure 4-13B). In the pLN, a site in which γδ T cells were not expanded in CD18 
KO mice, there was an increased percentage of ICAM-1+ Vγ4 and Vγ6 γδ T cells. 
The lungs and uterus are tissues in which Vγ6+ cells preferentially localise and sites 
of expanded γδ T cell numbers in the absence of CD18. Vγ6+ γδ T cells showed 
reduced expression of ICAM-1 in CD18 KO lungs compared to WT, whereas in the 
uterus there was no difference. Conversely for Vγ4+ cells, there was an increase in 
ICAM-1 expression in the uterus but not lungs of CD18 KO mice.  
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Figure 4-13 ICAM-1 expression is low on γδ T cells in the lungs and is expressed higher on 
γδ T cells from CD18 KO than WT spleen and LNs.  
Levels of ICAM-1 on γδ T cells from WT and CD18 KO mice were analysed by flow cytometry. 
Cells were gated on CD3+TCRγδ+ then Vγ1+, Vγ4+, or Vγ1-4- (Vγ6+). (A) Expression of ICAM-1 on 
total γδ T cells from WT tissues. (B) Representative plots and percentages of ICAM-1+ γδ T cell 
subsets from WT (Blue) and CD18 KO (red) mice. n=8, 3 independent experiments. Data 
represents mean + SD. Statistical differences were determined using a two-way ANOVA. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. 
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The loss of CD11a expression, but not any of the other three β2 integrin family 
members, is responsible for the increased number of γδ T cells identified in CD18 
KO mice. Detailed analysis of β2 integrin and ligand expression on γδ T cells across 
tissues identified that all γδ T cells in the tissues analysed express CD11a, but 
expression is higher on Vγ6+ cells in the lungs and uterus than on other subsets. 
Together this data suggests that CD11a is important in the regulation of Vγ6+ γδ T 
cells and that it’s expression on Vγ6+ cells may play a central role in their function 
within specific tissues.   
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4.4 Discussion 
4.4.1 Tissue-restricted increase in Vγ6Vδ1+ IL-17-producing γδ T 
cells in CD18 KO mice 
In this chapter I have identified that in mice lacking β2 integrins there is an expansion 
of γδ T cells specifically in the spleen, blood, lungs and uterus. It was previously 
reported that these mice have more γδ T cells in the spleen and cLNs but no 
difference in pLN (axillary and inguinal) 297,303. This is in agreement with my findings 
that CD18 KO mice have increased γδ T cells in the spleen but not pLN. However, 
prior studies did not examine γδ T cells in other tissues, therefore this is the first 
data to identify an increase in γδ T cells in the lungs and uterus of CD18 KO mice. 
Another novel finding is that the expanded γδ T cells are Vγ6Vδ1+, as previous 
studies did not investigate the subset of expanded γδ T cells in the absence of 
CD18. In a different mouse model where CD18 expression is reduced but not 
absent, mice develop psoriasis as they age, and increased numbers of γδ T cells 
were found in the psoriatic lesions of the skin and skin-draining lymph nodes 296. 
The mice used in that study only develops spontaneous skin inflammation when the 
CD18-deficiency was on a PL/J background, whereas on a C57BL/6 background 
the mice are resistant344. The CD18 KO strain used in this thesis was on a C57BL/6 
background, therefore it is unsurprising that the mice do not show any signs of skin 
inflammation. My results suggest that the enhanced γδ response in the absence of 
β2 integrins is occurs in multiple, but restricted tissue sites.  
One possible explanation for the increased number of γδ T cells in a restricted 
number of sites in CD18 KO mice is that there is a re-distribution due to migration 
into certain tissues being impaired. Calculation of the total γδ T cells across tissues 
found an overall 6.5 times increase in the number of γδ T cells in CD18 KO mice, 
with numbers increased in several tissues yet no sites with a defect in γδ T cells. It 
could be inferred that the increase in γδ T cell numbers is not due to a redistribution 
effect, but as not all tissues were examined there may be other sites with decreased 
γδ T cell numbers (e.g. peritoneum or liver). These data also suggest that migration 
of γδ T cells into tissues under homeostasis is not dependent on β2 integrins. 
Although migration was not directly tested, this is in agreement with studies showing 
that in inflammatory disease models of EAE and psoriasis, γδ T cells can migrate 
effectively to tissue sites (CNS and skin)295,296. Further work is required to determine 
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whether β2 integrins play any role in the migration of γδ T cells, but current evidence 
does not support their role in migrating into tissues.   
An increase in both the percentage and number of γδ T cells was found in the 
spleen, blood, lungs and uterus of CD18 KO mice. In other lymphoid tissues 
(Peyer’s patches, pLN, mLN, bone marrow) there was a higher percentage of γδ T 
cells as a proportion of total CD3+ cells, but not in absolute number of γδ T cells – 
this was due to a reduced number of αβ T cells. This finding is expected, as αβ T 
cell migration is dependent on β2 integrins hence CD18-deficient αβ T cells display 
reduced homing to lymphoid tissues, including pLN, mLN, Peyer’s patches and bone 
marrow64,68,186,297. Interestingly there was also a decreased number of αβ T cells in 
the colon of CD18 KO mice. Leukocyte migration to the intestines is largely 
dependent on the integrin α4β769, however this data suggests there may be a role 
for β2 integrins in migration of αβ T cells to the colon. There was some discrepancy 
with the data obtained from the small intestine LP. Analysis of total γδ T cell numbers 
displayed no difference, however the number of Vγ1-Vγ4-Vγ5- cells were 
significantly increased in this tissue. When quantified by imaging, there was no 
significant difference in the number of γδ T cells in the small intestine (data not 
shown). The predominant subset of γδ T cells found in the intestine express 
Vγ7202,349, therefore it is likely that a large proportion of the cells within the Vγ1-Vγ4-
Vγ5- population will express Vγ7. This variability in the data may indicate subtle 
changes in the γδ T cell populations in the intestine, however, as the effects in this 
tissue were unclear compared to other tissues it was decided not to pursue this 
further.  
Surface marker expression analysis revealed that β2 integrin-deficient γδ T cells 
exhibited an altered profile consistent with a Vγ6+ subset phenotype. Vγ6+ γδ T cells 
are known to be CD62Llo CD44hi , produce IL-17 and express high levels of CD3/γδ 
TCR but do not express CD27199,206,346,350,351. The Vγ6Vδ1+ phenotype of the 
expanded CD18 KO γδ T cells was then confirmed by PCR. In addition to the data 
from total γδ T cells, those expressing Vγ6 showed an increased production of IL-
17A in CD18 KO compared to their WT counterparts. This suggests that the altered 
phenotype seen in the total γδ population in CD18 KO mice is not only due to there 
being an increased number of Vγ6+ cells, but also due to alterations in cytokine and 
surface marker expression on this population of γδ T cells.  
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In CD18 KO mice the levels of IL-17 were increased in vivo in the serum and spleen. 
Analysis of the total IL-17+ cells showed that γδ T cells were the predominant source 
of IL-17 in CD18 KO mice following in vitro re-stimulation. In contrast to this, in WT 
mice the main population producing IL-17 in the spleen and lungs were non-T cells. 
A likely CD3- source of IL-17 are innate lymphoid cells (ILCs). This group of cells 
includes lymphoid-tissue transducer-like cells, natural killer cells, ILC2s and ILC3s, 
that are all known to produce IL-17352–354. In addition, the WT uterus also had a 
significant population of CD45-IL-17+ cells. This is in contrast to other papers that 
describe γδ T cells as the major IL-17-producing population in the uterus355,356, but 
in those analyses only CD45+ cells were examined. The CD45-IL-17+ cells are likely 
to be epithelial and stromal cells, which have previously been shown to express IL-
17 in the mouse uterus357.  
Despite an increased number of IL-17-producing γδ T cells in the lungs and uterus, 
no difference was detected in the cytokine levels from these tissues. This could 
indicate that the Vγ6+ cells have an increased potential to produce IL-17 but are not 
producing it in the lungs or uterus in vivo. This may be due to the absence of the 
appropriate stimuli required to induce IL-17 secretion, such as IL-1β and IL-23200 
that can be produced by activated macrophages and DCs358–361. Therefore, in an 
inflammatory setting when APCs come activated, Vγ6+ cells from CD18 KO mice 
may produce higher levels of IL-17. This also highlights that the IL-17 data obtained 
from PMA/ionomycin stimulation may not reflect cytokine production in vivo, 
therefore cells other than γδ T cells may be contributing to the IL-17 measured from 
the serum. The levels of another isoform of IL-17, IL-17F, were also measured but 
could only be detected at very low levels (<5% of γδ T cells). Using an IL-17F 
reporter mouse it was shown that 12% of γδ T cells in the spleen express this 
cytokine362. This discrepancy indicates that IL-17F staining may have been 
suboptimal or that stimulation with reagents other than PMA/ionomycin may be 
required to induce IL-17F secretion.  
Vγ6-expressing γδ T cells preferentially localise to the lungs, uterus, tongue, dermis 
and peritoneal cavity198–200. As the expanded population of γδ T cells identified in 
CD18 KO mice were Vγ6+, it was unsurprising that the lungs and uterus were sites 
with higher γδ T cell numbers. However, my data show that γδ T cell numbers were 
not increased in the skin or oral mucosa. For skin analysis the whole ear was 
digested, without separating the epidermis and dermis, with over 90% of the γδ T 
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cells identified expressing Vγ5. This subset is found exclusively in the epidermis363, 
suggesting that cells from the dermis only represent a small fraction of those 
analysed and therefore any subtle changes to γδ T cells in the dermis may be lost. 
In the gingiva of adult mice Vγ6+ cells represent only 14% of the total γδ T cell 
population364, meaning the effect may be much less in this tissue or the phenotype 
in CD18 KO mice is truly specific to the lungs, uterus and spleen. The spleen is not 
a site where Vγ6+ cells are described as preferentially homing to, although Vγ6-
expressing γδ T cells have been shown to reside in the spleen199,346,351. This raises 
the question of why there is a higher number of Vγ6+ γδ T cells in the spleen? A 
possible explanation is that the increasing number of Vγ6+ cells exceeds the 
capacity within their resident tissues (lungs and uterus), so the γδ T cells are forced 
into the circulation and accumulate in the spleen. The enhanced number of γδ T 
cells in the blood fits with this theory. However further experiments to determine 
which tissues γδ T cells migrate into, such as adoptive transfer of Vγ6+ γδ T cells 
into WT and CD18 KO hosts, are required to clarify this.  
In a model of reduced CD18 expression, mice developed a spontaneous psoriasis 
associated with an increase in IL-17-producing γδ T cells296. In this model the 
expanded γδ population expressed Vγ4, not Vγ6. The fact that a reduction in CD18 
expression is associated with increased Vγ4+ cells, whereas total loss of CD18 
results in Vγ6+ cell expansion suggests that β2 integrin regulation of γδ T cells is a 
finely tuned process. Alternatively, this may indicate a different mechanism during 
inflammation compared to homeostasis. Under homeostatic conditions, β2 integrins 
may play an important role in the regulation of Vγ6+ γδ T cells but during an 
inflammatory response, other stimuli may induce the specific expansion of Vγ4+ γδ 
T cells. It should also be considered that the mice with reduced CD18 expression 
are on a different background (PL/J compared to C57BL/6) that renders them 
susceptible to the development of psoriasis344,365. It was suggested there is a single 
recessive allele in the PL/J mice that is responsible for disease susceptibility. The 
discrepancy between β2 integrin loss causing expansion of Vγ4+ versus Vγ6+ γδ T 
cells could therefore be due to alterations in other genes that differ between mouse 
strains.  
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4.4.2 β2 integrin expression depends on TCR expression and 
tissue localisation of γδ T cells 
The expansion of IL-17-producing γδ T cells is due to the specific loss of CD11a. 
This β2 integrin is expressed highly on T cells, both αβ and γδ, whereas other 
leukocyte populations express other β2 integrins in combination with CD11a. I 
therefore hypothesise that the increase in Vγ6+ γδ T cells is due to CD11a loss on 
T cells. This could be mediated in two different ways: either the direct loss of CD11a 
on γδ T cells themselves or through an indirect mechanism whereby loss of CD11a 
on αβ T cells affects other cell populations, that in turn drive the expansion of γδ T 
cells. The finding that CD11a is expressed at higher levels on Vγ6+ γδ T cells in the 
lungs and uterus supports the idea that Vγ6+ cells are more dependent on CD11a 
and that the effect may be intrinsic to γδ T cells.  
In addition to CD11a expression, the CD11b subunit was also present on γδ T cells 
isolated from the pLN. This contrasts a previous report that γδ T cells in the spleen 
express low levels of CD11b whereas expression is absent in lymph node γδ T 
cells26. Another study found low level expression of both CD11b and CD11c on 
splenic γδ T cells 294. Both of these studies quantified integrin expression by RNA-
sequencing, therefore there may be discrepancies between expression at the RNA 
compared to protein level. It is clear that overall γδ T cell expression of CD11b and 
CD11c is very low or negligible. Therefore, the functional relevance of the 
expression of these integrin subunits in γδ T cells remains unclear.  
I also characterised expression of ICAM-1, the main ligand for CD11a, on γδ T cells. 
More than half of the γδ T cells in the spleen, pLN and uterus expressed ICAM-1, 
whereas expression of ICAM-1 was much lower on γδ T cells isolated from the 
lungs. There was an increase in the percentage of γδ T cells expressing ICAM-1 in 
CD18 KO mice compared to WT. Although this effect was not limited to the Vγ6 
subset but was found across Vγ1+ and Vγ4+ cells as well. This could indicate there 
is a regulatory loop between β2 integrin expression (receptor) and ICAM-1 (ligand), 
whereby engagement of the receptor causes downregulation of its ligand. However, 
to my knowledge this has not been reported in the literature. The functional role of 
ICAM-1 expressed on γδ T cells has not previously been studied. In αβ T cells it has 
been shown that stimulation of ICAM-1 can promote T cell activation and cytokine 
production366,367. On CD8 T cells a correlation was found between ICAM-1 
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expression and cytotoxic activity368. ICAM-1 may play a similar role in mediating cell 
interactions, contributing to cytokine production and cytotoxic function in γδ T cells, 
however further work is required to clarify this. The β2 integrin ligand ICAM-1 is 
expressed not only on leukocytes but also on endothelial, epithelial and stromal 
cells. In the lungs ICAM-1 is constitutively expressed on alveolar endothelial and 
epithelial cells369,370. In the uterus ICAM-1 expression is found on vascular, epithelial 
and stromal cells371. The levels of ICAM-1 on stromal cells were not assessed in WT 
and CD18 KO mice, but this may play a role in retaining γδ T cells in tissues or in 
regulating their function.  
4.5 Conclusion 
In this chapter I have provided a comprehensive analysis of γδ T cells in β2 integrin-
deficient mice. I have identified the specific expansion of γδ T cells in the spleen, 
blood, lungs and uterus of CD18 KO mice. These expanded γδ T cells are Vγ6Vδ1+ 
and express high levels of CD44, IL-17, RORγt and CD3/γδ TCR. This expands the 
knowledge from previous studies of γδ T cells in CD18 KO mice, as two additional 
sites (lungs and uterus) as well as the subset (Vγ6+) of expanded γδ T cells has 
been identified. In addition to this, analysis of γδ T cells from individual α-chain KO 
mice characterised that CD11a was the β2 integrin family member responsible for 
this increase in γδ T cells. Expression of CD11a was higher on Vγ6+ cells only in the 
lungs and uterus, potentially indicating an important functional role specific to the 
subset and tissue residency of the γδ T cells. Having characterised the specific 
subset of γδ T cells increased in CD18 KO mice, in the next chapter I will go on to 
investigate the potential mechanisms underlying their expansion.  
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Chapter 5 Defining the mechanism of γδ T cell 
increase in β2 integrin-deficient mice 
5.1 Introduction 
I have identified that the loss of CD18 expression in mice leads to a tissue-restricted 
increase in Vγ6+ IL-17 producing γδ T cells. The next step was to determine the 
underlying mechanism(s) of this expansion. I propose 3 possible mechanisms that 
could lead to the expansion of the Vγ6+ subset in CD18 KO mice: (i) an increase in 
thymic output, (ii) enhanced proliferation in the periphery, or (iii) increased 
survival/reduced cell death. It should be noted however, that these scenarios are 
not mutually exclusive. It may be one or a combination of these proposed 
mechanisms that are responsible for the expanded Vγ6+ population in mice lacking 
β2 integrins. 
5.1.1 Thymic output of γδ T cells 
The initial thymic development of γδ T cells occurs primarily during 
embryonic/neonatal life. IL-17-producing γδ T cells in particular develop exclusively 
in the embryonic thymus and are then retained in the periphery through self-
renewal243. Therefore, the loss of β2 integrin-ligand interactions in CD18 KO mice 
may either alter the initial γδ T cell thymic development or their regulation in the 
periphery. Several studies have identified CD11a as an important factor for normal 
T cell development. CD11a expression was found to be critical for the development 
of common lymphoid progenitors in the bone marrow 89 and blocking CD11a in foetal 
thymic organ cultures (FTOCs) reduced the development of CD4+CD8+ T cells, 
whereas blocking ICAM-1 increased γδ T cell numbers372. Conversely, another 
study using CD11a KO mice described normal thymic T cell development 373 and in 
other FTOC experiments, blocking CD11a impaired T cell development from foetal 
liver progenitors but not foetal thymus progenitor cells374. Based on these studies it 
is unclear whether CD11a is required for normal T cell development, and importantly 
the impact of CD11a on γδ T cell subset development during different foetal stages 
was not examined. In adult CD18 KO mice, I found no difference in the number of 
thymic γδ T cells (Figure 4-3) but as Vγ6+ cells are produced in the embryonic 
thymus, there may be an increased production in mice at this age.  
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5.1.2 Mechanisms of γδ T cell proliferation in the periphery 
The second potential mechanism of Vγ6 expansion in CD18 KO mice is enhanced 
proliferation in the periphery. There are several cytokines that are known to induce 
proliferation of IL-17+ γδ T cells including IL-7, IL-1β, IL-23 and TGF-β1, 235,303,375,376. 
IL-7 can stimulate the proliferation of IL-17-producing γδ T cells 235, and enhanced 
expression of IL-7 on thymic stromal cells was shown to expand Vγ6+ γδ T cells in 
the thymus of mice at E16.5 and at birth377. The production of IL-1β and IL-23 by 
myeloid cells can also stimulate the expansion of IL-17-producing γδ T cells376. This 
has led to the development of an in vitro protocol to expand IL-17-producing γδ T 
cells using a combination of IL-1β and IL-23213. It has been suggested that IL-1β is 
more important for inducing IL-17 production by Vγ4+ compared to Vγ6+ γδ T cells 
200. In agreement with this, Vγ6+ cells were induced during pneumococcal infection 
in mice, but the number of these cells was significantly reduced when IL-23 KO mice 
were infected compared to WT or IL-1R KO mice 378. This data indicates that IL-23 
may preferentially induce Vγ6+ over Vγ4+ γδ T cells. TGF-β1 is required during 
thymic development of γδ T cells; in mice that lack TGF-β1 itself or the signalling 
adapter Smad3, there is a loss of IL-17+ γδ T cells 375. These studies highlight 
potential cytokines that may be elevated in the serum and/or tissues of CD18 KO 
mice and induce the expansion of Vγ6+ γδ T cells. Some of these cytokines will be 
investigated in this chapter. 
5.1.3 γδ T cell survival and apoptosis 
The final proposed mechanism is that the increased number of Vγ6+ cells in CD18 
KO mice could be due to an accumulation resulting from increased survival and/or 
decreased apoptosis. In addition to driving proliferation, IL-7 has also been 
implicated in γδ T cell survival. There was a greater loss of BrdU-labelled γδ T cells 
in IL-7 KO mice compared to heterozygous controls 14 days post-BrdU 
administration, indicating that IL-7 is important for γδ T cell survival246. Another study 
suggested that IL-7 is required to induce proliferation but not survival of CD27- IL-
17+ γδ T cells. Following IL-7 stimulation in vitro, CD27- γδ T cells proliferated to a 
greater extent than their CD27+ counterparts but expressed lower levels of Bcl2, a 
gene associated with cell survival 235. However, in vivo administration of IL-7 was 
shown to upregulate expression of Bcl2 in IL-17+ γδ T cells but not IFNγ+ γδ T 
cells247. It is unclear the precise role that IL-7 plays in mediating the proliferation 
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versus survival of γδ T cells. This is a complex pathway that involves the 
coordination of many intracellular signalling molecules in addition to Bcl2. There 
may be a role for IL-7-mediated survival of Vγ6+ γδ T cells in CD18 KO mice and 
interestingly this pathway is also linked to inhibition of apoptosis through up-
regulation of anti-apoptotic proteins such as Bcl-xl and Mcl-1 379.  
Previous studies have demonstrated that β2 integrins may be involved in mediating 
γδ T cell apoptosis: the co-stimulation of γδ T cells in vitro through the TCR and 
CD11a resulted in calcium-dependent apoptosis, however, this effect was lost when 
either receptor was activated alone 380,381. This suggests that the engagement of 
both TCR and CD11a can trigger cell death in γδ T cells therefore, it is possible that 
in mice lacking CD11a/CD18 that a failure of apoptosis may occur.  
5.1.4 Hypothesis and Aims 
The overall aim of this chapter was to determine the mechanism of γδ T cell 
expansion/accumulation that occurs in CD18 KO mice. This was further divided into 
three main questions: 
1. Is there an increase in the thymic development of Vγ6+ γδ T cells in CD18 
KO mice? 
2. Are Vγ6+ γδ T cells expanded in CD18 KO mice due to increased proliferation 
in the periphery? 
3. Is there an accumulation of Vγ6+ γδ T cells in CD18 KO mice due to an 
increase in survival and/or reduction in cell death?  
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5.2 Results 
5.2.1 Thymic development of Vγ6+ γδ T cells is unaffected by the 
loss of CD18, whilst Vγ4+ development is impaired. 
The first hypothesis for the increase in γδ T cells was that the thymic output of Vγ6+ 
cells may be increased in CD18 KO mice compared to WT. The development of IL-
17-producing γδ T cells occurs prior to birth243 and for the Vγ6 subset is 
predominantly at embryonic days 16-18 (E16-18)222. To assess thymic development 
of Vγ6+ γδ T cells, the populations of γδ T cells present in the thymus of WT and 
CD18 KO mice were analysed by flow cytometry at different ages: E18.5, 1 day old, 
3 days old and 4 weeks old.  
The total number of γδ T cells within the thymus was similar across ages and 
showed no difference between WT and CD18 KO (Figure 5-1A). Further analysis of 
γδ T cell subsets based on Vγ chain expression revealed that at E18.5 the WT 
thymus contained a population of γδ T cells that expressed either Vγ1, Vγ4, Vγ5 or 
Vγ6 (Figure 5-1B). The percentage of Vγ6+ γδ T cells in WT mice was similar in 
E18.5, 1 day and 3 day old mice, then reduced in 4 week old mice. In the CD18 KO 
thymus there was an increased proportion of Vγ6+ cells compared to WT, 
accompanied by a decrease in Vγ4+, at E18.5, 1 day and 3 days but not in 4 week 
old mice. This could suggest a bias in γδ T cell development towards Vγ6 instead 
of Vγ4. 
To determine if this was the case, the absolute numbers of Vγ subsets were 
calculated (Figure 5-1C). Surprisingly, there was no difference in the number of Vγ6+ 
γδ T cells in the thymus at any age between WT and CD18 KO mice. However, the 
number of Vγ4+ cells was significantly reduced in the neonatal but not in 4 week old 
mice.  
Together, the data reveal that CD18 KO mice displayed no difference in the number 
of thymic Vγ6+ γδ T cells in young mice. This suggests that the increased number 
of Vγ6+ γδ T cells in CD18 KO mice is not due to enhanced thymic development. 
Unexpectedly however, the development of the other IL-17-producing subset, that 
express Vγ4, was impaired. This highlights that CD18 may be important for the 
development of Vγ4+ γδ T cells.  
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Figure 5-1 CD18 KO mice show no difference in Vγ6+ thymic development but have impaired 
development of Vγ4+ cells. 
WT and CD18 KO mice were culled at E18.5, 1 day old, 3 days old or 4 weeks old and thymic cells 
were analysed by flow cytometry. Samples were gated on CD3+TCRγδ+ then Vγ1+, Vγ4+, Vγ5+ or 
Vγ1-4-5- (i.e. Vγ6+). (A) Total number of γδ T cells. (B) Representative pie charts of the percentage 
of γδ T cells expressing each Vγ chain. (C) Absolute number of each Vγ subset. WT 3 days n=6, 
WT 4 weeks n=7, WT & CD18 KO 1-day n=8, WT E18.5 & CD18 KO 3 days and 4 weeks n=10, 
CD18 KO E18.5 n=11. Data from a minimum of 3 independent experiments; each symbol 
represents an individual mouse. Statistical differences were determined using a two-way ANOVA. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.   
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To further investigate the defect in Vγ4+ cell development identified in the thymus of 
neonatal CD18 KO mice, the stages of thymic γδ T cell development were analysed 
based on maturation marker expression. During thymic development γδ T cells go 
through different stages of maturation. The surface marker CD24 is commonly used 
to differentiate between immature (CD24+) and mature (CD24-) populations 
because CD24 is downregulated on γδ T cells prior to exit from the thymus 382–384.  
Within the immature population of thymic γδ T cells there was a significant decrease 
in the number of Vγ4+ cells in CD18 KO mice compared to WT at E18.5 (Figure 
5-2A). This was specific to the Vγ4+ cells as the numbers of all other γδ T cell 
subsets were equivalent. In 1 day old mice there was a trend towards a decreased 
number of CD24+ Vγ4+ cells in the CD18 KO thymus, however, this was not 
significant. By 3 days old and 4 weeks old, the immature Vγ4+ population was similar 
in number in WT and CD18 KO mice. This indicates that during embryonic 
development in CD18 KO mice there is a defect in the generation of immature Vγ4+ 
γδ T cells. 
During thymic development γδ T cells express different levels of the cell surface 
markers CD27, CD44 and CD45RB. CD27 is expressed on the earliest γδ-
committed T cell progenitors and is downregulated upon maturation of IL-17-
producing subsets 206,383. CD44 and CD45RB are not expressed during early γδ T 
cell development but are upregulated on terminally differentiated γδ T cells 203. Both 
IFNγ and IL-17-producers will express CD44, whereas CD45RB expression is only 
expressed by IFNγ-producers. Analysis of these surface markers showed a 
decreased percentage of CD44+ and concurrent increase in CD44- immature 
embryonic Vγ4+ cells from CD18 KO mice compared to WT (Figure 5-2B). Most of 
these cells (>90%) expressed CD27 and lacked CD45RB in both WT and CD18 KO, 
indicative of their expected immature phenotype. Conversely, the immature Vγ6+ 
population in the CD18 KO thymus displayed a small but significant increase in the 
percentage of CD27- cells, potentially indicating a more mature phenotype. Although 
in contrast to this, there was also a greater proportion of CD44- Vγ6+ cells, which 
may suggest a more immature phenotype. As the differences were not found in 
percentages of CD27+ and CD44+ Vγ6+ cells, it is unclear whether the maturation of 
these cells is truly different in the CD18 KO thymus.  
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Together, examination of the immature CD24+ γδ T cell populations in the thymus 
of WT and CD18 KO mice at E18.5 demonstrated a differential maturation status of 
the Vγ4-expressing γδ T cell subset. There was a reduced number of developing 
Vγ4+ cells, and they displayed a more immature phenotype (based on CD44 
expression). In contrast to this, the downregulation of CD27 and CD44 in Vγ6+ cells 
from CD18 KO mice does not indicate a clear change in maturation status.  
 
Figure 5-2 The embryonic CD18 KO thymus has a reduced number of Vγ4+ γδ T cells with an 
immature phenotype.  
Cells isolated from WT and CD18 KO thymus at E18.5 were analysed by flow cytometry. Cells 
were first gated on CD3+TCRγδ+CD24+, then Vγ1+, Vγ4+, Vγ5+ or Vγ1-4-5-, followed by CD27, 
CD44 or CD45RB. (A) Percentage and number of CD24+ γδ T cells according to Vγ chain 
expression. (B) Percentage of Vγ4+ or Vγ1-4-5- γδ T cells from E18.5 thymus that are positive or 
negative for CD27, CD44 and CD45RB. WT n=10, CD18 KO n=11. Data from 6 independent 
experiments. Statistical differences were determined using a two-way ANOVA. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.  
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Following the identification of reduced numbers and maturation of Vγ4+ cells within 
the immature γδ population in CD18 KO mice, the mature (CD24-) cells were then 
analysed. Due to the defect in Vγ4+ cells occurring at the E18.5 immature stage of 
development, a subsequent reduction in mature Vγ4+ cells was expected. The 
numbers of γδ T cell subsets within the CD24- thymic population were similar 
between WT and CD18 KO mice at the embryonic stage and immediately post-birth 
(Figure 5-3). However, by 3 days old the CD18 KO mice displayed a significantly 
reduced number of mature CD24- Vγ4+ cells compared to their WT counterparts. 
This reduction was maintained into adulthood, as mice at 4 weeks old also showed 
a decrease in CD24- Vγ4+ γδ T cells.  
Within the mature population of γδ T cells, different stages of γδ T cell development 
can be further identified. A recent study by Sumaria et al. described a gating strategy 
to analyse the mature γδ T cells committed to either IFNγ or IL-17 production 203. 
They showed that after gating on CD3+TCRγδ+CD24- cells, the expression of 
CD45RB and CD44 can segregate the cells into 4 discrete populations (Figure 
5-4A). CD45RB-CD44- cells have the potential to develop into either IL-17 or IFNγ 
producers. CD45RB+CD44- are a population of developing IFNγ-producers that will 
then upregulate CD44 to become CD45RB+CD44+, a more terminally differentiated 
population. Whereas, in the IL-17 development pathway, the cells will upregulate 
CD44 to become CD45RB-CD44+.  
Analysis of these 4 populations in the thymus of WT and CD18 KO mice showed 
that at E18.5 cells are present at all stages of the pathway (Figure 5-4B). At 1 and 
3 days old, the mature IL-17-producers (CD45RB-CD44+) predominate, whereas at 
4 weeks old most of the cells are of unknown commitment (CD45RB-CD44-). There 
was no difference in the number of cells at each stage of the development pathway 
at E18.5, 1 day and 3 day old mice between WT and CD18 KO. The only difference 
was seen at 4 weeks old, where the number of CD45RB-CD44- cells were 
significantly decreased in CD18 KO mice. This suggests that the commitment of 
mature CD24- γδ T cells to the IL-17- and IFNγ-producing lineages is unaffected by 
the loss of CD18 expression. Interestingly, at 4 weeks old the total number of thymic 
cells was decreased in CD18 KO mice (8.6x107+1.5x107 cells) compared to WT 
(1.04x108+3.4x107 cells) (Figure 5-4C). Therefore, the decreased number of 
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uncommitted mature γδ T cells may contribute to the overall decrease in cellularity 
in the thymus. 
 
Figure 5-3 The defect in Vγ4+ cell numbers in newborn CD18 KO mice is in the mature CD24- 
population of γδ T cells. 
Cells isolated from WT and CD18 KO thymus at various ages were analysed by flow cytometry. 
Cells were first gated on CD3+TCRγδ+CD24-, then Vγ1+, Vγ4+, Vγ5+ or Vγ1-4-5- (Vγ6+). Percentage 
of CD24- γδ T cells according to Vγ chain expression. WT n=10, CD18 KO n=11. Data from 6 
independent experiments. Statistical differences were determined using a two-way ANOVA. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 5-4 Commitment of mature (CD24-) γδ T cells in the thymus to IL-17- and IFNγ-
producing subsets is equivalent in WT and CD18 KO mice. 
Cells isolated from WT and CD18 KO thymus at various ages were analysed by flow cytometry. 
Cells were first gated on CD3+TCRγδ+CD24- then separated into 4 populations based on 
expression of CD45RB and CD44. (A) Gating shown with representative plots from 1 day old 
thymus. (B) Percentages of γδ T cells expressing CD45RB/CD44. (C) Total number of thymocytes. 
WT 3 days n=6, WT & CD18 KO 4 weeks n=7, WT & CD18 KO 1 day n=8, WT E18.5 & CD18 KO 
3 days n=10, CD18 KO E18.5 n=11. Data from a minimum of 3 independent experiments; each 
symbol represents an individual mouse. Statistical differences were determined using a two-way 
ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.   
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A defect in the thymic development of Vγ4+ γδ T cells was identified in CD18 KO 
mice. This population is one of the predominant γδ T cell subsets present in 
lymphoid organs, along with Vγ1+. I have already established that there is no 
difference in the number of Vγ4+ cells in the spleen, blood or mucosal tissues of 
CD18 KO mice (Chapter 4, Figure 4-8). As this subset tends to reside within 
lymphoid tissues, the peripheral LNs (pLN), mediastinal LN (medLN), mesenteric 
LNs (mLN) and bone marrow were examined for the number of γδ T cell subsets. 
My hypothesis was that the defect in development of Vγ4 cells in CD18 KO mice 
would result in a peripheral defect in lymphoid tissues.  
Calculation of Vγ4+ cell numbers revealed a defect in the pLN of CD18 KO mice but 
no difference in the medLN, mLN or bone marrow (Figure 5-5). The number of Vγ1+ 
and Vγ6+ γδ T cells were equivalent between WT and CD18 KO at all the lymphoid 
sites analysed. This suggests that the impaired development of Vγ4+ cells results in 
a peripheral defect specifically in the pLN.  
 
Figure 5-5 CD18 KO mice have a defect in numbers of Vg4+ γδ T cells only in the pLN. 
Cells isolated from the peripheral LN (pLN; axillary, brachial and inguinal pooled), mediastinal LN 
(medLN), mesenteric LN (mLN) and bone marrow of adult WT and CD18 KO mice were analysed 
by flow cytometry. Cells were gated on CD3+TCRγδ+ then Vγ1+, Vγ4+, Vγ6+ (Vγ1-4-5- for bone 
marrow and mLN; Vγ1-4- for pLN and medLN). Absolute cell numbers shown. pLN, mLN and bone 
marrow n=9 from 3 independent experiments. medLN n=6 from 2 independent experiments. Each 
symbol represents an individual mouse. Statistical differences were determined using a two-way 
ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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The results shown in figures 5-1 to 5-4 indicate that thymic development of Vγ6+ 
cells was unaffected by the loss of β2 integrin expression. Therefore, enhanced 
thymic output is not the reason for the increase in Vγ6+ cell numbers in the CD18 
KO adult mice. The next question was to determine when during the lifespan of the 
mouse this Vγ6+ cell expansion occurs. To answer this, the Vγ repertoire was 
analysed from the spleen and lungs of WT and CD18 KO mice across different ages.  
The Vγ repertoire in the WT lungs showed the presence of Vγ1, Vγ4, Vγ5 and Vγ6-
expressing γδ T cells (Figure 5-6A). The percentage of Vγ6+ cells increased from 
embryonic to newborn mice and was retained up to 4 weeks old. In contrast to this, 
the percentage of Vγ6+ cells in CD18 KO lungs was higher than WT at 1 day old 
and further increased at 3 days and 4 weeks old. There was also a large proportion 
of Vγ5+ cells in both genotypes at E18.5, that decreased by 1 day and was absent 
in the 4 week old mice. As Vγ5+ cells are found exclusively in the epidermis of adult 
mice363, it could be assumed that these are circulating cells that will become resident 
in the skin. The WT spleen showed a large proportion of Vγ1+ and Vγ4+ cells, with 
a smaller percentage of Vγ6+ at all ages that were analysed. Note, for the spleen of 
E18.5 mice the percentage of γδ T cell subsets is not shown due to very low cell 
numbers, meaning that there were no representative plots due to high variability. 
The proportion of Vγ6+ cells in the WT spleen was similar across all ages studied. 
In contrast to this, the CD18 KO spleen displayed a greater proportion of Vγ6+ cells 
in 1 day old mice that was further increased at 3 days and again at 4 weeks old. In 
the lungs at E18.5 most of the cells were Vγ5+, this population decreased with age 
and was absent by 4 weeks regardless of genotype, as these cells have homed to 
the skin. 
There was a similar number of Vγ6+ cells in the spleen and lungs of embryonic WT 
and CD18 KO mice. In the lungs, the number of Vγ6+ cells was significantly 
increased in CD18 KO mice compared to WT from 1 day old onwards (Figure 5-6B). 
Whereas a higher number of Vγ6+ cells in the CD18 KO spleen was only seen from 
3 days old relative to WT mice. This data indicates that the increased number of 
Vγ6+ γδ T cells in CD18 KO mice is present initially in the lungs from 1 day post-
birth and by 3 days also in the spleen.  
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Figure 5-6 Increase in Vγ6+ γδ T cells in the spleen and lungs of young CD18 KO mice.  
Analysis of γδ T cells from the spleen and lungs of WT and CD18 KO mice at various ages. Cells 
were gated on CD3+TCRγδ+ then Vγ1+, Vγ4+, Vγ5+ or Vγ1-4-5-. (A) Representative pie charts of 
the percentage of γδ T cells expressing each Vγ chain. E18.5 spleen not shown due to very low 
cell number. (B) Absolute number of Vγ6+ (Vγ1-Vγ4-Vγ5-) γδ T cells. WT spleen & lungs 3 days 
n=6. CD18 KO spleen 1 day, WT/CD18 KO lungs 1 day, WT/CD18 KO spleen 4 weeks, WT lungs 
4 weeks n=7. WT spleen 1-day n=8. CD18 KO spleen 3 days, CD18 KO lungs 3 days/4 weeks, WT 
spleen E18.5 n=10. CD18 KO spleen/lungs E18.5 n=11. E18.5 data from 6 litters, 1 day old from 6 
litters, 3 day old from 4 litters, 4-week old from 5 litters; data from 4-6 independent experiments; 
each symbol represents an individual mouse. Statistical differences were determined using a 
Student’s t test with false discovery rate approach two-stage linear step-up procedure of Benjamini, 
Krieger and Yekutieli. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
Having determined that CD18 KO mice show an increased number of Vγ6+ cells in 
the lungs and spleen by 1 and 3 days old, respectively, the γδ T cells were then 
analysed for the expression of markers associated with IL-17-producing γδ cells 
(CD45RB-, CD44+, CD27-). The lungs of CD18 KO mice displayed a higher 
percentage of CD45RB-, CD44+ and CD27- γδ T cells than WT mice at 1 day, 3 days 
and 4 weeks old (Figure 5-7). There was also an increased percentage of CD45RB, 
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CD44+ and CD27- γδ T cells in the spleen of 3 day and 4 week old CD18 KO mice 
In addition, there was a small increase in the proportion of CD27- γδ T cells in 1 day 
old mice. This data fits with the findings from Figure 5-6 that there is an increased 
number of Vγ6+ cells with an IL-17-producing phenotype in CD18 KO mice from 1 
day old in the lungs and from 3 days old in the spleen. 
 
Figure 5-7 Increase in IL-17-producing (CD45RB-CD44+CD27-) γδ T cells in the spleen and 
lungs of young CD18 KO mice 
Analysis of γδ T cells from the spleen and lungs of WT and CD18 KO mice at various ages. Cells 
were gated on CD3+TCRγδ+. Data shown as percentage of γδ T cells that were CD45RB-, CD44+ 
or CD27-. WT spleen & lungs 3 days n=6. CD18 KO spleen 1 day, WT/CD18 KO lungs, WT/CD18 
KO spleen & lungs 4 weeks, n=7. WT spleen 1 day n=8. CD18 KO spleen & lungs 3 days, n=10. 
Data from 4-6 litters, with each litter run as an independent experiment; each symbol represents an 
individual mouse. Statistical differences were determined using a two-way ANOVA. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. 
In summary, the loss of β2 integrin expression resulted in a reduced number of 
immature Vγ4+ cells in the thymus and a delayed upregulation of maturation 
markers, revealing a novel role for β2 integrins in promoting the development of Vγ4+ 
γδ T cells. In contrast, thymic development of Vγ6+ cells was unaffected but these 
cells were increased in CD18 KO lungs from 1 day old and in the spleen from 3 days 
old. This data indicates that the expanded population of Vγ6+ cells in CD18 KO mice 
is not due to enhanced thymic output.  
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5.2.2 CD18 KO mice show no evidence of enhanced γδ T cell 
proliferation 
The increased number of Vγ6+ γδ T cells in CD18 KO mice was not due to enhanced 
thymic output. Next, I explored the second potential mechanism of Vγ6+ cell 
expansion: that there may be increased proliferation of Vγ6+ cells in the periphery of 
CD18 KO mice. The primary aim was to determine if the environment in mice lacking 
β2 integrins preferentially induced proliferation compared to WT mice. To address 
this question, total T cells (CD3+) were isolated from the spleen of CD18 KO mice, 
labelled with CFSE, and then transferred i.v. into either WT or CD18 KO hosts. The 
mice were culled 1-, 4- or 8-days post-transfer. Ideally, WT γδ T cells would be used 
as a control in this adoptive transfer experiment; however, due to low γδ T cell 
numbers and different subset ratios in WT mice, this was neither feasible nor 
appropriate.  
Following the transfer of CD18 KO T cells, the thymus, spleen, blood, mLN, pLN 
and lungs of host mice were analysed by flow cytometry. The percentage of 
transferred cells that were recovered was calculated by dividing the sum of CFSE+ 
cells from all tissues by the number that were initially transferred, then multiplying 
by 100. There was an average of 10% cell recovery from both WT and CD18 KO 
mice across all timepoints (Figure 5-8A). Prior to transfer the T cells were labelled 
with CFSE to allow assessment of cell proliferation. There was a loss of CFSE 
expression over the timecourse, however only a single peak was present, 
suggesting that the cells did not proliferate (Figure 5-8B). Although as there was no 
positive control to confirm this conclusion. Comparison of the mean CFSE 
expression showed no difference between WT and CD18 KO, indicating that the 
proliferative capacity of γδ T cells was unaltered between WT or CD18 KO hosts.  
There was no evidence of γδ T cell proliferation over the 8 day timecourse, but the 
experimental set-up allowed the analysis of γδ T cell homing to different tissues in 
WT and CD18 KO mice. The number of transferred γδ T cells found in tissues would 
reflect the preferential migration and/or retention at this site. The ratio of γδ to αβ T 
cells was calculated in the initially transferred cells and in the CFSE+ cells found in 
each tissue at 1-day post transfer. An increased ratio indicates a preferential 
migration/retention of γδ T cells to that tissue, whereas a decreased ratio indicates 
a preference for αβ T cells. A similar ratio of αβ:γδ T cells was found in the thymus 
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as in the transferred cells (shown as a grey dotted line) (Figure 5-8C), indicating 
equivalent migration of αβ and γδ T cells to this site. The ratio was increased in the 
spleen and blood, and to a greater extent in the lungs. Conversely, the ratio was 
decreased in the mLN and pLN. This suggests that there was a preferential 
recruitment and/or retention of γδ T cells in the spleen, blood and lungs, and for αβ 
T cells in the mLN and pLN. These findings were as expected because the majority 
of the transferred γδ T cells expressed Vγ6, and these cells are known to 
preferentially home to the lungs199, whereas αβ T cells tend to home to LNs. The 
spleen, blood and lungs were the sites where most of the transferred γδ T cells were 
located. Therefore, the number of CFSE+ γδ T cells was calculated in these tissues 
from WT and CD18 KO hosts. There was no difference in the number of transferred 
γδ T cells that were found in the spleen, blood or lungs of WT and CD18 KO hosts 
across all of the timepoints studied (Figure 5-8D), indicating that there was not a 
preferential migration or retention of γδ T cells in CD18 KO mice compared to WT.  
Overall, this experiment demonstrated that, following adoptive transfer, CD18 KO 
γδ T cells do not proliferate within 8 days. Additionally, the CD18 KO γδ T cells 
preferentially migrate and/or are retained in the spleen, blood and lungs compared 
to αβ T cells. As there were no differences found in the γδ T cell numbers whether 
transferred into WT or CD18 KO mice, there is no evidence of an altered 
environment in the absence of CD18 that leads to enhanced proliferation or 
migration/retention.  
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Figure 5-8 CD18 KO γδ T cells do not proliferate and display similar migration/retention 
when transferred into WT and CD18 KO hosts.  
CD3+ cells were purified from CD18 KO splenocytes, labelled with CFSE and then 2x106 cells were 
transferred i.v. into WT or CD18 KO hosts. 1, 4 or 8 days after transfer, cells from the thymus, 
spleen, blood, mesenteric LNs (mLN), peripheral LNs (pLN) and lungs were analysed by flow 
cytometry. (A) Percentage of transferred cells calculated as the number of CFSE+ cells (total from 
all tissues harvested) divided by the number of CFSE+ cells transferred, multiplied by 100. (B) The 
mean expression of CFSE on γδ T cells. Representative plot shown from WT spleen. (C) The ratio 
of CFSE+ γδ to αβ T cells in different tissues of WT mice 1 day after transfer. Grey dotted line 
shows the ratio in the transferred cells. (D) The absolute number of CFSE+ γδ T cells from WT and 
CD18 KO hosts. n=6, data pooled from 2 independent experiments; each symbol represents an 
individual mouse. Statistical differences were determined using a two-way ANOVA. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. 
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The data obtained from adoptive transfer of CD18 KO γδ T cells showed no 
evidence of proliferation in either WT or CD18 KO hosts. To further assess the 
proliferative capacity of γδ T cells in vivo within their native setting, WT and CD18 
KO mice were administered with a single i.p. dose of BrdU, followed by 7 days in 
the drinking water. γδ T cells were then analysed by flow cytometry for BrdU 
incorporation as a measure of proliferation (BrdU labels cells undergoing DNA 
replication, i.e. in S-phase). Cells were also assessed for their expression of Ki67, 
a marker that is only expressed during active cell cycle (G1, S, G2 and M) 385. The 
hypothesis was that Vγ6+ cells, which increased in the spleen and lungs of CD18 
KO mice, may display enhanced proliferation compared to WT. Vγ4+ cells were used 
as controls as they display comparable numbers in the CD18 KO spleen and lungs 
to WT.  
The levels of Ki67 were higher in γδ T cells from the lungs compared to the spleen, 
regardless of the subset (Figure 5-9A). When compared to WT, the expression of 
Ki67 was significantly increased in Vγ6+ γδ T cells from both the spleen and lungs 
of CD18 KO mice. In Vγ4+ cells, Ki67 levels were equivalent between genotypes. 
Similar to Ki67, the expression of BrdU was higher in the lungs than the spleen for 
both Vγ6+ and Vγ4+ γδ T cells (Figure 5-9B). This suggests that γδ T cells may 
proliferate preferentially in the lungs rather than the spleen. However, there was no 
difference in BrdU incorporation when comparing either the Vγ4+ or Vγ6+ γδ T cell 
subsets from WT and CD18 KO mice. This indicates that very few γδ T cells are 
actively undergoing DNA replication (S-phase) in either WT or CD18 KO mice within 
a 1 week period.  
The levels of both Ki67 and BrdU detected in γδ T cells was very low, when 
compared with a positive control of cells from an inflamed LN. The increased 
expression of Ki67 on Vγ6+ cells from CD18 KO mice could indicate that more cells 
are in active cell cycle. Based on this data it can be concluded that very few Vγ6+ 
γδ T cells are proliferating within a 1 week period, and the levels of proliferation are 
similar between WT and CD18 KO mice.  
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Figure 5-9 Increased expression of Ki67 in Vγ6+ CD18 KO γδ T cells but low levels of 
proliferation measured by 1 week of BrdU. 
WT and CD18 KO mice were injected with 1mg BrdU i.p. then fed 0.8mg/ml BrdU in the drinking 
water for 7 days. Cells isolated from the spleen and lungs were analysed by flow cytometry for the 
expression of Ki67 (A) and BrdU incorporation (B). Representative histograms shown from the 
spleen. Grey dotted line indicates the FMO, blue line is WT, red line is CD18 KO and green line is a 
positive control of cells from the inguinal LN of mice with tail lesions. Data is representative of 2 
experiments; each symbol represents and individual mouse. Statistical differences were 
determined using a two-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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There was no difference found in the proliferation of Vγ6+ γδ T cells in CD18 KO 
mice, measured by BrdU incorporation over 1 week. However, there was an 
enhanced expression of Ki67, which may indicate that the cells have a higher 
proliferation but at low levels, over a longer period of time. I next investigated the 
quantities of IL-1β and IL-23 in WT and CD18 KO mice, as these cytokines are 
known to induce the proliferation of IL-17-producing γδ T cells200. In addition to this, 
both IL-1β and IL-23 can induce IL-17 production by γδ T cells244,386, therefore, 
higher levels of these cytokines could explain why CD18 KO Vγ6+ cells produce 
more IL-17 (Figure 4-10). Previous studies using CD18 KO mice have also identified 
higher levels of IL-1β in the spleen387 and increased IL-23 transcript was measured 
in the mLN of these mice303. However, the levels in the serum or other tissues where 
I have found increased Vγ6+ cells (lungs and uterus) were not measured.  
The levels of IL-1β and IL-23 in WT and CD18 KO mice were measured by ELISA, 
from the serum and tissues where γδ T cells were expanded. The serum cytokine 
results were inconclusive, as in at least half of the samples the cytokines were below 
the limit of detection (Figure 5-10A). Statistically, there was no significant difference 
in the serum levels of IL-1β or IL-23 from CD18 KO mice compared to WT, although 
it is possible that differences may be found with a more sensitive method of 
detection. Cytokine levels were detectable in tissues, where supernatant samples 
isolated from CD18 KO spleen cultures showed significantly higher levels of both 
IL-1β and IL-23 than WT. In contrast to this, the lungs and uterus displayed 
equivalent levels of both cytokines regardless of the genotype.  
It is not only the levels of cytokine present that dictate the cellular response, but the 
expression of the corresponding receptor will also influence the strength of signal 
that the cell will receive. As the levels of IL-1β and IL-23 were increased in the spleen 
of CD18 KO mice, the levels of the receptors for these cytokines were measured on 
γδ T cells from the spleen and lungs of WT and CD18 KO mice. 
WT and CD18 KO γδ T cells from the spleen and lungs expressed low levels of IL-
1βR and IL-23R (Figure 5-10B). In the spleen, the expression of IL-1βR was absent 
on Vγ4+ cells and very low on Vγ6+ cells (Figure 5-10C). Although significantly 
higher expression of IL-1βR was detected on CD18 KO Vγ6+ cells compared to WT, 
the levels were only slightly above the FMO. IL-23R was detected on both subsets 
Chapter 5 Defining the mechanism of γδ T cell increase in β2 integrin-
deficient mice 
 
  173 
of γδ T cells in the spleen, with equivalent expression on Vγ4+ cells, and a small, 
but significant increase in expression on CD18 KO Vγ6+ cells compared to WT. The 
increased expression of IL-1βR and IL-23R on Vγ6+ cells in the CD18 KO spleen is 
a very subtle effect therefore may not have any biological significance. Similar to 
those in the spleen, Vγ4+ cells from the lungs did not express the IL-1βR regardless 
of genotype. Expression was found on Vγ6+ cells from both WT and CD18 KO mice. 
γδ T cells from the lungs showed higher expression of IL-23R than in the spleen. 
However, as the data from the lungs was n=2, the experiment would have to be 
repeated to determine if there are any differences in the expression of IL-1βR or IL-
23R on γδ T cells from WT and CD18 KO lungs.  
In sum, no differences were detected in the serum levels of IL-1β or IL-23 as 
samples were largely below the limit of detection, but higher levels of IL-1β and IL-
23 were found specifically in the spleen of β2 integrin-deficient mice compared to 
WT. The expression of the corresponding receptors could be detected on both WT 
and CD18 KO γδ T cells, but only at low levels. 
Chapter 5 Defining the mechanism of γδ T cell increase in β2 integrin-
deficient mice 
 
  174 
 
Figure 5-10 CD18 KO mice have increased levels of IL-1β and IL-23 in the spleen and higher 
expression of IL-1βR and IL-23R on Vγ6+ γδ T cells. 
(A) Levels of IL-1β and IL-23 were measured by ELISA from serum and tissues isolated from WT 
and CD18 KO mice, tissue supernatants were collected by incubating the tissue in complete media 
for 4h at 37°C. Dotted line indicates the limit of detection: IL-23 8pg/ml, IL-1β 16pg/ml. Levels of 
the IL-1βR (CD121a) and IL-23R were measured on γδ T cells from the spleen and lungs of WT 
and CD18 KO adult mice by flow cytometry. (B) Representative plots of IL-1β and IL-23 expression 
on total γδ T cells from the spleen and lungs. Grey dotted line indicates the FMO, blue line is WT 
and red line is CD18 KO. (C) Mean expression of IL-1β and IL-23 on Vγ4+ and Vγ6+ cells. Serum 
n=14, spleen n=9, WT IL-1β/IL-23 uterus n=8, CD18 KO IL-1β uterus n=7, CD18 KO IL-23 uterus 
n=6. Each symbol represents an individual mouse. IL-1βR/IL-23R spleen n=9; data pooled from 3 
independent experiments. IL-1βR/IL-23R lungs n=2; data from one experiment. Data represents 
mean + SD. Statistical differences were determined using a two-way ANOVA. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
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In summary, there was no evidence of enhanced proliferation of Vγ6+ γδ T cells in 
CD18 KO mice after adoptive transfer or by BrdU incorporation. There were small 
but significantly increased levels of IL-1β and IL-23 identified in the spleen of CD18 
KO mice, although the effect of this is unclear as the proliferation of γδ T cells in the 
spleen was equivalent in WT mice. Overall, this data indicates that either the 
mechanism of Vγ6+ cell expansion in CD18 KO mice is not due to proliferation or 
that the cells proliferate in younger mice and are then retained in the adults.  
5.2.3 Vγ6+ γδ T cells from CD18 KO mice show no evidence of 
enhanced survival signalling downstream of the IL-7R but 
show reduced apoptosis in the lungs 
Having found no differences in the thymic development or proliferation of Vγ6+ γδ T 
cells in CD18 KO mice, I next explored my third hypothesis to explain the increased 
Vγ6+ cell numbers in CD18 KO mice. I hypothesised that Vγ6+ cells may accumulate 
due to an increased survival and/or failure of homeostatic cell death. IL-7 is an 
important pro-survival signal for γδ T cells247,388, and in mice with reduced CD18 
expression levels of the IL-7R were increased on CD27- γδ T cells (IL-17-producers) 
compared to WT296. Based on this knowledge, I further investigated IL-7 and the 
downstream survival signalling in Vγ6+ cells from WT and CD18 KO mice.  
First, the serum levels of IL-7 were measured by ELISA. The quantity of IL-7 was 
undetectable in the majority of serum samples from both WT and CD18 KO mice 
(Figure 5-11A). Suggesting that in general the circulating levels of IL-7 are very low. 
Next the expression of the IL-7Rα (CD127) was assessed on γδ T cells from the 
spleen and lungs. The IL-7R was expressed at higher levels on γδ T cells from the 
spleen of CD18 KO mice compared to WT whereas, expression on γδ T cells from 
the lungs was similar (Figure 5-11B). When compared on γδ T cell subsets, Vγ4+ 
cells (which are equivalent in number) had similar levels of IL-7R whether from WT 
or CD18 KO mice (Figure 5-11C). Whereas, Vγ6+ cells from CD18 KO mice 
(increased in number) had higher IL-7R expression than WT in the spleen but not 
the lungs. Interestingly, in the lungs almost 100% of γδ T cells stained positive for 
the IL-7R, and this was also true for those in the spleen of CD18 KO mice but not 
WT. This could indicate that there is an increased recirculation of Vγ6+ cells from 
the lungs to the spleen in CD18 KO mice compared to WT. Alternatively, factors 
present in the CD18 KO spleen may induce upregulation of the IL-7R.  
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Figure 5-11 Vγ6+ cells from the CD18 KO spleen express higher levels of IL-7R and IL-1βR 
than WT. 
(A) Levels of IL-7 were measured by ELISA in serum from WT and CD18 KO adult mice. Grey 
dotted line indicates the limit of detection, 6.3pg/ml. (B&C) Levels of the IL-7R (CD127) were 
measured on γδ T cells from the spleen and lungs of WT and CD18 KO adult mice by flow 
cytometry. (B) Representative plots of cytokine receptor expression on total γδ T cells. Grey dotted 
line indicates the FMO, blue line is WT and red line is CD18 KO. (C) Mean expression of cytokine 
receptors. n=8. Data pooled from 3 independent experiments. Data represents mean + SD. 
Statistical differences were determined using a two-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
It was found that Vγ6+ γδ T cells in the CD18 KO spleen expressed higher levels of 
IL-7R, this raised the question of whether this increased receptor expression could 
result in increased downstream survival signalling, which may contribute to the 
increased Vγ6+ cells in CD18 KO mice. One of the major anti-apoptotic molecules 
known to be induced by IL-7 and enhance cell survival is Bcl2 389,390. To assess if 
pro-survival signalling is altered in CD18 KO γδ T cells, Bcl2 expression was 
assessed by flow cytometry in γδ T cell subsets from WT and CD18 KO mice.  
Chapter 5 Defining the mechanism of γδ T cell increase in β2 integrin-
deficient mice 
 
  177 
Initially, Bcl2 expression was examined in γδ T cells from the spleen of adult mice 
(Figure 5-12A&B). Vγ4-expressing cells from WT and CD18 KO mice expressed 
Bcl2 to a similar level. In contrast to this, the Vγ6+ cells from WT mice expressed 
similar levels to Vγ4+ cells whereas in CD18 KO mice Bcl2 was significantly 
decreased only in the Vγ6+ population. This suggests that the increased expression 
of IL-7R on Vγ6+ cells in the spleen does not correlate with an enhanced expression 
of Bcl2, in fact the data shows the opposite. As the increased number of Vγ6+ cells 
were present in young CD18 KO mice, meaning that the mechanism driving γδ T 
cell expansion is likely present prior to adulthood, Bcl2 expression was then 
analysed in 4-week old mice. γδ T cells from the spleen and lungs showed no 
significant difference in expression of Bcl2, regardless of subset, when comparing 
WT and CD18 KO mice (Figure 5-12C). 
Despite expressing more IL-7R, Vγ6+ γδ T cells in the spleen of CD18 KO mice do 
not express higher levels of the anti-apoptotic molecule Bcl2. This data does not 
support the hypothesis that Vγ6+ cells in CD18 KO mice have enhanced survival 
signalling downstream of the IL-7R. On the contrary, Vγ6+ cells in the spleen of adult 
mice display reduced Bcl2, but expression is unaltered in 4 week old mice. This 
suggests a potentially age-dependent effect on Bcl2 expression, but there was no 
evidence of increased survival downstream of the IL-7R mediated by Bcl2. Bcl2 is 
one of many anti-apoptotic molecules that enhance cell survival in a complex 
pathway, so it is possible that other pro-apoptotic or anti-apoptotic molecules, such 
as Bcl-xL, Mcl-1 or BIM, may be altered in CD18 KO Vγ6+ γδ T cells.  
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Figure 5-12 Bcl2 expression is decreased in splenic Vγ6+ cells from adult CD18 KO mice but 
not in 4-week old mice.  
Bcl2 expression was analysed by flow cytometry in γδ T cells from WT and CD18 KO mice in the 
spleen of adults (A&B) and in the spleen and lungs of 4-week old mice (C). Adult spleen n=8, 4-
week old spleen/lungs n=7. Data pooled from a minimum of 3 independent experiments; each 
symbol represents an individual mouse. Statistical differences were determined using a two-way 
ANOVA. **p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Vγ6+ γδ T cells in the spleen of CD18 KO mice express higher levels of IL-7R and 
reduced levels of Bcl2, whereas in the lungs the expression of IL-7R was equivalent 
to WT. This suggests that despite expressing higher levels of the receptor for IL-7 
compared to WT, Vγ6+ cells in the CD18 KO spleen do not have elevated 
downstream Bcl2. I next tested IL-7R signalling to determine if the reduced levels of 
Bcl2 could be explained by an impaired ability of CD18 KO Vγ6+ cells to activate 
signalling pathways in response to IL-7. Cells isolated from the spleen and lungs of 
WT or CD18 KO mice were stimulated in vitro with IL-7 and the response of Vγ6+ 
cells (higher IL-7R expression in the spleen) was compared with Vγ4+ cells 
(equivalent IL-7R expression). The levels of the downstream phosphorylated 
signalling molecules pSTAT5 and pSTAT3 were measured 1, 10 and 30mins after 
stimulation.  
Stimulation with IL-7 resulted in the upregulation of pSTAT5 in γδ T cells and to a 
lesser extent pSTAT3 (Figure 5-13A), as seen previously235. In both Vγ6+ and Vγ4+ 
γδ T cells from WT spleen there was a time-dependent increase in pSTAT5, with 
highest levels seen after 30mins (Figure 5-13B). When compared with CD18 KO γδ 
T cells, the levels of pSTAT5 were significantly higher in the WT cells after 10 and 
30mins of IL-7 treatment. This was true for both Vγ4+ and Vγ6+ cells. This suggests 
that the induction of STAT5 phosphorylation in response to IL-7 is impaired in CD18 
KO γδ T cells. The expression of pSTAT3 in splenic γδ T cells was not upregulated 
until 10mins after stimulation with IL-7. Unlike pSTAT5, the expression of pSTAT3 
was induced to a similar extent in Vγ6+ cells from WT and CD18 KO mice. While for 
Vγ4+ cells, a defect in pSTAT3 levels in CD18 KO cells was seen after 10 and 
30mins of IL-7, similar to the effect on pSTAT5. This shows that the loss of CD18 
reduces the ability of Vγ4+ cells to induce pSTAT3 downstream of the IL-7R, but not 
in Vγ6+ cells. In the unstimulated samples, the expression of both pSTAT5 and 
pSTAT3 were slightly lower, although not significant, in the CD18 KO γδ T cells 
compared to WT.  
The effect of IL-7 on signalling in γδ T cells from the lungs displayed different 
dynamics than those from the spleen (Figure 5-13C). For Vγ4+ cells, the expression 
of pSTAT5 peaked after 10mins and only at this timepoint was there a significant 
decrease in expression in CD18 KO cells compared to WT. Unlike the Vγ4+ cells 
from the spleen, where lower levels of pSTAT3 were seen, the dynamics of pSTAT3 
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induction in response to IL-7 were similar in cells from the lungs regardless of 
genotype. This shows that the reduced responsiveness of Vγ4+ cells in the spleen 
is not mirrored in the lungs, indicating that the loss of β2 integrin expression causes 
a tissue-specific rather than cell-intrinsic effect. pSTAT3 increased after 1min of IL-
7 stimulation, peaked after 10mins then was slightly decreased after 30mins in Vγ4+ 
cells from both WT and CD18 KO mice. This same effect was seen in Vγ6+ cells, 
with no difference in the levels of pSTAT3 between WT and KO. This suggests that 
in Vγ6+ γδ T cells, pSTAT3 signalling downstream of the IL-7R is unaffected by the 
loss of CD18. The induction of pSTAT5 differed in Vγ6+ cells from the lungs: after 
exposure to IL-7 for 10mins, Vγ6+ cells upregulated pSTAT5, however this high 
expression was retained after 30 mins. There was no significant difference pSTAT5 
in Vγ6+ cells from the lungs of WT and CD18 KO mice at any time following 
treatment with IL-7. This reiterates the point that the impaired IL-7R-mediated 
signalling in β2 integrin-deficient γδ T cells is a tissue-specific effect.  
Overall, Vγ4+ and Vγ6+ γδ T cells from CD18 KO spleen failed to upregulate pSTAT5 
to the same extent as WT in response to IL-7. This effect was also seen for pSTAT3 
in Vγ4+ but not Vγ6+ cells. In contrast, CD18 KO γδ T cells from the lungs 
upregulated pSTAT5 and pSTAT3 in a similar manner to WT, with the exception of 
Vγ4+ cells that displayed reduced pSTAT5 at the peak of the response, although the 
difference was much smaller than those seen in the spleen. This indicates that the 
ability of γδ T cells to signal downstream of the IL-7R is altered in CD18 KO mice 
depending on their subset and location.  
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Figure 5-13 Vγ4+ and Vγ6+ γδ T cells from the spleen of CD18 KO mice display impaired 
STAT signalling in response to IL-7. 
Cells from adult WT and CD18 KO spleen and lungs were stimulated in vitro with 100ng/ml IL-7 for 
1, 10 or 30mins. Cells were then analysed by flow cytometry for the expression of phosphorylated 
STAT3 and STAT5. Samples were gated on CD3+TCRγδ+ then Vγ4+ or Vγ1-4-5- (Vγ6+). (A) 
Representative plots from the total γδ T cells in CD18 KO lungs. Mean expression of pSTAT3 and 
pSTAT5 in cells from the Spleen (B) and Lungs (C). n=7. Data pooled from 2 independent 
experiments; each symbol represents an individual mouse, with mean shown. Statistical 
differences were determined using a two-way ANOVA. **p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
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I did not find any evidence to suggest that the increased Vγ6+ cell numbers in CD18 
KO mice corresponded to enhanced IL-7R-mediated signalling or downstream Bcl2 
expression. I next explored the hypothesis that the cells may be accumulating due 
to decreased apoptosis. Apoptosis was measured in WT and CD18 KO γδ T cells 
by ex vivo staining with Annexin V and 7AAD, which stain cells undergoing early 
and late apoptosis. During the early stages of death Phosphatidylserine (PS), a 
phospholipid normally absent from the plasma membrane, translocates to the outer 
layer of the membrane. Annexin V is a protein that binds to PS and can therefore 
be used as a marker for early apoptosis 391. As cell death progresses, the membrane 
integrity is lost, which allows the cell to passively take up dyes such as 7-amino-
actinomycin-D (7AAD) 392,393. 
Co-staining of cells with Annexin V and 7AAD allows segregation into three 
populations that indicates the state of apoptosis (Figure 5-14A). Cells that are alive 
will be Annexin V- 7AAD-. Cells that are Annexin V+ 7AAD- are undergoing early 
apoptosis.  In the transition into late apoptosis, loss of membrane integrity will allow 
7AAD to enter into the cell, resulting in a population of Annexin V+ 7AAD+ cells. Using 
this gating strategy, γδ T cell subsets were assessed for the different stages of 
apoptosis. The percentage of Vγ4+ γδ T cells that were live, undergoing early or late 
apoptosis remained equivalent regardless of the tissue they were isolated from or 
the genotype of the mice (Figure 5-14B). In contrast, Vγ6+ cells from the spleen of 
CD18 KO mice showed a significant increase in late apoptotic cells, accompanied 
by a decrease in those undergoing early apoptosis. In Vγ6+ cells isolated from the 
lungs, there was a decreased proportion of late apoptotic cells, with an increase in 
live cells (Figure 5-14B&C).  
The altered apoptotic state of Vγ6+ cells in CD18 KO mice implies that, in the 
absence of β2 integrins, more Vγ6+ cells in the spleen are undergoing late stage 
apoptosis, as opposed to the early stage. Importantly, the most striking effect was 
seen in the lungs where there was a reduction in γδ T cell death in the CD18 KO 
mice specifically in the Vγ6+ population. This decrease in apoptosis may contribute 
to the accumulation of Vγ6+ cells in CD18 KO mice.  
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Figure 5-14 Reduced apoptosis of Vγ6+ γδ T cells in the lungs of CD18 KO mice. 
Cells were isolated from WT and CD18 KO spleen and lungs then analysed by flow cytometry. 
Samples were gated on CD3+TCRγδ+ followed by Vγ4+, or Vγ1-4- (Vγ6+), then Annexin V- 7AAD- 
(live cells), Annexin V+ 7AAD- (early apoptotic) or Annexin V+ 7AAD+ (late apoptotic). (A) Gating 
strategy from WT spleen. (B) Representative plots of Vγ6+ cells from the lungs. (C) Percentages of 
γδ T cell subsets at each stage of apoptosis. n=9. Data pooled from 3 independent experiments; 
each symbol represents and individual mouse. Statistical differences were determined using a two-
way ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
  
Chapter 5 Defining the mechanism of γδ T cell increase in β2 integrin-
deficient mice 
 
  184 
An increase was found in the apoptosis of Vγ6+ γδ T cells in the lungs of WT mice 
compared to CD18 KO, however the expression of apoptosis markers indicates the 
current stage of death the cell is in, but not the upstream mechanism that triggered 
the apoptotic pathway within the cell. Therefore a potential upstream regulator of 
this altered cell death was explored. Fas (CD95) is a death receptor that when 
engaged on T cells triggers death by apoptosis394. Fas is known to be expressed on 
γδ T cells and it has been shown previously that in mice lacking Fas there is an 
expansion of γδ T cells395. I hypothesise that the reduced apoptosis of Vγ6+ γδ T 
cells in the lungs of CD18 KO mice may be linked to reduced Fas expression.  
The results show that Fas expression can be detected on γδ T cells (Figure 5-15A), 
and the levels of Fas were similar across Vγ4- and Vγ6-expressing γδ T cells in the 
spleen from both WT and CD18 KO mice (Figure 5-15B). Likewise, in the lungs 
there was no difference in the percentage of Fas+ Vγ4+ cells. Conversely, a 
significantly lower proportion of Vγ6+ γδ T cells expressed Fas in the lungs of CD18 
KO mice compared to WT (Figure 5-15A&B). This fits with my hypothesis that Vγ6+ 
cells display reduced apoptosis, specifically in the lungs of CD18 KO mice due to 
reduced Fas expression.  
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Figure 5-15 Expression of Fas is reduced on Vγ6+ γδ T cells in the lungs of CD18 KO mice 
compared to WT.  
Cells were isolated from adult WT and CD18 KO thymus, spleen and lungs then analysed by flow 
cytometry. Samples were gated on CD3+TCRγδ+ followed by Vγ1+, Vγ4+, or Vγ1-4- (Vγ6+), then 
Fas+ (CD95). (A) Representative plots of the FMO and Vγ6 cells from the lungs. (B) Percentages of 
Fas+ γδ T cell subsets. n=9. Data pooled from 3 independent experiments; each symbol represents 
and individual mouse. Statistical differences were determined using a two-way ANOVA. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001.   
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There was a reduced expression of Fas on Vγ6+ γδ T cells in the lungs of CD18 KO 
mice and these cells displayed a decreased apoptosis compared to WT mice. Based 
on these findings, I hypothesised that the increased number of Vγ6+ γδ T cells in 
CD18 KO mice is due, at least partially, to a failure of homeostatic cell death which 
results in their accumulation. To examine if CD18 KO mice show an enhanced 
accumulation of Vγ6+ cells as a result of reduced apoptosis (identified in adult mice), 
I determined the number of Vγ6+ cells in the spleen and lungs of aged mice (20-24 
weeks old) and plotted this alongside the numbers previously shown from 
embryonic, neonatal, 4 week old and adult mice (Figure 4-3 and Figure 5-6).  
The number of Vγ6+ γδ T cells in the lungs of WT mice steadily increased from E18.5 
to 4 week old, were slightly reduced in adults then further increased in aged mice. 
In the CD18 KO lungs an increase in Vγ6 numbers was also seen between E18.5 
and 4 weeks, but at a faster rate than in WT. The number of Vγ6+ cells did not 
increase between 4 week old and adult mice, but did increase between adult and 
aged mice, at a similar rate to WT. In the spleen the difference in Vγ6 numbers 
between WT and CD18 KO mice then remained consistent in adult and aged mice.  
Taken together, this data suggests that the number of Vγ6+ cells in CD18 KO mice 
increases at a greater rate than in WT during early life. By 4 weeks old, the 
established difference in Vγ6 numbers between WT and CD18 KO mice does not 
further increase in adults or aged mice. Further work is therefore required to 
determine if the decreased apoptosis of Vγ6+ γδ T cells in the lungs of CD18 KO 
results in an increased accumulation of these cells relative to WT mice.   
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Figure 5-16 Differences in the number of Vγ6+ γδ T cells found in young CD18 KO mice 
compared to WT do not further increase from 4 weeks old onwards.  
WT and CD18 KO mice were culled at E18.5, 1 day old, 3 days old, 4 weeks old, 8-12 weeks old 
(adult) and 20-24 weeks old (aged) and cells from the spleen and lungs were analysed by flow 
cytometry. Samples were gated on CD3+TCRγδ+ then Vγ1-4-5- (Vγ6+). Absolute number of Vγ6+ 
cells in the spleen and lungs are shown. WT spleen & lungs 3 days n=6. CD18 KO spleen 1 day, 
WT/CD18 KO lungs 1 day, WT/CD18 KO spleen 4 weeks, WT lungs 4 weeks n=7. WT spleen 1 
day n=8. CD18 KO spleen 3 days, CD18 KO lungs 3 days/4 weeks, WT spleen E18.5 n=10. CD18 
KO spleen/lungs E18.5 n=11. Adult spleen/lungs n=10. Data pooled from 4-6 independent 
experiments. Aged spleen/lungs n=4 from 1 experiment. Data represents mean + SD.  
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5.3 Discussion 
The aim of this chapter was to explore potential mechanisms to explain the 
increased number of Vγ6+ γδ T cells in CD18 KO mice. I found no evidence of 
enhanced thymic development or proliferation of these cells in the periphery, that 
would account for the elevated numbers of Vγ6+ cells. In the spleen, Vγ6+ cells 
expressed higher levels of the IL-7R accompanied by reduced downstream 
signalling and lower expression of Bcl2, whereas no differences were seen in the 
lungs. It can be concluded there is no evidence of enhanced IL-7-mediated survival 
of Vγ6+ cells from CD18 KO mice. Reduced apoptosis was detected in Vγ6+ cells 
from the lungs of CD18 KO mice, associated with a decreased expression of Fas. 
This data suggests that in β2 integrin-deficient mice there is an accumulation of Vγ6+ 
cells due, at least in part, to a reduced Fas-mediated apoptosis in the lungs. 
5.3.1 Role for β2 integrins in thymic development of Vγ4- but not 
Vγ6-expressing γδ T cells 
The first hypothesis for the mechanism underlying Vγ6+ γδ T cell expansion in CD18 
KO mice explored, was an increase in thymic output. Surprisingly in embryonic and 
newborn mice the number of Vγ6+ cells in the thymus was unaffected by β2 integrin 
loss. As there was no difference in the thymic numbers of Vγ6+ γδ T cells at any of 
the ages studied, it seems unlikely that the increased numbers in CD18 KO mice 
are due to altered development. In addition to this, greater numbers were seen in 
the tissues from 1-day post birth but at this age or during prior embryonic 
development the Vγ6+ population in the thymus was normal. Unexpectedly, analysis 
of the embryonic/neonatal thymus identified a defect in the development of Vγ4+ γδ 
T cells.  
This defect was present in the immature Vγ4+ cells in the embryonic thymus and in 
the mature population from 3 days old onwards. This suggests that CD18 is an 
important factor in promoting Vγ4+ cell development but is not completely 
necessary. As CD18 loss initially affected the immature Vγ4+ cells it is likely that the 
β2 integrin-ligand interaction plays a role in the early stages of Vγ4+ cell 
development. Within the immature population, the Vγ4+ cells expressed lower levels 
of CD44, a marker that is upregulated during maturation, therefore in addition to the 
defect in Vγ4+ cell selection there may be a delay in maturation. The impaired initial 
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thymic production also impacted the numbers of mature Vγ4+ cells in the thymus 
and periphery. Interestingly, in adult mice the defect in Vγ4+ cell numbers was only 
found in the peripheral LNs, but not at any other lymphoid site. In WT mice Vγ4+ γδ 
T cells represented a significant proportion of the γδ T cells in the spleen, blood and 
lungs, yet in CD18 KO mice there was no difference in the number of Vγ4+ cells 
despite their reduced development. This could indicate that the migration of Vγ4+ 
cells into peripheral LNs is partially dependent on β2 integrins. Alternatively, there 
may be factors present in the spleen/lungs but not pLNs that either expand or retain 
the Vγ4+ cells. The expansion of Vγ4+ cells in the spleen/lungs could overcome the 
thymic defect, or the absence of factors that retain Vγ4+ cells in the pLNs would 
result in a preferential retention in other sites such as the spleen/lungs.  
What remains unclear is how the loss of CD18 expression causes impaired 
development of Vγ4-expressing γδ T cells. To answer the question of which β2 
integrin subunit and ligand are required for normal Vγ4 development, in vitro foetal 
thymic cultures (FTOCs) using WT thymus and integrin/ligand blocking antibodies 
could be used. Blocking using an anti-CD18 would determine if β2 integrin receptor-
mediated interactions are required and using an anti-CD11a would confirm if this 
effect is CD11a-dependent, as was found for the peripheral effect on Vγ6+ γδ T cells 
(Figure 4-11). Experiments using the α-chain KO mice to analyse thymic γδ T cell 
development in embryos/neonatal mice would also help to elucidate which β2 
integrin receptor(s) is involved in promoting Vγ4+ cell development.  
The main ligand for CD11a is ICAM-1, which is expressed on both thymic epithelial 
cells and thymocytes372,396. Therefore, the interaction between γδ T cell progenitors 
expressing CD18/CD11a and thymic epithelial cells expressing ICAM-1 may be 
required for optimal Vγ4+ cell development. In particular, cortical thymic epithelial 
cells (cTECs) are known to play a role in IL-17-producing γδ T cell development: 
The loss of cTECs results in a defective production of Vγ4+ cells, whereas the 
generation of Vγ6-expressing γδ T cells continues in greater numbers after birth397. 
This study highlights that epithelial cells in the thymus can play a differential role in 
Vγ4+ versus Vγ6+ cell development. Another factor known to be involved in thymic 
development of IL-17+ γδ T cells is the transcription factor SRY-related HMG-box 
13 (Sox13). The expression of Sox13 in Vγ4+ cells is highest at the immature 
(CD24+) stage, and in mice deficient in Sox13 there is a specific defect in the 
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development of these γδ T cells218,219. In CD18 KO mice it is also only Vγ4+ cell 
thymic development that was impaired and at the earlier stage of development, not 
other γδ T cell subsets, therefore the loss of β2 integrin expression may cause a 
defective upregulation of Sox13 that is required for optimal Vγ4+ γδ T cell 
development. Examination of Sox13 expression in γδ+ thymocytes from neonatal 
WT and CD18 KO mice would clarify whether Sox13 plays a role in the impaired 
development of Vγ4+ γδ T cells in β2 integrin-deficient mice. Another important 
consideration is which phenotype of Vγ4+ cells show impaired development in CD18 
KO mice. Vγ4+ γδ T cells can produce either IL-17 or IFNγ, and the loss of Sox13 
specifically affects the IL-17-producers218,219. Further analysis of Vγ4+ cells during 
thymic development for the expression of CD27 and CD45RB (expressed only on 
IFNγ-producers) or for cytokine production following in vitro re-stimulation would 
identify which subset of Vγ4+ are defective in CD18 KO mice.  
5.3.2 No evidence for enhanced proliferation of Vγ6+ γδ T cells in 
adult CD18 KO mice 
There was no evidence of enhanced proliferation of γδ T cells from CD18 KO mice 
compared to WT within a 1-week timeframe in adult mice. This was concluded 
following measurement of proliferation by two methods: adoptive transfer of CFSE-
labelled cells and in vivo labelling with BrdU. It is not entirely surprising that an 
enhanced proliferation of Vγ6+ γδ T cells was not detected in adult CD18 KO mice 
compared to WT, because both Vγ4+ and Vγ6+ cells have a reduced rate of 
proliferation in adults compared to younger mice 200. In addition to this, a study using 
a tamoxifen-induced γδ T cell-specific RFP labelling, the frequency of CD27-CD44hi 
RFP+ γδ T cells (IL-17-producers, both Vγ4+ and Vγ6+) was the same at 7 weeks 
post tamoxifen treatment as after 2 weeks 245. This suggests that the homeostatic 
turnover of these cells is slow, because they retained RFP expression.  
There was a discrepancy in the data measuring proliferation of Vγ6+ cells by Ki67 
and BrdU (Figure 5-9), whereby expression of Ki67 was higher in CD18 KO cells 
but BrdU incorporation remained the same as WT. Ki67 is commonly referred to as 
a marker of proliferation247,398, although it is more specifically associated with a cell 
being in active cell cycle385. A recent study described that Ki67 accumulates within 
cells during the S, G2 and M phases and is degraded during the G1/G0 phases of 
the cell cycle 399. They described that although Ki67 levels increase during cell cycle 
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progression, the initial expression depends on how long a cell has been quiescent 
for, i.e. the more time spent quiescent, the lower the initial level of Ki67. Whereas 
BrdU will be incorporated into a cell during DNA replication (i.e. S-phase), in the 
timeframe where BrdU is present. Taken together, the increased expression of Ki67, 
but not incorporation of BrdU, that I found in CD18 KO Vγ6+ cells could indicate that 
they spend a longer time in active cell cycle whilst not progressing into proliferation. 
Alternatively, these cells may be proliferating at an increased rate, but slowly, i.e. 
longer than 1 week. Therefore, it can be concluded that there is no evidence to 
support enhanced proliferation of adult CD18 KO Vγ6+ γδ T cells in a 1 week period, 
but a role for greater proliferation in these cells cannot be completely excluded.  
The suggestion of potential changes in the cell cycle in β2 integrin-deficient γδ T 
cells is interesting, as integrin receptors are known to be involved in cell cycle 
regulation. The progression of the cell cycle requires interactions between the cell 
and extracellular matrix (ECM) via integrins400. The cell cycle is tightly regulated by 
cyclin-dependent kinases (CDKs). Activation of the kinase activity of CDKs by 
cyclins stimulates the phosphorylation of substrate molecules, which drives 
progression into the next stage of the cell cycle. In human T cells the activation of 
the beta2 integrin ligand ICAM-1 has been shown to induce phosphorylation and 
subsequent inactivation of cdc2 Kinase367. In mice the homolog for cdc2 is CDK1, 
which is important for increasing the activation of integrins and their clustering at the 
site of cell adhesion (e.g. area of the cell interacting with the endothelium) in the G1 
to S phase401. Following this, CDK1 inhibition triggers a loss of adhesion to enable 
entry into mitosis401. These studies highlight the potential interplay between integrin-
mediated adhesion and cell cycle regulation, although further work is required to 
determine if these pathways are altered in β2 integrin-deficient γδ T cells.  
One of the remaining questions is where Vγ6+ γδ T cells are expanding in CD18 KO 
mice. No difference was found in the proliferation of Vγ6+ cells in adult mice, 
therefore there is not an obvious site of expansion. When γδ T cells from newborn 
mice were analysed, the Vγ6+ cells were increased in number in the lungs of CD18 
KO mice from 1 day old, but not in the spleen until 3 days old. I therefore hypothesise 
that the Vγ6+ cells are expanding within the lungs; hence the increased numbers 
are first seen in this tissue, then due to recirculation the Vγ6+ numbers are then 
higher in the spleen of CD18 KO mice. Although Vγ6+ cells are thought of as a 
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tissue-resident population, a proportion of the cells have been shown to traffic into 
the blood and LNs under homeostasis, but migration to the spleen was not 
explored402. It is also possible that the loss of CD18 expression on Vγ6+ cells impairs 
their retention within the lung tissue, thereby increasing their recirculation. The 
adoptive transfer of CD18 KO T cells did not show a difference in the number of γδ 
T cells that migrated to the lungs or spleen between WT and CD18 KO hosts. This 
suggests that the migration and/or retention of KO γδ T cells to the lungs is not due 
to a difference in factors present in the CD18 KO microenvironment but due to an 
intrinsic property of the KO γδ T cells. However, as this was not compared to the 
migration of transferred WT γδ T cells (due to issues with cell yield from WT) it 
cannot be concluded whether β2 integrin deficiency affects γδ T cell retention in the 
lungs. The co-transfer of labelled WT and CD18 KO Vγ6+ γδ T cells would allow a 
direct comparison to determine the effect on β2 integrin loss on Vγ6 retention in the 
lungs, but this would require the in vitro expansion of the cells to obtain sufficient 
numbers for transfer.  
Although there was no evidence for altered environmental factors in CD18 KO mice 
compared to WT causing altered expansion or migration of Vγ6+ cells following 
adoptive transfer, increased levels of IL-1β and IL-23 were found in the spleen but 
not the lungs of CD18 KO mice. This is in agreement with a previous study 
describing increased IL-1β in the spleen of CD18 KO mice387. This could indicate 
that there is a higher number of cells producing these cytokines, or that production 
is increased by cells in the spleen. APCs are the predominant producers of both IL-
23 and IL-1β. An increased number of MFs and DCs were found in the spleen of 
CD18 KO mice but not the lungs (McIntyre & Morrison; data not shown), both of 
which are known sources of IL-1β and IL-23. A previous study suggested that in 
CD18 KO mice the expansion of γδ T cells is due to enhanced levels of IL-23303,403. 
They describe a model whereby under homeostatic conditions MFs and DCs 
phagocytose apoptotic neutrophils, leading to the downregulation of IL-23. Whereas 
in CD18 KO mice the defective migration of neutrophils into tissues prevents IL-23 
downregulation, leading to an increase in IL-17 production by γδ T cells. They 
showed that in vitro culture of BMDCs with apoptotic neutrophils decreased their IL-
23 secretion (measured by the ability of conditioned media to induce IL-17 secretion 
from splenocytes) and in vivo transfer of WT neutrophils, but not CD18 KO, 
decreased the mRNA expression of the p40 subunit of IL-23 in the mLN, and serum 
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levels of IL-17. This suggests that neutrophil migration can affect the levels of IL-23 
and IL-17, however the direct impact of IL-23 on the number of γδ T cells was not 
demonstrated. In agreement with this model, I found increased levels of IL-23 in the 
spleen of CD18 KO mice, although the study did not directly measure IL-23 levels. 
Furthermore, I have demonstrated that the increase in IL-17-producing γδ T cells in 
CD18 KO mice is due to a specific subset of Vγ6-expressing cells. It should also be 
noted that the neutrophilia described in the CD18 KO mice (caused by a defect in 
neutrophil migration) was found in both the CD11a and CD11c KO strains (McIntyre 
& Morrison; unpublished data), but the γδ T cell expansion was specific to the 
CD11a-deficient mice. This suggests that there is not an intrinsic link between the 
expanded neutrophils and γδ T cells, which was the mechanism suggested in the 
paper, therefore alternative or additional mechanisms may be involved. I have 
identified a novel mechanism for the increase in γδ T cells through a reduced 
apoptosis of Vγ6+ cells in the lungs. This may occur in addition to the neutrophil-
mediated effects, although further experiments are required to determine whether 
the defect in neutrophil migration affects the γδ T cell numbers through the proposed 
mechanism.  
There could be altered levels of additional cytokines (other than IL-1β or IL-23) in 
CD18 KO mice that induce the proliferation of Vγ6+ γδ T cells, which I did not look 
at in my study. IL-2 has been implicated in the maintenance or expansion of Vγ6+ 
cells, as mice deficient in IL-2 or IL-25 (IL-2R) displayed reduced numbers in the 
periphery despite normal thymic development350. It has also been shown that Vγ6+ 
cells bind IL-2 with a higher affinity than Vγ4+ cells248. Overall, as there were no 
differences found in the proliferation of Vγ6+ γδ T cells in adult CD18 KO mice, the 
levels of IL-23, IL-1β, IL-7, and IL-2 should be compared in WT and CD18 KO 
neonatal mice, where there is more likely to be an enhanced proliferation that is 
potentially cytokine-driven.  
Environmental factors other than cytokines could also play a role in the increased 
number of Vγ6+ cells in CD18 KO mice. In recent years there has been evidence 
suggesting a role for the microbiota in the regulation of Vγ6+ γδ T cell numbers. Vγ6+ 
CD3bright γδ T cells in WT mice were decreased when they were housed in germ-
free conditions or treated with antibiotics346. Another study found that, in the 
absence of the IL-17 receptor, Vγ6+ IL-17-producing γδ T cells were increased and 
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the proposed mechanism was that microbiota-activated CD103+ DCs were driving 
γδ T cell proliferation through cell-cell contacts351. It is therefore possible that the 
absence of CD18 results in alterations to the microbiota that modify the immune 
response, resulting in Vγ6 expansion. Although the role of the microbiota in 
regulating the increased number of Vγ6+ cells in CD18 KO mice was not directly 
addressed, it can be speculated whether it is likely to play a role. Firstly, it should 
be noted that the CD18 KO mice were housed in individually vented cages, which 
limits environmental exposure. Secondly, I used littermate controls in some 
experiments to control for potential differences in the microbiota. The analysis of γδ 
T cells in embryonic/neonatal mice used WT littermates, where an increased 
number of Vγ6+ cells was found in the spleen and lungs. Also, for the experiments 
in chapter 4 where Vγ chains were analysed by flow cytometry, a mixture of WT 
mice that were bought externally and WT littermates from the CD18 KO colony were 
used. Importantly, the increased number of Vγ6+ cells in CD18 KO mice was 
consistent regardless of the source of the WT mice. It was also shown in a model of 
reduced CD18 expression that mice developed psoriasis at the same incidence and 
magnitude when under germ-free or specific-pathogen free conditions365. This 
suggests, though does not definitively prove, that the mechanism of γδ T cell 
expansion in CD18 KO mice is likely to be independent of the microbiome. 
5.3.3 Vγ6+ γδ T cells in β2 integrin-deficient mice display no 
difference in IL-7-mediated survival  
The increased expression of IL-7R on Vγ6+ cells in the spleen but not the lungs of 
CD18 KO mice highlights that the cells may have a different capacity to respond to 
IL-7 or be exposed to different levels of IL-7, depending on the tissue 
microenvironment in which they reside. Interestingly, Vγ6+ cells in the lungs of both 
WT and CD18 KO mice expressed high levels of the IL-7R. In the WT spleen IL-7R 
expression was reduced compared to the lungs, whereas in the CD18 KO spleen 
the Vγ6+ cells expressed levels similar to those in the lungs. This could be explained 
by an increased recirculation of Vγ6+ cells from the lungs to the spleen in CD18 KO 
mice, compared to WT where the cells remain more tissue-resident. If the increased 
numbers of Vγ6+ cells originate in the lungs, then the numbers may exceed the level 
at which the cells can be effectively retained in the tissue, therefore the cells enter 
the circulation and accumulate in the spleen. If Vγ6+ cells from the lungs retain their 
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high levels of the IL-7R when they migrate to the spleen, this would explain why in 
CD18 KO mice the Vγ6+ cells in the spleen express higher levels of the IL-7R.  
Given that differences were found in the IL-7R expression on γδ T cells, I further 
explored the downstream signalling. The in vitro stimulation of spleen and lung cells 
from WT and CD18 KO mice with IL-7 resulted in the upregulation of pSTAT5 and 
to a lesser extent pSTAT3, as seen previously235. In CD18-deficient cells the 
upregulation of pSTAT5 was impaired in both Vγ4+ and Vγ6+ cells whereas a 
pSTAT3 defect was only seen in the Vγ4-expressing γδ T cells. The phosphorylation 
of both STAT3 and STAT5 are known to be induced by IL-7R engagement404 but 
pSTAT3 upregulation occurs to a greater extent in IL-17-producing γδ T cells than 
in IFNγ producers235. Again, the alterations in γδ T cells from the CD18 KO spleen 
were not found in those isolated from the lungs, re-enforcing the tissue specific 
differences seen between lungs and spleen. The IL-7 stimulation assay was 
performed using unsorted cells, so the number of Vγ6+ cells per well from CD18 KO 
mice would have been higher than from WT. It could be argued that the quantity of 
IL-7 per cell would therefore be lower in the cultures from KO mice, however it has 
been estimated that using 0.01-0.1ng/ml IL-7 in vitro recapitulates the levels found 
in vivo 405 and maximal levels of pSTAT5 should be induced after exposure to 
0.1ng/ml of IL-7 406. As the levels used here were far in excess of this (100ng/ml), 
the maximal signalling is likely to have been achieved. The defect in pSTAT5 
signalling was also found in the Vγ4+ population, for which numbers were equivalent 
between WT and CD18 KO mice, suggesting that cell numbers and IL-7 availability 
are not responsible for the defect in STAT phosphorylation.  
Vγ6+ cells in the spleen showed impaired signalling immediately downstream of the 
IL-7R (Figure 5-13) despite expressing higher levels of receptor (Figure 5-11). This 
higher expression of IL-7R was accompanied by a decreased expression of Bcl2 
(Figure 5-12), which is in agreement with a previous study that identified higher 
expression of Bcl2 in IL-7Rlow γδ T cells compared to IL-7Rhigh 407. The reduced 
expression of Bcl2 in CD18 KO splenic Vγ6+ cells suggests a reduced survival, 
which fits with the apoptosis data, where Vγ6+ cells from the spleen of CD18 KO 
mice displayed an increase in apoptosis compared to WT. However, this reduced 
Bcl2 expression was only found in Vγ6+ cells from the spleen of adult mice (8 weeks 
or older) but not in mice aged 4 weeks old (Figure 5-12). This may indicate that there 
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is an age-dependent effect, whereby the initial increase in Vγ6+ cells occurs in the 
young mice following birth then during adulthood the cells accumulate. This 
accumulation is at least partially driven by a reduced apoptosis in the lungs, 
although in the spleen there may not be enough survival signals to sustain the 
expanded Vγ6+ population, hence the increased apoptosis and decreased Bcl2 
expression. Expression of the IL-7R is downregulated in response to IL-7 binding, 
so the increased expression on Vγ6+ cells in the spleen may reflect lower levels of 
IL-7. I also found that Vγ6+ cells in the spleen showed impaired signalling 
downstream of the IL-7R.  
It was only the initial signalling immediately downstream if the IL-7R in response to 
IL-7 that was measured. Therefore, the impact this impaired signalling through 
pSTAT3 and pSTAT5 has on downstream pathways and on cell proliferation is 
unknown. In vitro IL-7 stimulation of cells with reduced CD18 expression for 5 days 
selectively increased the CD27- γδ T cells compared to cells from WT mice408. 
Therefore, a longer culture of γδ T cells from WT and CD18 KO mice using IL-7 
would help to elucidate if there is a difference in their functional response to IL-7, 
however as the starting cell populations from the spleen/lungs of WT and CD18 KO 
mice are different, the γδ T cells would need to be sorted prior to culture. This adds 
the caveat of the low number of γδ T cells that can be obtained from WT mice. 
Overall, there was no evidence of enhanced IL-7-mediated survival of Vγ6+ γδ T 
cells in CD18 KO mice, shown by short-term in vitro cultures and ex vivo staining 
for Bcl2.  
5.3.4 Vγ6+ γδ T cells in β2 integrin-deficient mice display reduced 
Fas-mediated apoptosis in the lungs  
There was a decreased apoptosis of Vγ6+ cells in the lungs of CD18 KO mice 
compared to WT. This effect was found to be both γδ subset-dependent and tissue-
specific as the apoptosis of Vγ4+ cells was unaffected by β2 integrin loss, as were 
the Vγ6+ cells in the spleen. Analysis of the death receptor Fas on Vγ6+ cells, 
showed that in the lungs of CD18 KO mice these cells express lower levels of Fas, 
in addition to their reduced apoptosis. It is therefore likely that the reduced apoptosis 
of Vγ6+ cells in the lungs of CD18 KO mice is at least partially mediated by reduced 
Fas-mediated signalling compared to WT mice. A decrease in apoptosis indicates 
that there is an increase in cell survival, although the mechanism of this higher 
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survival is unclear as this was not an IL-7-dependent effect. Bcl2 expression in Vγ6+ 
cells was either unchanged or significantly reduced in CD18 KO mice compared to 
WT. This suggests that the increase in Vγ6+ γδ T cells in β2 integrin-deficient mice 
is not due to an enhanced survival mediated by the upregulation of Bcl2. The anti-
apoptotic molecule Bcl2 is part of the intrinsic death pathway, whereas the Fas 
receptor activates the extrinsic apoptosis pathway409. Given that reduced 
expression of Fas was identified on Vγ6+ cells in the lungs of CD18 KO mice, it is 
likely that the increased survival was mediated by a reduction in signalling 
downstream of the extrinsic apoptosis pathway. Caspase-8 is activated downstream 
of Fas, which can cleave other downstream caspases such as caspase-3410. 
Assessment of these caspase molecules in Vγ6+ cells from WT and CD18 KO mice 
would determine if there are differences in the activation of caspases downstream 
of the Fas receptor.  
The lower levels of Vγ6+ cell apoptosis in the lungs of CD18 KO mice were identified 
in adult mice, therefore I hypothesised that there may be an increased accumulation 
of Vγ6+ cells compared to WT, due to a failure of homeostatic cell death. Analysis 
of aged mice showed that the difference between WT and CD18 KO Vγ6+ cell 
numbers present in adults does not become greater as the mice age, indicating that 
there is not an enhanced accumulation of these cells in CD18 KO mice compared 
to WT. However, reduced apoptosis may contribute to the retention of Vγ6+ cells in 
CD18 KO mice, while other mechanisms could retain the cells in WT mice. The 
comparison of Vγ6+ γδ T cell numbers across all the ages analysed (Figure 5-16) 
highlights that the difference between WT and CD18 KO mice occurs prior to 4 
weeks of age. Data from neonatal CD18-deficient mice, showed that Vγ6+ cells are 
increased in the tissues from 1 day post birth. Taken together with the data showing 
that there is no difference in Vγ6+ cell proliferation in adult mice, I propose that there 
is an expansion of Vγ6-expressing γδ T cells in young CD18 KO mice and these 
cells are then retained in the adults.  
5.3.5 The loss of CD18 may affect the expression of receptors and 
ligands that are β2 integrin-dependent or independent 
One of the important questions that remains unanswered is whether the loss of β2 
integrin expression has a cell-intrinsic effect on the γδ T cells or affects another cell 
type that indirectly leads to the expansion of Vγ6+ cells. The generation of mice with 
Chapter 5 Defining the mechanism of γδ T cell increase in β2 integrin-
deficient mice 
 
  198 
a γδ T cell-specific loss of CD18 expression would be an effective way to test this, 
although this would first require a CD18-floxed mouse to be created. It could be 
argued that as the Vγ6+ cell expansion is dependent on CD11a (Figure 4-11), and 
T cells rely on CD11a, whereas other leukocytes express multiple β2 integrin 
receptors that may compensate for the loss of CD11a, the defect could be T cell-
mediated. To rule out the potential involvement of αβ T cells, the CD18 KO mice 
could be crossed with an αβ-deficient line. Alternatively, CD18 KO γδ T cells could 
be used to reconstitute γδ T cell deficient mice by adoptive transfer. If the γδ T cell 
phenotype remained, then an indirect effect of αβ T cells would be excluded. 
Determining if the Vγ6+ cell expansion effect is intrinsic to γδ T cells will be pivotal 
in the future plans for this study. 
A second question is why the expansion effect is restricted to Vγ6-expressing γδ T 
cells. For some subsets of γδ T cells, molecules that drive their specific expansion 
and retention have been identified. Both the development and retention of Vγ5+ cells 
is linked to their interaction with Skint1 214,215. The expression of Skint1 in thymic 
epithelial cells is involved in Vγ5+ cell selection, after which they home to the 
epithelium where Skint1 is expressed in keratinocytes. Similarly the expression of 
Btnl1 in the intestines selectively drives the maturation and expansion of Vγ7+ γδ T 
cells216. The expression of such a ligand for the Vγ6-expressing γδ T cells has not 
yet been identified. It is possible that a specific ligand exists that is important for the 
proliferation and retention of Vγ6+ cells in sites such as the lungs, and that it is 
upregulated in CD18 KO mice. Alternatively, the γδ T cell interactions with the 
epithelium mediated by β2 integrins themselves may be driving the enhanced 
population of Vγ6+ γδ T cells, as discussed previously.  
Unlike αβ T cells, γδ T cells are not restricted to recognising peptides presented in 
the context of MHC molecules. Several ligands for the γδ TCR have been identified 
including the algal protein phycoerythrin250, phospholipid antigens in the context of 
CD1d251 and more recently it was shown that the Vγ7 TCR has distinct sites to bind 
both antigen and the co-stimulatory molecule Btnl217. However, to date the ligand 
for Vγ6+ γδ T cells has not been identified. This population of γδ T cells express a 
TCR with an identical sequence (invariant), but can be induced by a variety of stimuli 
including infection with Mycobacterium411 or Listeria412, ovarian cancer283 and 
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CFA199. It is therefore likely that Vγ6+ cells are not solely activated through a single 
TCR-restricted ligand.  
Finally, it is possible that the increase in Vγ6+ cells in CD18 KO mice may not be 
due directly to the loss of CD18, but instead to an indirect effect whereby CD18 loss 
results in the upregulation of another integrin receptor, or downregulation of 
something else within the cell. In CD18 KO mice the expression of VCAM-1 was 
found to be upregulated in the pulmonary arteries, accompanied by an 5-fold 
increase in the number of VLA-4+ (α4β1) leukocytes in the alveolar walls of these 
mice413. These VLA-4+ leukocytes may represent the expanded population of γδ T 
cells. In humans, VLA-4-ICAM-1 interactions were shown to be involved in the 
interactions between γδ T cells and endothelial cells298 and in mice Vγ1+ and Vγ4+ 
γδ T cells were described as expressing VLA-4294. Analysis of VLA-4 expression on 
Vγ6+ γδ T cells from WT and CD18 KO mice may reveal an α4β1 integrin-mediated 
migration or retention of these cells in the lungs. Although an increase in VLA-4 may 
cause the altered distribution of γδ T cells, it doesn’t explain the increased numbers 
of Vγ6+ cells found in CD18 KO mice, or the reduced apoptosis and expression of 
Fas that I have identified.  
5.4 Conclusions 
In conclusion, β2 integrin receptors play an important role in promoting the 
development of Vγ4+ γδ T cells and in the peripheral regulation of Vγ6+ γδ T cells. 
The thymic production of Vγ4+ cells was reduced in CD18 KO mice from the 
embryonic stage and into early life, which resulted in a defect in Vγ4+ numbers, 
specifically in pLNs. The increased numbers of Vγ6+ cells were present in the lungs 
of CD18 KO mice from 1 day post-birth and in the spleen from 3 day old mice. In 
adult mice there was no difference in IL-7R-mediated signalling or survival on Vγ6+ 
cells, but they accumulated due to reduced apoptosis in the lungs of CD18 KO mice 
compared to WT. The decreased expression of Fas on CD18 KO Vγ6+ cells 
suggests that the lower level of apoptosis was due to reduced Fas-mediated cell 
death. These findings highlight the novel and differential roles for β2 integrins on IL-
17-producing γδ T cell subsets. Further work is required to determine the precise 
mechanisms of these roles and establish the functional outcomes.  
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Chapter 6 Final Discussion 
The β2 integrins are a family of leukocyte-specific adhesion receptors that play key 
roles in cell migration, adhesion and interactions. Traditionally, the functions of β2 
integrins have been associated with immune activation. This is based on their 
involvement in the migration of αβ T cells and neutrophils to LNs and tissue sites 
during inflammation, immune synapse formation between αβ T cells and APCs, 
binding of cytotoxic T cells/NK cells to target cells, and phagocytosis of complement-
coated particles by myeloid cells/granulocytes. More recently, there is accumulating 
evidence that β2 integrins also play a regulatory role in the immune system. In both 
mice and humans, the loss of β2 integrin expression is associated with inappropriate 
inflammation and autoimmunity. The overall aim of this thesis was to understand the 
immunoregulatory roles of β2 integrins. This was explored in DCs and γδ T cells, 
based on preliminary evidence in the literature for integrin-mediated regulation of 
these cell types.  
6.1 Summary of the role for β2 integrins in DC regulation 
In the absence of β2 integrin expression, DCs were hyperresponsive to TLR-
mediated signalling182 and in the absence of TLR signals, DCs with functionally-
deficient β2 integrins displayed enhanced activation based on co-stimulatory 
molecule expression and IL-12 production73. These studies suggest that β2 integrins 
act as a negative regulator of DC activation. In chapter 3, I showed the specific loss 
of CD11a or CD11c expression causes the enhanced co-stimulatory molecule 
expression on DCs generated. In addition, BMDCs lacking CD11a were capable of 
inducing greater T cell responses. This furthers our understanding of how β2 
integrins regulate DCs, through identification of the specific subunits responsible for 
this regulation, namely CD11a and CD11c.  
6.2 Mechanisms of DC regulation by β2 integrins 
The primary aim in chapter 3 was to determine which β2 integrin subunits are 
responsible for regulating DCs and what effect this has on the subsequent T cell 
response. Importantly, these studies were conducted using DCs deficient in each of 
the four α-subunits (CD11a, CD11b, CD11c or CD11d) to provide a complete and 
unbiased assessment of β2 integrin-mediated regulation in DCs. This provides 
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additional knowledge compared to previous studies where DCs were examined from 
total β2 integrin-deficient mice73,97,182, CD11b KO alone185 or CD11a compared with 
CD11b KO mice182.  
Whilst these studies were ongoing, it was discovered that the CD11a, CD11c and 
some CD11d KO mice expressed an additional mutation in the Dock2 gene 
(Dock2Hsd). The focus of chapter 3 then became to identify which effects described 
in the CD11a and CD11c KO mice were integrin-dependent and which were due to 
the unknown defect in Dock2 function. Crucially, I identified that the enhanced co-
stimulatory molecule expression by CD11a and CD11c KO BMDCs in these KO 
mice was due to the β2 integrin-deficiency and independent of Dock2Hsd. 
Heterozygous expression of CD11a/CD11c was sufficient to induce these effects 
relative to WT or mice with hom/het expression of Dock2Hsd. The alterations in DC 
phenotype should be confirmed in CD11a and CD11c KO mice with Dock2WT 
expression to consolidate these findings.  
The enhanced co-stimulatory molecule expression on CD11a and CD11c KO 
BMDCs generated in vitro may suggest that the loss of integrin expression has a 
cell-intrinsic effect on DCs, meaning that β2 integrin receptors directly regulate DC 
activation. Alternatively, there may be changes in epigenetic programming in the 
mouse due to the altered environment. The enhanced expression of CCR7 on 
CD11a KO BMDCs suggests that integrin loss can also have indirect effects on DC 
function. To determine whether the increased levels of CCR7 enhance CD11a KO 
BMDC migration, transwell assays could be used to compare the migration of WT 
and CD11a KO BMDCs to the CCR7 ligands CCL19 and CCL21. In addition, the 
co-transfer of labelled WT and KO BMDCs would determine if there are differences 
in CD11a KO BMDC ability to migrate to LNs in vivo.  
It is well established that CD11a expressed on CD4 T cells binds to ICAM-1 on the 
APC to mediate immune synapse formation, but what is less well characterised, is 
the importance of CD11a expressed on the DC binding to ICAM-1 on the T cell. I 
showed that the loss of CD11a on BMDCs reduced their ability to bind to ICAM-1, 
which is in agreement with previous findings where BMDCs expressing 
constitutively active CD11a displayed enhanced adherence to ICAM-188. A 
decreased number of DC-T cell conjugates form when CD4 T cells are cultured with 
CD18 KO BMDCs compared to WT (Morrison, unpublished data), suggesting that 
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the loss of β2 integrin expression on DCs does reduce their ability to form contacts 
with T cells. Despite this evidence for reduced adhesion to T cells, the co-culture of 
CD11a KO BMDCs with antigen-specific CD4 T cells demonstrated their ability to 
induce greater levels T cell activation, proliferation and differentiation than WT 
BMDCs. This may indicate that β2 integrin expression on the T cell mediates binding 
that is sufficient for T cell activation. It should be noted; this data should first be 
confirmed using CD11a KO BMDCs with WT Dock2 expression. Perhaps there is a 
threshold for the strength of interaction that is required to enable T cell activation, 
and despite reduced adherence by CD11a KO BMDCs, the binding is still above the 
required threshold. To investigate if this is the case, TCR signal strength could be 
measured using T cells from Nur77GFP mice, which express GFP from the Nr4a1 
(Nur77) locus, so GFP is activated in response to TCR signalling and correlates with 
signal strength414. Co-culturing Nur77GFP T cells with WT and CD11a KO BMDCs 
would determine if there are differences in the strength of signal provided to T cells 
and using anti-CD11a antibody to block the integrin on the T cell side of the 
interaction would determine if CD11a expressed on the T cell is required for 
sufficient TCR signalling. Further to this, the titration of an inhibitor of TCR signalling, 
e.g. Zap-70 inhibitor415, would determine whether there is a threshold of TCR 
signalling required for T cell activation.  
This reductionist approach of using β2 integrin-deficient BMDCs generated in vitro, 
allowed the specific effects of integrin subunit loss in BMDCs to be assessed and 
enabled the generation of sufficient numbers of BMDCs to carry out functional 
assays. It will be important for future studies to validate these results in vivo to 
determine the physiological relevance and functional significance of these findings. 
When I analysed DCs ex vivo from β2 integrin-deficient mice, I found no difference 
in their activation marker expression. There are several possible reasons for this 
discrepancy between integrin-deficient BMDCs in vitro and endogenous DCs in vivo. 
It is possible that the in vitro system is simply not representative of DCs in vivo. The 
GM-CSF/IL-4-cultured bone marrow cells that I refer to as BMDCs (based on 
expression of MHC II) are in fact derived from both common DC precursors (CDP) 
and common monocyte precursors337. This is in contrast to endogenous DCs that 
only develop from CDPs128 therefore, BMDCs actually represent a mixed population 
of DCs and macrophages. However, a previous study using β2 integrin signalling-
deficient mice showed that in vivo splenic DCs, gated by CD11c+ MHC II+ cells, did 
express higher levels of CD8673. The β2 α-chain KO mice have a global integrin 
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deficiency, therefore not only the DCs will be affected by integrin loss, and 
alterations in other immune cell populations may indirectly impact on the activation 
status of the DCs. The generation of a DC-specific β2 integrin KO mouse, using 
CD11cCre and CD11aflox mice, would determine any effects of integrin loss that are 
due to the absence on DCs. The analysis of DCs ex vivo encompassed a mixed 
population of DCs, as cells were gated on dump negative (to exclude T cells, B cells, 
NK/NKT cells, monocytes/MFs, pDCs and neutrophils) then MHC II+. Therefore, the 
separation into specific subsets, e.g. cDC1 and cDC2, may reveal that β2 integrin-
mediated regulation of DCs is a subset-specific effect. Finally, the improvement of 
DC purity for analysis, as discussed in chapter 3, would also reduce variability in the 
data because the study using signalling-deficient mice73 gated through CD11c which 
was not possible in my case, due to the use of CD11c KO mice.  
6.3 The relevance of β2 integrin-mediated regulation of 
DCs to disease 
There is clear evidence that the loss of β2 integrin expression is linked to the 
development of autoimmunity in both humans119,120 and mice122,124. My data and 
previously published studies73,88,97,182 suggest that loss of β2 integrin function in DCs 
results in increased activation and enhances their ability to induce T cell responses. 
What remains to be determined is whether these two phenomena are linked. Does 
the loss of β2 integrin expression/function in DCs contribute to the development of 
autoimmunity? The aberrant activation of DCs has been described in many 
autoimmune diseases416. It is possible that a reduction in β2 integrin activation or 
expression results in a loss of negative regulation, thereby promoting DC-mediated 
priming of autoreactive T cells. This could be tested using mouse models of 
autoimmune disease but would require a DC-specific system. This could be 
achieved through the adoptive transfer of WT or integrin-deficient DCs, or the 
generation of DC-specific integrin KO mice. Work is also currently ongoing in the 
lab to assess β2 integrin expression and activation on DCs from rheumatoid arthritis 
patients, which will help to determine the potential relationship between integrin-
mediated regulation of DCs and autoimmune disease.  
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6.4 Summary of the mechanism of β2 integrin-mediated 
regulation in γδ T cells 
Mouse models of β2 integrin-deficiency can develop inflammation in the skin or oral 
mucosa that is associated with an increase in IL-17-producing γδ T cells296,302. It 
was also shown under steady state conditions that CD18 KO mice have an 
increased number of γδ T cells in the cervical LNs297 and IL-17+ γδ T cells in the 
spleen303. Based on these findings my hypothesis was that β2 integrins are a novel 
regulator of IL-17-producing γδ T cells. In chapter 4, I identified that in addition to 
the spleen, the loss of CD18 expression leads to increased numbers of γδ T cells in 
the lungs, uterus and blood. This increase was due to the specific expansion of 
Vγ6Vδ1+ γδ T cells that display an enhanced potential for IL-17 production. This is 
the first evidence identifying β2 integrins as a negative regulator of Vγ6+ γδ T cells.  
In chapter 5 I explored the potential mechanism(s) underlying the increase in Vγ6+ 
γδ T cells in CD18 KO mice. Analysis of γδ T cells in the thymus and peripheral 
tissues of CD18 KO mice from foetal stage to adults revealed that β2 integrins play 
different roles in Vγ4- and Vγ6-expressing γδ T cell subsets (summarised in Figure 
6-1). The thymic development of Vγ6-expressing cells was unaffected by β2 integrin-
loss, whereas Vγ4+ γδ T cell development was impaired (Figure 6-1A). This reduced 
thymic development resulted in a lower number of Vγ4+ cells in peripheral LNs. On 
the contrary, an increased number of Vγ6+ γδ T cells were found in the tissues (lungs 
& spleen) of neonatal mice (Figure 6-1B) and their numbers continued to increase 
in CD18 KO mice above their WT counterparts up to 4 weeks old. In the periphery 
of adult mice, the active proliferation of Vγ6+ cells could not be detected, and I found 
no evidence to suggest any factors present in CD18 KO mice that were driving Vγ6+ 
γδ T cell expansion. Vγ6+ γδ T cells did display reduced apoptosis in the lungs and 
expressed lower levels of Fas, suggesting a reduced susceptibility to induced cell 
death via the Fas pathway (Figure 6-1C). Overall, these studies reveal a previously 
unknown role for β2 integrins in promoting the thymic development of Vγ4+ γδ T cells 
and regulating Vγ6+ γδ T cell numbers in the periphery. 
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Figure 6-1 Differential effects of β2 integrin loss of Vγ4+ and Vγ6+ γδ T cells 
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6.5 Potential mechanisms of γδ T cell expansion in β2 
integrin-deficient mice 
The main unanswered question from this data is whether or not the increase in γδ 
T cells is due to a cell-intrinsic effect. β2 integrins are expressed on most leukocytes 
but the levels of individual family members varies according to cell type. I identified 
the specific loss of CD11a causes an increase in γδ T cell numbers. CD11a is highly 
expressed on both γδ and αβ T cells, potentially indicating the increase in γδ T cells 
is a T cell-mediated effect. This raises the question of whether integrin loss on αβ T 
cells could indirectly increase γδ T cell numbers. A previous study demonstrated 
that αβ T cells inhibit the homeostatic expansion of γδ T cells417. As αβ T cell 
migration to LNs and tissues is impaired in CD18 KO mice this raises the possibility 
that the loss of β2 integrin expression prevents αβ T cell-mediated regulation of γδ 
T cells due to altered localisation of αβ T cells. However, the mechanism of γδ T cell 
regulation identified was through competition with αβ T cells for IL-15417, a cytokine 
required for the expansion of CD27+ but not CD27- γδ T cells235. As the expanded 
population in CD18 KO mice are CD27- γδ T cells, this competition for IL-15 is 
unlikely to be the mechanism here. In addition to this, there is contradictory evidence 
that CD4 T cells in fact enhance IL-17+ γδ T cells numbers and cytokine 
production418. However, my data showed increased numbers of γδ T cells present 
in mice from 1 day post-birth, an age at which very few αβ T cells are present, 
making it unlikely to be an αβ T cell-driven mechanism of γδ T cell expansion in the 
CD18 KO mice. 
I propose that the loss of CD11a/CD18 expression on γδ T cells leads to a loss of 
regulation as a direct result of the absence of CD11a-mediated signals, thereby they 
increase in number. Analysis of CD11a expression on γδ T cells in WT mice showed 
higher expression on Vγ6+ cells than other γδ T cell subsets in the lungs and uterus, 
the tissues where these cells usually reside. This may partially explain why the loss 
of CD18 expression only affects Vγ6-expressing cells in specific tissues. Under 
homeostasis, signals in the lungs/uterus tissues may induce CD11a upregulation to 
perform important functions in Vγ6+ γδ T cells. In αβ T cells, particularly CD8+, TCR-
mediated signalling leads to the upregulation of CD11a74,329. Therefore, there may 
be a Vγ6 TCR ligand present in the lungs and uterus that drives enhanced CD11a 
expression. There is evidence that CD11a expression on γδ T cells is required for 
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their cytotoxic functions79,80, but its functional role in other types of γδ T cell remains 
undetermined.  
It cannot be ruled out that CD18 loss on a non-T cell population may be responsible 
for the increased number of γδ T cells in β2 integrin-deficient mice. Expression of 
CD11a has been identified on neutrophils66, dendritic cells27 and macrophages31, 
therefore the loss of CD11a is likely to also have a functional impact on these cells. 
A common approach to determine cell-intrinsic effects is to use bone marrow 
chimeras, however as Vγ6+ γδ T cells are produced exclusively during 
embryonic/neonatal stages of thymic development, this would not provide any 
insight. It has previously been shown that following irradiation and bone marrow 
transplantation, Vγ6+ cells remain absent whereas Vγ1- and Vγ4-expressing γδ T 
cells can develop243. The best approach to determine if β2 integrin loss has a cell-
intrinsic effect on γδ T cells would be to create a γδ-specific knockout of CD11a or 
CD18. This requires mice with a CD11a or CD18 lox-P flanked sequence (which do 
not currently exist) crossed with mice expressing TCRδ Cre recombinase.  
The increased number of Vγ6+ γδ T cells in CD18 KO mice occurs despite normal 
thymic output, indicating that factors in the periphery are contributing to the 
expansion of γδ T cells above the numbers found in WT mice. I was unable to detect 
proliferation of γδ T cells in vivo following BrdU labelling in adult mice or adoptive 
transfer of cells from adult mice, indicating that KO γδ T cells are not undergoing 
proliferation in adult mice. I identified that Vγ6+ cells in the adult lungs express lower 
levels of Fas and display reduced apoptosis. This indicates a reduction in cell death, 
therefore is likely to contribute to the accumulation of Vγ6+ cells in CD18 KO mice. 
Further experiments are required to determine if reduced Fas expression on CD18 
KO Vγ6+ cells renders them resistant to Fas-induced cell death. This could be 
determined by measuring the apoptosis of Vγ6+ cells following incubation with Fas 
ligand and a cross-linking antibody in vitro. In addition to this, the reduction in Vγ6+ 
γδ T cell apoptosis implies they have an increased survival. My data suggests that 
this survival is independent of IL-7R-mediated signalling and Bcl2, but further 
analysis of survival pathways may identify alterations in other survival-related 
signalling molecules.  
Analysis of γδ T cell numbers in the tissues of WT and CD18 KO mice across 
different ages identified that the higher number of γδ T cells is present from 1 day 
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following birth. This indicates that the factor/s driving the increase in Vγ6+ γδ T cells 
is present in CD18 KO mice from neonatal age. This raises the question of what 
mechanism is responsible for the increased γδ T cell numbers in neonatal CD18 KO 
mice. There are a number of factors that could be contributing to the increase in γδ 
T cells in CD18 KO newborn mice such as cytokines, loss of signalling downstream 
of β2 integrin receptors or altered signalling via other receptors/ligands. RNA 
sequencing of Vγ6+ cells from WT and CD18 KO neonatal mice would provide 
further information on the pathways that are altered in γδ T cells in the absence of 
β2 integrins and may provide indications for the upstream regulators. For example, 
alterations in integrin-related pathways would indicate an intrinsic effect on the γδ T 
cells whereas changes in cytokine-related pathways would suggest the impact of 
factors in the microenvironment. It is possible that although no differences in the 
proliferation of Vγ6+ cells are being detected in adult mice, there is an enhanced 
expansion of these cells in young CD18 KO mice. Analysis of γδ T cell proliferation 
in WT and CD18 KO neonatal mice would confirm if Vγ6+ cells are proliferating 
earlier in life. Alternatively, the increased number of Vγ6+ cells may be due to an 
enhanced survival, as suggested by the data obtained from adult mice. When Vγ6+ 
cells leave the thymus, presumably only a proportion of those cells that migrate to 
the lungs will actually survive therefore there may be an increased survival of Vγ6+ 
cells that initially seed the lungs in CD18 KO mice compared to WT. It has been 
hypothesised that Vγ5+ γδ T cells initially colonise the epidermis to form small 
clusters that undergo homeostatic expansion to fill the niche419. Perhaps, if the same 
phenomenon occurs for Vγ6+ cells, then either the initial colonisation or homeostatic 
expansion of Vγ6+ γδ T cells is enhanced in the lungs of CD18 KO mice compared 
to WT. 
6.6 Implications of the expanded Vγ6+ γδ T cell 
population in CD18 KO mice 
Having established there is an expansion/accumulation of Vγ6+ γδ T cells in β2 
integrin-deficient mice, the next step would be to determine the functional 
consequences. There are many studies that have described protective or 
pathogenic effects of Vγ6+ IL-17-producing γδ T cells in the setting of infection, 
autoimmunity or cancer. Mice deficient in γδ T cells showed impaired clearance of 
Staphylococcus aureus and efficient bacterial clearance was dependent on 
neutrophil recruitment via IL-17 production by γδ T cells271,420,421. In a similar 
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mechanism, fungal clearance following Candida albicans infection also required γδ 
T cell IL-17 production to induce neutrophil migration274. These studies show that 
Vγ6+ γδ T cells are protective in response to certain infections. In an Aldara-induced 
model of psoriasis, Vγ6+ γδ T cells were the main producers of IL-17 in the inflamed 
skin and exacerbated pathology422. In a model of autoimmune arthritis Vγ6+ cells 
were also the predominant source of IL-17, and migration of these cells via CCL2 
increased disease incidence423. In contrast to the examples of infection, Vγ6+ cells 
play a pathogenic role in autoimmune disease. In the ID8 model of ovarian cancer, 
IL-17 production by Vγ6+ cells enhanced tumour growth through recruitment of small 
peritoneal macrophages283. Similar to their role in autoimmunity, Vγ6+ γδ T cells are 
also pathogenic in cancer.  
Using these models in WT and CD18 KO mice, it would be expected that the 
increased population of Vγ6+ γδ T cells would enhance the clearance of S. aureus 
or C. albicans, whereas exacerbate psoriasis, arthritis or cancer development. It 
was previously shown that CD11a KO mice display an increased susceptibility to 
tumour development using the B16 melanoma cancer model, despite NK cell 
cytotoxicity being unaffected373. As IL-17+ γδ T cells have been shown to promote 
tumour growth in this model424, the expanded population of Vγ6+ cells may explain 
the increased susceptibility of CD11a KO mice to tumour development. However, 
the major caveat to infecting or inducing disease models in β2 integrin-deficient mice 
is that the β2 integrin defect is a global deficiency; therefore it would be difficult to 
attribute effects specifically to the expanded population of γδ T cells. In addition to 
this, the defective function of other immune cells may exacerbate or protect against 
disease. For example, the migration of αβ T cells is defective in CD18 KO mice and 
arthritis development is αβ T cell-dependent, meaning that CD18 KO mice will likely 
not develop disease to the same extent as WT. This was demonstrated in a study 
using the K/BxN model of arthritis, where CD11a KO mice were resistant to 
developing arthritis124. To circumvent this issue, models could be induced in WT 
mice or γδ T cell KO mice and then Vγ6+ γδ T cells adoptively transferred. This 
would provide a more direct readout of γδ T cell function. Another question that 
remains is whether the CD18 KO γδ T cells are functionally different to WT. My data 
demonstrated that the Vγ6+ cells have an enhanced capacity to produce IL-17 when 
re-stimulated in vitro, suggesting that they may produce higher levels of IL-17 than 
the WT counterparts. The transfer of WT and CD18 KO Vγ6+ cells into WT mice 
during an infection or disease model would test this, however this would require ex 
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vivo expansion of the cells as only a small number of Vγ6+ γδ T cells exist in WT 
mice, making it difficult to obtain sufficient numbers for transfer.  
In addition to the question of what effect the increased number of Vγ6+ γδ T cells in 
CD18 KO mice will have on their ability to respond to infection or disease, there are 
also a number of unanswered questions about the direct impact that integrin loss 
has on γδ T cell functional ability. An important function of β2 integrins in several 
leukocyte populations is to enable migration64,65,68, this raises the question of 
whether CD18 KO γδ T cells are able to efficiently migrate to target sites, e.g. to a 
tumour. My data showed that under steady state conditions, there was no defect in 
γδ T cell numbers in any of the tissues analysed, which suggests that γδ T cell 
migration is not dependent on β2 integrins. However, this may not be the case during 
inflammation or disease and could be different depending on the subset of γδ T cell. 
The transfer of specific subsets of WT and CD18 KO γδ T cells into mice during an 
infection or cancer model would directly assess whether β2 integrins are required to 
mediate γδ T cell migration to effector sites.  
In addition to contributing to migration, β2 integrins are also important for facilitating 
cell contacts. There is evidence from in vitro studies using human γδ T cells and 
integrin blocking antibodies to suggest that β2 integrins are required for optimal 
killing of target cells by γδ T cells79,80, although this has not yet been demonstrated 
in vivo. The cytotoxic capacity of γδ T cells also requires the delivery of signals 
mediated by receptors/ligands such as NKG2D190 and FasL425. The ability of γδ T 
cells to receive signals via NKG2D and provide signals to target cells via FasL may 
be impacted by β2 integrin loss, either through indirect effects on expression levels 
or by loss of cell interactions that are required to facilitate receptor-ligand binding. 
Analysis of NKG2D/FasL levels on γδ T cells from WT and CD18 KO mice, 
combined with culturing these γδ T cells with target cells to measure killing would 
help to clarify the effect of β2 integrin loss on γδ T cell cytotoxic capability.  
6.7 β2 integrins promote Vγ4+ γδ T cell development 
My initial hypothesis was that β2 integrins are a negative regulator of IL-17-
producing γδ T cells. However, analysis of γδ T cell thymic development revealed 
an unexpected defect in Vγ4+ γδ T cell development in the absence of CD18, 
suggesting that integrins play a role in promoting the development of this γδ T cell 
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subset. The mechanisms involved in the development of specific γδ T cell subsets 
are still not well understood. Vγ4+ γδ T cells are capable of producing either IL-17 
or IFNγ depending on their functional pre-programming. It has been suggested that 
IL-17-producers (that express Vγ6 or Vγ4) are generated in the thymus during 
embryonic and neonatal life, whereas Vγ4+ cells that produce IFNγ are produced at 
the postnatal stage426,427. I did not characterise the phenotype of the Vγ4+ cells that 
display impaired development in CD18 KO mice compared to WT. This could be 
done by staining cells from the neonatal thymus for IL-17/IFNγ and other markers 
that distinguish these subsets such as CD27, CD45RB and CD73203,206,427. The 
defect in Vγ4+ γδ T cell development is present in the thymus of neonatal mice but 
not adults, which may suggest that the impaired development is likely to be the IL-
17-producing Vγ4+ cells. In the absence of Sox13, mice display a complete loss of 
Vγ4+ γδ T cells but Vγ6+ cells are present at normal frequency in the periphery219, 
meaning the loss of β2 integrin expression may reduce the levels of Sox13 and 
thereby impair Vγ4+ γδ T cell development. Alternatively, the development of IFNγ-
producing Vγ4+ cells may be reduced in CD18 KO mice. There is evidence to 
suggest that strong TCR signals favour the development of IFNγ-producing γδ T 
cells205,428, therefore cell adhesion via β2 integrins could be required for optimal 
signalling, a function that has been demonstrated in αβ T cells83,84. The development 
of IFNγ-producing γδ T cells can also be promoted by co-stimulation via CD70-
CD27206, and again β2 integrins may facilitate the cell interactions necessary to 
facilitate co-stimulatory molecule interactions. Further analysis of signalling 
pathways in thymic γδ T cells from WT and CD18 KO mice would elucidate the 
potential involvement of these molecules in promoting Vγ4 development 
downstream of β2 integrin signalling.  
The importance of β2 integrin receptor interactions in promoting Vγ4+ cell 
development in the thymus should also be further explored. Foetal thymic organ 
cultures (FTOCs) using a CD18 blocking antibody would confirm that β2-mediated 
interactions are required for optimal Vγ4+ γδ cell development. In addition, 
comparing Vγ4+ cell development in FTOCs using CD18 KO donor thymocytes and 
WT stromal cells, with WT donor cells and CD18 KO stromal cells, would determine 
whether the defect in CD18 has an intrinsic effect on the γδ T cells.  
Finally, the functional outcome of the reduced number of Vγ4+ γδ T cells in CD18 
KO mice should also be considered. In the B16 melanoma model, Vγ4+ γδ T cells 
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play a protective role in decreasing the tumour burden through IFNγ and perforin 
production279,429. In CD18 KO mice the absence of anti-tumour Vγ4+ cells in 
combination with the expanded pro-tumour Vγ6+ cells would likely result in 
exacerbation of disease. Following infection with respiratory syncytial virus, Vγ4+ 
cells producing IFNγ enhanced viral control and reduced disease severity430 
therefore, the reduced numbers of Vγ4+ cells may enhance disease following viral 
infection. The protective role of Vγ4+ cells has also been demonstrated in a model 
of sepsis, where IL-17 production by Vγ4-expressing γδ T cells delayed mortality in 
mice431 whereas in a model of psoriasis IL-17-producing Vγ4+ cells contributed to 
pathology432,433. The lower number of Vγ4+ cells in CD18 KO mice could result in 
protection against pathology in psoriasis but exacerbated pathology in sepsis. 
Altogether these studies clearly demonstrate that the role of Vγ4+ γδ T cells is model-
dependent and differs according to their cytokine production. The determination of 
which type of Vγ4+ cells (IFNγ- and/or IL-17-producers) show impaired development 
in β2 integrin-deficient mice will elucidate the potential functional outcome.  
6.8 Links to human γδ T cells 
The data presented in this thesis demonstrated that in the absence of β2 integrins, 
mice have an increased number of Vγ6+ IL-17-producing γδ T cells. In future work 
the significance of these findings for human biology must be considered. In humans, 
β2 integrin-deficiency exists in a disease called leukocyte adhesion deficiency 
(LAD). In type I LAD, patients have a mutation in the CD18 gene leading to reduced 
or absent β2 integrin expression and in type III LAD, patients have mutations in 
kindlin-3 that prevent β2 integrin activation114. It was shown previously that LAD I 
patients with periodontitis have an increase in IL-17-producing CD3+ cells in their 
gingival tissue but not peripheral blood302. These cells were defined as TCRγδ- 
(although the data was not shown), and in the blood only the percentage of total T 
cells producing IL-17 was analysed. Further characterisation of the γδ T cell 
populations in LAD patients would provide more information on whether the loss of 
β2 integrin expression results in an increase of γδ T cells in humans, as found in 
mice. Although a subset equivalent to the Vγ6+ γδ T cells identified in mice does not 
exist in humans, analysis of the Vδ1- and Vδ2-expressing subsets, both of which 
have been shown to produce IL-17236,237,434, may reveal a potential role for β2 
integrins in regulating specific subsets of human γδ T cells.  
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6.9 Potential therapeutic targeting of β2 integrins 
Pre-clinical and clinical studies have assessed the potential use of β2 integrin 
blocking molecules, with mixed sucess435. In pre-clinical studies odulimomab, a 
monoclonal antibody against CD11a, reduced graft rejection in mice436 and rats437, 
and odulimomab protected against ischaemia and reperfusion injury following 
transplantation in primates438. This drug was not taken further into clinical trials. The 
blocking of CD11a or CD11b had a therapeutic effect in the mouse model of multiple 
sclerosis, EAE439. Whereas, rovelizumab, a humanised anti-CD11a, did not show 
any clinical benefit in a phase II trial using patients with acute exacerbations of 
MS440. Efalizumab, another humanised anti-CD11a, was shown to be an effective 
treatment for plaque psoriasis441. However, it was subsequently withdrawn due to 4 
reported cases of multifocal leukoencephalopathy, a rare side effect thought to be 
caused by immunosuppression442. The CD11a antagonist BMS-587101 was shown 
to be protective in a mouse model of arthritis and inhibited T cell adhesion, 
proliferation and Th1 cytokine production443. It was designed for topical use in a 
phase II trial for psoriasis but was stopped after showing signs of hepatotoxicity444. 
A CD11a antagonist currently in clinical use is Lifitegrast, a small molecule inhibitor 
that acts as a competitive antagonist of CD11a binding to ICAM-1445. This drug is 
used in eye drops to decrease T cell-mediated inflammation and reduce eye 
dryness446. The success of Lifitegrast may be partially attributed to the topical 
application that limits potential side effects, such as broad immunosuppression. 
These studies emphasise the potential issues with translating studies from animal 
models and the potential side effects of blocking β2 integrins, such as 
immunosuppression. My data showed that in contrast to the functions previously 
described where β2 integrins contribute to immune activation, these receptors also 
play a role in the negative regulation of DCs and γδ T cells. Taken together, this 
highlights the need for careful and effective drug design, considering the differential 
roles for β2 integrins in the immune system.   
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6.10 Concluding Remarks 
The data presented in this thesis has characterised the immuno-regulatory roles of 
β2 integrins in DCs and γδ T cells. CD11a and CD11c act as negative regulators of 
DC activation and restrict the ability of DCs to induce T cell responses. Whereas in 
γδ T cells β2 integrins play differential roles in γδ T cell subsets, promoting Vγ4+ γδ 
T cell development and regulating Vγ6+ γδ T cells in the periphery. These findings 
highlight the importance of β2 integrins in regulating immune responses. Further 
work to understand the downstream pathways of this regulation will identify potential 
therapeutic targets for diseases where DC or γδ T cell responses are dysregulated.  
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